Insulin-like Growth Factor I and its Binding Proteins in Health, Aging and Disease by Janssen, J.A.M.J.L. (Joop)

Insulin-like Growth Factor I and its Binding Proteins 
in Health, Aging and Disease 

Insulin-like Growth Factor I and its Binding Proteins 
in Health, Aging and Disease 
OVER INSULIN-LIKE GROWTH FACTOR I EN HAAR 
BINDINGSEIWITIEN BIJ GEZONDHEID, BIJ HET 
OUDER WORDEN EN BIJ ZIEKTEN 
PROEFSCHRIFT 
Ter verkrijging van de graad van doctor 
aan de Erasmus Universiteit Rotterdam 
op gezag van de rector magnificus 
Prof. dr P.W.C. Akkermans M.A. 
en volgens het besluit van het college voor promoties 
De open bare verdediging zal plaatsvinden op 
woensdag 14 october 1998 om 15.45 uur 
door 
Joseph Alphons Marie Johan Laurentius Janssen 
geboren te Roermond 
Promotiecommlssle 
Promotor: 
Overige leden: 
ISBN 90-901189-7 
Prof. dr S.w.J. Lamberts 
Prof. dr S.L.S. Drop 
Prof. dr D.E. Grobbee 
Prof. dr T.J. Visser 
The investigations presented in this thesis were performed at the Department of 
Internal Medicine of the University Hospital Dijkzigt, Rotterdam, The Netherlands 
The study was financially supported by a grant from the Netherlands Diabetes 
Fonds, which is gratefully acknowledged. 
The publication of this thesis was financially supported by Novo Nordisk and Ely 
Lilley 
No part of this thesis may be reproduced or transmitted In any form by any means, electronic or 
mechan/cal, Including photocopying, recording or any storage and retrieval system, without 
permission in writng from the publisher. 
'~rinted by: Haveka b.v., Alblasserdam, The Netherlands 
Ter nagedachtenis aan mijn vader en moeder 
"A new scientific truth does not triumph by convincing its opponents and making 
them see the light, but rather because its opponents eventually die, and a new 
generation grows up that is familiar with it" 
Max Planck, in: Scientific Autobiography and Other Papers, 
trans. F Gaynor (New York, 1949), pp 33-34. 
Contents 
Contents 
page 
Chapter 1 General Introduction and Aim of the Thesis 11-32 
Chapter 2 The IGF·I/IGFBP system and blood celis In 
healthy subjects 
§ 2.1 Introduction: The role of IGF-I and IGFBPs in blood 35-38 
cells under physiologic and experimental 
circumstances. 
§ 2.2 The IGF-I receptor on human blood cells: theoretical 39-42 
background. 
§ 2.3 IGF-I receptors on blood cells: their relationship to 43-60 
circulating total and free IGF-I, IGFBP-l, IGFBP-3, and 
insulin levels in healthy subjects. 
§2.4 The relationships between circulating total and free 61-74 
IGF-I, IGFBP-l, IGFBP-3, and insulin levels after an 
oral glucose load. 
Chapter 3 The IGF·I/IGFBP system and aging 
§ 3.1 Serum free IGF-I, total IGF-I, IGFBP-l and IGFBP-3 77-92 
levels in an elderly population: relation to age and 
sex steroid levels. 
§ 3.2 Serum totaIIGF-I, free IGF-I and IGFBP-l levels in an 93-111 
elderly population: relation to cardiovascular risk 
factors and disease. 
§ 3.3 Gender-specific relationship between serum free and 112-127 
total IGF-I and bone mineral density in elderly men 
and women. 
§3.4 Serum free and totaIIGF-I, IGFBP-l and IGFBP-3 levels 128-138 
in healthy elderly: relation to self-reported quality of 
health and disability. 
Contents 
page 
Chapter 4 The diagnostic value of the IGF-I/IGFBP system In 
growth hormone deficiency and growth hormone 
excess states. 
§ 4.1 Diagnosis of growth hormone deficiency in adults. 141-160 
§ 4.2 IGFBP3 is a poor parameter for assessment of 161-171 
clinical activity in acromegaly. 
§ 4.3 Acromegaly: the significance of serum total and free 172-182 
IGF-I and IGF-binding protein-3 in the diagnosis 
Chapter 5 The IGF-I/IGFBP system in 100M and congenital 
partial lipodystrophy. 
§ 5.1 Free and Total IGF-I, IGFBP-l and IGFBP-3 and 185-205 
their relationships to the presence of diabetic 
retinopathy and glomerular hyperfiltration in 
insulin·dependent diabetes mellitus (100M) 
§ 5.2 The IGF-I/IGFBP system in congenital partial 206-226 
lipodystrophy 
Chapter 6 Conclusions and General Discussion 227-246 
Summary 247-254 
Samenvatting 255-262 
Dankwoord 265-266 
Curriculum Vitae 267-268 
Lijst van publikaties 269-271 
List of Abbreviations 
IGF-I 
IGFBP-1 
IGFBP-3 
BMD 
BMI 
DHEAS 
ERPF 
GFR 
GH 
IDDM 
IRMA 
RIA 
SHBG 
WHR 
Conversion factors 
-IGF-I «ng/mL) X 0_1307)~ 
-IGFBP-1 «ng/mL) : 25_3)~ 
Insulin-like Growth Factor-I 
Insulin-like Growth Factor Binding Protein-1 
Insulin-like Growth Factor Binding Protein-3 
Bone Mineral Density 
Body Mass Index 
DeHydroEpiAndrosteroneSulphate 
Effective Renal Plasma Flow 
Glomerular Filtration Rate 
Growth Hormone 
Insulin-Dependent Diabetes Mellitus 
ImmunoRadioMetric Assay 
RadioimmunoAssay 
Sex Hormone-Binding Globulin 
Waist Hip Ratio 
-> nmol/L 
-> nmol/L 
-IGFBP-3 «mg/L) X 1000 : 28_75)~ -> nmol/L 

1 
General Introduction and 
Aim of the Thesis 

General Introduction and Aim of the Thesis 
Introduction 
The insulin-like growth factors (IGFs) were discovered in 1956 by William D. 
Salmon Jr. and William H. Daughaday at Washington University, St Louis, USA (1). 
Initially IGFs were called sulfation factors because they were able to replace the 
sulfation factor activity of growth hormone (GH)(l). Moreover, the IGFs were found 
to be able to stimulate DNA synthesis (2), proteoglycan synthesis (3), 
glycosaminoglycan synthesis (4), and protein synthesis (5). 
In 1963 Froesch et al. from the University of ZOrich, Switzerland, described excess 
insulin-like activity in serum (6). Only a small fraction of the insulin-like activity by 
normal serum on adipose tissue and muscle could be blocked by specific 
antibodies against insulin. The mediator of this excess insulin-like activity was not 
detectable with the radioimmunoassay developed for insulin in 1959, and was 
termed non-suppressible insulin-like activity (NSILA)(6). 
Dulak and Temin demonstrated that serum-free medium conditioned by a rat 
hepatoma cell line contained mitogenic activity, which they termed multiplication-
stimulating activity (MSA) (7). 
In 1972 these three apparently distinct peptides (sulfation factor, NSILA, MSA) were 
unified under the term somatomedin, because it apparently mediated the actions of 
GH (also called somatotropin) (8). 
In 1978 Rinderknecht and Humbel purified somatomedin from serum, and it turned 
out to be two closely related peptides, which were termed Insulin-like growth 
factor-I (IGF-I) and Insulin-like growth factor-II (IGF-II) (9, 10). 
13 
Chapter 1 
Evolutionary aspects 
The IGF-I molecule is highly conserved throughout vertebrate evolution (11). 
Amphioxus, a protochordate, expresses a hybrid insulin/IGF-I molecule (12). This 
strongly suggests that IGF-I diverged from the main line of insulin evolution at a 
stage antedating the jawless vertebrates. 
IGF-I gene stucture and expression 
In humans the IGF-I gene is a single gene copy located on chromosome 12 and 
consists of at least six exons (13). Although the liver was traditionally 
considered to be the sole producer of IGF-I, recent studies have shown that most 
tissues express IGF-I (14). Expression of IGF-I mRNA resulting from different 
transcription initiation sites is tissue-specific, and developmentally and hormonally 
regulated (11). 
Stuctural aspects of IGF-I 
IGF-I, IGF-II and insulin are members of a family of polypeptides which are 
characterized by a high degree of sequence homology (15)(see figure 1). IGF-I is 
50·60 % homologous with human pro insulin (16). IGF-I is synthesized as a larger 
prepro-IGF-I molecule containing a signal peptide as well as a carboxy-terminal 
extension peptide, the E peptide (17). The signal and E peptide are cleaved off 
during processing of the mature IGF-I (17). Mature IGF-I is a 70 amino acid 
peptide, which is different from insulin; at the carboxy terminus it contains an 
additional sequence the D domain (18). 
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INSULIN PROINSULIN 
IGF (I) IGF (II) 
Figure 1 
Predicted structure of the insulin-like growth factor family of peptides. The 
heavy line represents the A chain, double lines represent a D extension to the 
A chain or the C chain joining the A and B chains (from: LeRoith D. Insulin-
like growth factors in health and disease. Ann Intern Med 1992; 116: 855; 
with permission from the American College of Physicians) 
IGF-I purified from brain, bovine colostrum, and uterus lacks three amino-
terminal amino acid residues (gly-pro·glu) (19). This truncated form of IGF-I, 
called des-IGF-I, has a much greater biological potency than mature IGF-I 
because it has a lower affinity for the insulin-like growth factor binding 
proteins (IGFBPs) (see infra). It is therefore more available for interacting directly 
with the IGF-I receptor. The cleavage of the tripeptide presumably occurs as a 
posttranslational event, although the biomechanisms responsible have not yet 
been identified. 
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Functions of IGF-I 
IGF-I exerts many biological functions on distant target tissues via the blood stream 
(endocrine effects), on its own cells of origin (autocrine effects), and on 
neighboring tissues (paracrine effects)(20). IGF-I has both anabolic and mitogenic 
effects in vitro and in vivo, which often overlap with the biological effects of insulin 
(Table 1) (20-23): IGF-I stimulates cell differentiation and it is a mitogen for most 
cultured cells stimulating ['H] thymidine incorporation into DNA and ['H] uridine 
incorporation into RNA (21). In vitro glucose uptake, amino acid uptake and ion 
fluxes are increased by IGF-I (21). In vivo, IGF-I promotes longitudinal bone growth 
and suppresses GH and insulin secretion (20). IGF-I infusions in normal volunteers 
increases glucose uptake, reduces free fatty acid and triglyceride levels, and 
decreases protein breakdown (20). Moreover, insulin stimulates the constitutive 
secretion of IGF-I from the liver (24). IGF-I in turn, suppresses insulin secretion 
even in euglycemic conditions (25). In calorically restricted patients administration 
of IGF-I improves nitrogen balance (26). IGF-I increases glomerular filtration rate 
and renal plasma flow and enhances creatinine clearance (27). 
IGF-I thus influences many cell functions and is considered as growth factor and 
hormone with important anabolic and metabolic regulatory functions. Another 
action of IGF-I which is complementary to its stimulatory effect on cell proliferation, 
is its capacity to inhibit programmed cell death in certain cells, the so called 
apoptosis (28, 29). 
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Table I. Biological effects of IGF-I and insulin (modified after references 20-23) 
Stimulation of glucose uptake 
Stimulation of glucose oxidation 
Stimulation of glycogen synthesis 
Antilipolytic effect 
Stimulation of protein synthesis 
Stimulation of DNA synthesis 
Stimulation of RNA synthesis 
Stimulation of cell growth and 
differentiation 
Promotion of longitudinal bone growth 
Stimulation of mitogenesis in culture 
Suppression of GH secretion 
Suppression of insulin and C-peptide secretion 
Stimulation of creatinine clearance 
Stimulation of renal plasma flow 
Stimulation of glomerular filtration rate 
Stimulation of erythropoiesis 
Effect on thymus architecture 
Chemotaxis of T-Iymphocytes 
Production of immunoglobulins in plasma cells 
Stimulation of glucose uptake 
Stimulation of glucose oxidation 
Stimulation of glycogen synthesis 
Stimulation of lipogenesis 
Antilipolytic effect 
Stimulation of protein synthesis 
Stimulation of DNA synthesis 
Stimulation of RNA synthesis 
Stimulation of cell growth and 
differentiation 
The free Insulin-like growth factor-I concentration 
Free IGF-I, by analogy with sex and adrenal steroids and thyroid hormones, may 
be a major biological active hormonal form of IGF-I (30) (Figure 2). Determination 
of serum free unbound IGF-I was not possible until very recently (30, 31). In 1994 
Frystyk et a!. and Lee et a!. separately described a method to determine free 
unbound IGF-I in serum (30, 31). 
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Figure 2 
Distribution of IGFs in serum. Ninety-five percent of the IGFs are found as part 
of the ternary complex of IGF-I and IGF-II bound to IGFBP-3 and acid-labile 
subunit (ALS). Less than 5% are bound to other IGFBPs, and a very small 
component circulates as the free form (from: Collett-Solberg PF, Cohen P. 
The role of insulin-like growth factor binding proteins and the IGFBP 
proteases in modulation of IGF action. Endocrinol Metab Clin North Am 
1996; 25: 593; with permission from WB Saunders) 
The method of Frystyk et coworkers used ultrafiltration under in vivo 
conditions (physiological pH, ionic milieu and temperature) to measure IGF-I, 
while the free IGF-I assay of Lee and coworkers is an IRMA which initially 
needs no sample extraction as part of the standard procedure to measure 
IGF-I. Samples are added directly to tubes containing a dense coating of 
high-affinity free IGF-I antibody, incubated for 2 hr at room temperature, 
washed, incubated with a labeled antibody directed to a second epitope, 
washed and counted. It is likely that the free IGF-I fraction measured with this 
assay is a combination of the true free and the fraction of IGF-I which can be 
readily dissociated from IGFBPs under the specific assay conditions (31). 
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Most circulating IGF-I is bound to the insulin-like growth factor binding proteins 
(IGFBPs), which titrate the supply of IGF-I to its receptors in the target tissues, 
while a very small component circulates as the free form (32). The levels of free 
IGF-I in a system are modulated by the rate of IGF-I production, clearance, and 
degree of binding to IGFBPs (33). The metabolic clearance of serum free IGF-I is 
estimated as 2.62 ± 0.94 ml/min with a production rate of 4.75 ± 1.74 mg/day 
(621 ±227.34 nmol/day) (34). IGF-I bioavailability is probably an important factor in 
determining the different physiological functions served by IGF-I and insulin (20). 
The IGF-I receptor 
There are at least two classes of insulin-like growth factor receptors: the insulin· like 
growth factor-I (IGF-I) receptor and the IGF 11/ mannose -6-phosphate 
(Man-6-P) receptor (35). The IGF-I receptor gene, like the insulin receptor gene, 
consists of 22 exons (36). It is the product of a single copy gene located at the 
distal arm of chromosome 15 (37). The insulin-like growth factor receptors are 
expressed in many cells and in many tissues (38). The overlapping biological 
effects of IGFs and insulin were initially attributed to the structural homologies 
between the peptides themselves, but this interpretation turned out to be too 
simple, after it was shown that the receptors for insulin and IGF-I are also 
structurally similar (39) (Figure 3). 
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Figure 3 
The IGF family of circulating peptides (from: Lowe WL. Insulin-like growth 
factors. Science & Medicine 1996; 3: 65; with permission from Science & 
Medicine) 
Chapter 1 
Moreover, IGF-I, IGF-II and insulin can crossreact with each other's receptors 
(Figure 3) (15). The IGF-I receptor preferentially binds IGF-I, but also binds 
IGF-II and more weakly insulin. The IGF-II receptor binds IGF-II with higher 
affinity than IGF-I, but does not interact with even high concentrations of 
insulin (40). Because IGF-I, IGF-II and insulin can produce the same 
biological responses, and because many cells possess IGF-I, IGF-II as well 
as insulin receptors, it has been difficult to determine which receptor is 
mediating a particular response (40). 
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Attempts to assess the relative contributions of these three receptors to an 
observed biologic response have included 1] determination of the receptors 
present on a cell type and the binding affinities for these three ligands, 
2] determination of the biological dose response to IGF-I, IGF-II and Insulin and 3] 
selective blockade of IGF-I or insulin receptors with specific antireceptor antibodies 
without intrinsic biological effects (40). These investigations have yielded the insight 
that insulin and the IGFs are complementary hormones in their anabolic action: 
insulin and the insulin receptors are especially involved in the regulation of the 
short term fluctuations of major metabolites such as glucose, amino acids and free 
fatty acids. The IGFs and the IGF-I receptor are especially involved in the regulation 
of the long term processes which are responsible for cell growth and differentiation 
(41). 
In some tissues and cells expressing high numbers of both IGF-I and insulin 
receptors, hybrids may form (11). These hybrids are tetrameric receptors consisting 
of an a-f3 heterodimer of the insulin receptor linked by disulfide bonds to a-f3 
heterodimer of the IGF-I receptor. A possible role for these hybrid receptors is that 
they might mediate overlapping functions in which insulin, under certain 
circumstances, may induce cellular proliferation and IGF-I may stimulate metabolic 
functions (11). 
I! is assumed that most of the biological effects of IGF-II are mediated through the 
IGF-I receptor (42). However, IGF-I-mediated intracellular signaling has at present 
only been demonstrated for the IGF-I receptor (also called the type 1 IGF-I 
receptor) (20). 
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The insulin-like growth factor binding proteins (IGFBPs). 
The IGFBPs are a family of proteins that non-covalently bind IGF-I and IGF-Ii with 
high affinity (dissociation constants in the order of magnitude 10-11 moilL) and 
specificity (Table 2) (43, 44). To date at least six IGFBPS have been identified (20, 
33). They have a high degree of sequence homology (44) and are numbered 1 to 
6 in the order in which their primary structure was determined (45)(Figure 3). The 
IGFBPs have been proposed to have four major functions that are essential to 
coordinate and regulate the biological activities of the IGF-I: lJ to act as transport 
proteins in plasma and to control the efflux of IGF-I and IGF-Ii from the vascular 
space; 2J to prolong the half-life of IGF-I and IGF-Ii and thereby regulating its 
metabolic clearance; 3J to provide a means of tissue- and cell-type specific 
localization; 4J to directly modulate interaction between IGF-I and the IGF-I 
receptor, thereby indirectly controlling its biological actions (20). IGFBPs not only 
regulate the bioavailability of IGF-I but also seem to have their own receptors, 
which mediate IGF-I- independent actions (33). IGFBPs are produced by a variety 
of different tissues, each of which contain specific levels of these IGFBPs (33). 
The cleavage of IGFBPs by IGFBP-protease plays a key role in modulating free 
IGF-I and IGFBP levels and actions by two mechanisms: lJ IGFBP binding to IGFs 
decrease the concentration of free IGF-I available to interact with the IGF-I receptor, 
2J cleavage of the IGFBPs into fragments with lower affinity to IGF-I allows for 
increased receptor activation (33). In various biological systems the IGFBPs have 
been shown to inhibit or potentiate IGF-I action (41). 
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IGFBP-l and IGFBP-3 are discussed more extensively, because the role of the four 
other binding proteins is less well established at present. IGFBP-l is a 25 Kd 
protein and found in high concentrations in amniotic fluid (32). IGFBP-l is secreted 
by hepatocytes, kidney, decidua and endometrium (33). The half-life in plasma is 
approximately 90 minutes (46). IGFBP-l has been proposed as an acute regulator 
of IGF-I activity (47). Insulin is a major regulator of hepatic IGFBP-l production 
(33): plasma IGFBP-l levels are inversely related to insulin levels in vivo (48). 
IGFBP-l exists in different forms (phosphorylated and non-phosphorylated) (49). 
Non-phosphorylated IGFBP-l has a 4- to 6-fold lower affinity to IGF-I than 
phosphorylated IGFBP-l (49). This would favor sequestration of IGF-I by 
phosphorylated IGFBP-l and a more complete release of IGF-I to the IGF-I 
receptor by the non-phosphorylated form. Most studies have shown inhibition of 
IGF-I activity by IGFP-l (20). The IGFBP-l form which potentiates IGF-I activity is 
non-phosphorylated, has a lower affinity and is able to associate with the cell 
surface (50). IGFBP-l stimulates cell migration by itself (51). The stimulus appears 
to be the binding of IGFBP-l to an integrin on the cell surface, initiating an 
intracellular pathway which involves a series of kinases (45). 
Quantitatively the most important IGFBP in the circulation is IGFBP-3 (52). The 150 
kD complex consists of IGF-I (or IGF-II) , IGFBP-3, and an acid-labile subunit (ALS) 
that is glycosylated and does not bind IGF-I (53). The ALS is present in excess in 
human plasma and is growth hormone dependent (53, 54). IGFBP-3 is secreted by 
hepatocytes and many other cells. About 75-95 % of IGF-I in the circulation is 
carried in the 150 kD IGF-I-IGFBP3- complex (20, 33) (see figure 2). It is considered 
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Table 2, Biochemical properties of human IGFBPs (modified after references 20, 44) 
IGFBP-1 IGFBP-2 IGFBP-3 IGFBP-4 IGFBP-5 
Amino acids 259 289 264 237 252 
Cystine residues 18 18 18 18 18 
Mr(kDa) 28.1 31.3 28.7 26.3 28.6 
Phosphorylation + + + 
Glycosylation + + 
IGF-I/IGF-II preference 1>11 1<11 1,,11 1=11 1<11 
Chromosome 7 2 7 17 5 
as a reservoir for IGF-I in the circulation: The 150 kD complex cannot cross the 
endothelial barrier of the blood vessels (52). This is considered critical for avoiding 
potential hypoglycemic insulin-like effects of the high concentrations of IGF-I which 
are present in plasma (52)_ The binding of IGF-I within the the 150 kD complex 
extends its half life time in the plasma from 10 minutes in the free form to 12 to 15 
hours if bound in the complex form (55). 
The expression of the gene for IGFBP-3 is Increased by p53, the well characterized 
product of a tumor suppressor gene, which is considered important in the inhibition 
of tumor formation (56). Recently it has been demonstrated that p53 increases 
IGFBP-3 production by cells and that the IGFBP-3 produced in response to p53 is 
able to inhibit IGF-I induced growth of cells (56). IGFBP-3 thus appears one of 
those proteins which mediate the effects of p53 on cell growth, possibly by 
apoptosis. 
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Relations between IGF-I, IGFBPs, growth hormone and insulin. 
Figure 4 
The relations between IGF·I, IGFBPs, growth hormone and insulin{from: Bondy 
CA. Clinical uses of insulin-like growth factor-I. Ann Intern Med 1994; 120: 594; 
with permission from the American College of Physicians) 
Growth hormone (GH) and insulin both stimulate hepatic IGF-I production, and 
IGF-I feeds back to suppress GH and insulin release. IGFBP-3 and the 
associated acid-labile subunit (ALS) are positively regulated by GH, whereas 
IGFBP-1 levels are negatively regulated by insulin (40) (Figure 4). 
IGF-I and age 
Age is a major determinant of plasma IGF-I concentrations (57). Serum levels of 
IGF-I increase significantly from very low levels in cord serum through the first 
9 months of life, whereafter there is an almost linear increase from early 
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90 
Serum IGF·I levels (vertical axis) according to age (horizontal axis) throughout 
life in a healthy population (n=1236 subjects). Note the peak at puberty and 
the wide range of IGF·I levels at each age (from Juul A. Serum levels of IGF·I 
and IGFBp·3 in healthy children, adolescents and adults. Methodological 
aspects and definition of reference values with special emphasis on puberty 
(Ph D Thesis, University of Copenhagen, 1995; with permission of 
NovoNordisk, Denmark) 
childhood into adolescence (Figure 5) (58). After puberty, a 2.5·fold decrease 
occurs in the mean IGF·I values by the third decade, and a further twofold 
decrease occurs between the third and eights decade (57). Part of this decrement 
is believed to be due to the known age·related decrease in GH secretion (57). Very 
little is known on the effects and clinical consequences of the decrease of the GH· 
IGF·I system during aging. 
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IGF-I and diabetes 
Many patients with insulin-dependent diabetes mellitus type 1 have some degree of 
growth hormone resistance, as shown by lowered circulating IGF-I levels, despite 
increased GH concentrations (59-61). They lack the ability to produce an 
appropriate increase in IGF-I response to exogenous GH. This functional 
refractoriness to GH is also seen during starvation and may be due to lowered 
portal vein insulin concentrations, insufficient to stimulate normal hepatic IGF-I 
synthesis (40). Treatment with subcutaneous insulin injections may not normalize 
all liver functions, such as IGF-I synthesis, which mainly depends on the presence 
of high portal insulin levels (40). In addition, increased growth hormone levels 
exacerbate hyperglycemia and low IGF-I levels may also contribute to deficient 
glucose metabolism and hyperglycemia (40). 
Hyperglycemia is considered as an important pathogenetic factor for the 
development of diabetic micro- and macrovascular complications (62). The DCCT-
trial has suggested that treatment of type I diabetic patients that does not result in 
normoglycemia will not prevent the development and progression of diabetic 
complications. Moreover, it has been reported in an animal model of diabetes that 
glucose levels playa major role in the regulation of IGF-I receptor mRNA (63)_ After 
hyperglycemia an increase in IGF-I receptor mRNA was observed, which was 
reversible by normoglycemia, even after long-standing hyperglycemia. 
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Aim of the thesis 
The aim of this thesis was to investigate the (patho)physiologic role of the 
IGF-I/IGFBP system in adult subjects in health and disease under several 
conditions like aging, GH deficiency, acromegaly, diabetes mellitus and congenital 
partial lipodystrophy_ 
The thesis consists out of four parts (I, II, III, IV): 
In part I (Chapter 2), we have investigated the relationship between the IGF-I/IGFBP 
system and blood cells in healthy subjects. Is it possible to measure IGF-I 
receptors on blood cells in vitro and what is the (clinical) importance of this assay. 
We studied especially the following questions: do IGF-I receptors on peripheral 
blood cells reflect what happens with the IGF-I receptors on other IGF-I target cells 
elsewhere in the body and what are the relationships and effects of (free and total) 
IGF-I and the IGFBPs on IGF-I receptor characteristics? 
In part II (Chapter 3) we have investigated the relationships between the 
IGF-I/IGFBP system and age, sex steroids, cardiovascular diseases, bone mineral 
density and quality of health in a healthy elderly population. Other questions 
studied were: what is the potential significance of measuring serum free IGF-I levels 
and does the measurement of serum free IGF-I levels give additional and/or other 
information than the total IGF-I assay? 
In part '" (Chapter 4) the potential role of the IGF-I/IGFBP system in disorders of 
GH secretion (GH deficiency, acromegaly) were investigated. We have the studied 
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the following questions: Whom is to be tested and how to diagnose growth 
hormone deficiency in adults? Which components of the circulating IGF-I/IGFBP 
system can be used for this purpose? Do serum IGFBP-3 and/or free IGF-I levels 
reflect the clinical activity in acromegaly better than serum total IGF-I levels? 
In part IV (Chapter 5) we have focused on the relationship between the IGF-I/IGFBP 
system, age and the presence of diabetic microvascular complications in insulin-
dependent diabetes mellitus (100M) type I. 
In this Chapter we have also studied the relationships between the IGF-I/IGFBP 
system and the IGF-I receptors on peripheral blood cells in patients with congenital 
partial lipodystrophy in order to study the role of the IGF-I/IGFBP system in the 
development of this syndrome which is characterized among other things by 
severe insulin resistance, hyperinsulinemia and acromegaloid features. 
Finally, conclusions and the general discussion are presented in Chapter 6. 
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§ 2.1 Introduction: The role of IGF-I and IGFBPs in blood cells under 
physiologic and experimental circumstances. 
IGF-I has been implicaled as a hematopoietic regulatory cytokine as it has growth-
promoting effects on a range of hematopoietic precursor cells. IGF-I enhances the 
growth of erythroid and granulocytic cells in vitro, but does not substitute the 
requirement for erythropoietin or granulocyte colony-stimulating factor (1-7). IGF-I 
increases thymocyte cell content and the size of the thymus size (8). Geffner et al. 
showed that locally generated IGF-I stimulates the growth of T-Iymphoblasts after 
previous growth hormone stimulation, an effect which is mediated via the IGF-I 
receptor (9). These in vitro results were heralded by the obseNation that the 
stimulating effect of serum on the proliferation of PBMCs is increased in 
acromegalics and decreased in pituitary dwarfs (10). IGF-I may be involved in 
lymphocyte transformation and appears to be important for the process of 
lymphocyte proliferation. Mitogen-activated lymphocytes bear cell surface IGF-I 
receptors, which are only minimally expressed on quiescent lymphocytes (11-14). 
Nanomolar concentrations of IGF-I have been found to enhance anabolic 
processes or DNA synthesis in activated lymphocytes (10, 15, 16). IGF-I can 
partially substitute for serum in milogen-induced T-cell proliferation (10). 
Moreover, IGF-I may stimulate chemotaxis of T-Iymphocytes (17) and cytotoxic 
T cell function in vitro can be potentiated by IGF-I (18). Immunosuppressive effects 
of IGF-I have also been demonstrated in vitro (19). These divergent findings can at 
least be partly explained by the used culture methods in which the inclusion of 
serum with its high content of IGF-I and IGFBP- binding proteins was a 
confounding factor (20). In the absence of serum and phytohaemagglutin (PHA), 
IGF-I has also been demonstrated to stimulate [3Hl thymidine incorporation into 
mononuclear cells (21) and to enhance immunoglobulin production and 
proliferation of plasma cells (22). 
However, the in vitro actions of IGF-I and the IGFBPs on blood cells are very 
complex: IGF-I has been found to be a potent signal for priming human 
polymorphonuclear neutrophils to secrete superoxide anion (23). IGF-I acting via 
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the IGF-I receptor is able to potentiate the release of histamine from basophils in 
response to immunoglobulin E (24). 
Growth factors are believed to play an important role in the regulation of blood cell 
apoptosis, i.e. programmed cell death (25). In human erythroid progenitor cells, 
DNA breakdown from apoptosis due to serum deprivation is prevented by IGF-I 
(26). Apoptosis in an IL-3-dependent cell line of murine pre-B lymphocytes is 
inhibited by IGF-I (27). Overexpression of recombinant IGF-I receptors relieves 
hematopoietic cells of their dependency on IL-3 for their growth and survival (28). 
All these observations support the hypothesis that the inhibition of apoptosis in 
hematopoietic cells is mediated by the IGF-I receptor (28). IGF-I can thus influence 
both cell viability as well as the proliferation of hematopoietic cells. Inhibition of 
apoptosis in hematopoietic cells by IGF-I may help to expand a cell population 
which normally is destined to die (29). 
Finally, human peripheral lymphocytes are not only potential target cells for 
IGF-I action, but are also a potential source of IGF-I and the IGFBPs in human 
serum (30). Stimulation of lymphocytes can affect the expression of IGF-I 
receptors, the production of IGF-I as well as of IGFBPs (30). Furthermore, human 
macrophages and rat leukocytes have also been reported to produce IGF-I (31, 
32). 
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§ 2.2. The IGF·I receptor on human blood cells: theoretical background. 
Studies of adipocytes, muscle, and liver cells in vitro are unsuitable for the 
assessment of IGF-I receptors in a large number of subjects or for a repeated rapid 
evaluation of the characteristics of IGF-I receptors within the same individual. Blood 
cells offer a feasible alternative for this dilemma but this choice has also some 
disadvantages and shortcomings. Which type(s) of blood cell is (are) the most 
appropriate one(s) to use in an IGF-I receptor study? Do blood cells represent 
pathophysiological IGF-I receptor states in other target tissues? The study of IGF-I 
receptors resembles in this respect in many aspects the study of insulin receptors 
(1 ). 
Circulating mononuclear cells can be divided into monocytes and 
lymphocytes. Most mononuclear cells make only a brief appearance in the blood 
stream on their way from the bone marrow to the tissues. Under normal conditions 
blood monocytes leave the blood stream with a half time of 4.5 to 10 hours (2, 3). 
In some disease states alterations in monocyte kinetics have been observed. For 
B-Iymphocytes the transit time in the blood is less than 30 minutes (4). 
T-Lymphocytes have the property of migrating continuously between the 
circulation and the lymphatiC system. For the IGF-I receptor, differences in the 
number and Kd of T-cells, B-Cells, natural killer cells and monocytes have been 
described (5-8). 
In contrast, different age groups of red cells from a single individual 
demonstrate distinctly different degrees of IGF-I binding capacity. It has been found 
that mature erythrocytes possess only 15% of the number of IGF-I binding sites of 
reticulocytes (6). Erythrocytes lack the capacity to synthesize new receptors and 
are thus unable to renew IGF-I receptors lost during their aging process. 
Consequently, the majority of detectable IGF-I receptors per cell type is probably 
present on reticulocytes and other young red blood cells (9). 
Hematological disorders that alter the normal erythrocyte half life of 60 days may in 
theory significantly affect IGF-I binding on this cell population (10). Many factors, 
including previous phlebotomy, as well as various hemolytic and other diseases 
39 
Chapter 2 
may affect the reticulocyte percentage and the mean erythrocyte age (6). Such 
confounding factors complicate the interpretation of IGF-I binding studies involving 
erythrocytes. However, some authors find this phenomenon unlikely, since they did 
not observe a correlation between IGF·I binding to erythrocytes and the number of 
reticulocytes (11). 
IGF·I receptors are subject to down· regulation in the same manner as many 
other peptide hormone receptors, and expression of the IGF·I receptor gene 
inversely relates to serum levels of IGF·I (12, 13). No results of studies have been 
published sofar, in which in various clinical conditions the number and Kd of the 
IGF·I receptor on blood cells were compared to those on other important target 
organs for IGF·I. However, it has been found that defects of insulin binding on 
erythrocytes, which are not metabolically important targets for insulin action, 
correspond to defects of insulin binding on liver receptors in vivo (14). Since the 
insulin and IGF·I receptor are structurally similar, it suggests that the same 
relationship may exist for the IGF·I receptor. 
The characteristics of insulin receptors in both mononuclear and erythrocytes have 
been repeatedly investigated in various clinical conditions (6). Significant 
correlations were observed between specific insulin binding to both cell types for a 
large number of subjects under a variety of physiological and pathological 
conditions, while the total number of binding sites and the affinity of the insulin 
receptor did not correlate between both cell types. In general, insulin binding to 
red blood cells changed more slowly after a change in the metabolic status than in 
monocytes (6). 
Although there are no data available concerning the IGF·I receptor status on 
mononuclear cells and erythrocytes under different clinical situations, it seems very 
likely that similar to the findings for the insulin receptor (6), IGF·I receptors on red 
cells primarily reflect the chronic IGF·I receptor status, wheras IGF-I receptors on 
mononuclear cells reflect adaptation to the most recent metabolic changes. 
Beck-Nielsen and Pedersen have found a diurnal variation for insulin binding 
to peripheral monocytes in healthy subjects, with a nadir at 1400 h and a peak at 
2200 h (15). As fasting abolished these diurnal variations, this pattern seems likely 
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to be influenced by the diet. At present there are no data available whether IGF-I 
binding to peripheral blood cells also shows a diurnal rhythm. 
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Summary 
We have studied the relationships between the IGF-I/IGFBP system and the IGF-I 
receptor characteristics on erythrocytes and PBMCs in healthy subjects in the 
fasting state to establish whether this would be a valid way of examining IGF-I 
receptors in vivo. The Kd of the IGF-I receptor on erythrocytes was positively 
related to circulating free IGF-I levels. For the IGF-I receptor on PBMCs no relation 
was observed with free IGF-I levels. 
IGFBP-3 levels were inversely related to the number of IGF-I binding sites on 
erythrocytes and to the Kd of the IGF-I receptor on PBMCs. TotaIIGF-I, insulin and 
IGFBP-l levels showed no relation to the IGF-I receptor on erythrocytes and 
PBMCs in the fasting state. Our report suggests that studies of IGF-I receptor 
characteristics on erythrocytes and PBMCs in the fasting state are cell specific and 
cannot cannot be extrapolated to other cell types, which may be more relevant 
target tissues for IGF-I action in vivo. 
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Introduction 
Insulin-like growth factor I (IGF-I) binds to high-affinity receptors which are 
expressed in a variety of cell types and tissues. In addition, IGF-I is capable of 
binding to the insulin receptor (l).The overlapping biological effects of IGF-I and 
insulin were initially ai1ributed to the structural homologies between the peptides 
themselves, but subsequently it was shown that the receptors for insulin and IGF-I 
also have structurally similarities (2). Insulin and IGF-I receptors are both plasma 
membrane glycoproteins composed of two alpha and two beta subunits. The 
extracellular alpha subunit contains the ligand-binding domain, whereas the beta 
subunit contains the transmembrane anchoring domain as well as the putative 
tyrosine kinase activity (3). 
In previous investigations significant correlations were found between insulin 
binding to insulin receptors on both peripheral blood mononuclear cells (PBMCs) 
and on erythrocytes in large numbers of subjects under a variety of physiological 
and pathological conditions (4). 
Although there is considerable homology between IGF-I and insulin, and 
between the IGF-I and insulin receptor, insulin·like growth factor binding proteins 
(IGFBPs) form an important difference between these systems (5). IGFBPs are 
exclusively able to bind IGF-I but not insulin. Therefore they are considered as 
important modulators of IGF-I action. Previous studies demonstrated the presence 
of IGF-I receptors on both erythrocytes and PBMCs (6, 7). 
We report here the results of simultaneously performed studies of IGF-I 
receptor characteristics on erythrocytes and PBMCs in healthy volunteers under 
fasting conditions. Their relation with the circulating IGF-I/IGFBP system and 
insulin was investigated in parallel to establish whether the study of the IGF-I 
receptor on these cells can be used to get an impression of IGF-I actions on more 
important target tissues for IGF-I in vivo. 
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The study was performed according to the rules of the hospital medical ethics 
committee. Healthy human volunteers entered the study after informed consent. 
Twenty-one subjects (aged 23-47 yr) were investigated after an overnight fast. 
Blood was drawn from these subjects between 8.00-9.00 am. 
Cells 
Human erythrocytes were isolated from freshly obtained heparinized blood. 
Cell separation was performed by density centrifugation on Ficoll-Paque 
(Pharmacia, Uppsala, Sweden) at 400 G for 30 min at room temperature. The 
interphase containing the mononuclear cells and granulocytes was collected and 
prepared as described below. The pellet containing the erythrocytes was 
resuspended in 0.9 % saline and centrifuged again on Ficoll-Paque under the same 
conditions. Erythrocytes were recovered from the pellet after the second 
centrifugation, and washed with two volumes ice·cold assay buffer (For 
composition see Peptides and Medium). Next the erythrocytes were centrifuged at 
400 G for 10 min at 4 "C. After this centrifugation step the erythrocytes were 
resuspended in ice-cold assay buffer (two volumes cells, one volume assay buffer). 
This resulted in all experiments in a cell concentration above 5 x 10· celis/mL. The 
remaining part of the IGF-I receptor assay was performed at 4 "C. The number of 
cells was determined with the aid of an electronic cell counter model AD-260 
(Sysmex, Kobe, Japan). 
Human PBMCs were isolated from the same freshly taken heparinized blood 
sample. Isolation was performed by density centrifugation on Ficoll-Paque, as 
described above. Centrifugation on Ficoll-Paque yields an interface of PBMCs in 
which 95 +/- 5 % are mononuclear lymphocytes. PBMCs were recovered from the 
Ficoll medium interface, washed twice with 0.9% saline and after each washing, 
centrifuged during 5 minutes at 670 G at room temperature. The PBMCs were 
resuspended in 1,75 mL assay, which resulted in cell concentrations above 15 x 
10'/mL. The number of cells per ml was counted with the aid of a 
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hematocytometer. After resuspension in assay buffer cells were kept at 4 • C. 
Peptides and Medium 
3-[' 25ljiodotyrosyl-IGF-1 was purchased from Amersham International Inc. 
(Amersham, Buckinghamshire, United Kingdom) and used as radioligand in the 
competitive IGF-I receptor assay. The radiolabeled IGF-I had a specific activity of 
2,000 Ci/mmol. Competitive binding studies were performed with 0.05 nM '25 1_ 
labeled hIGF-1 and increasing concentrations of unlabeled purified human 
recombinant IGF-I (hIGF-I), IGF-II (hIGF-II) and insulin. hIGF-1 and hlGF-li were 
purchased from Saxon Biochemicals GmBH (Hannover, Germany). Human 
recombinant insulin was purchased from Novo Nordisk (Bagsvaerd, Denmark). 
The monoclonal anti-IGF-I receptor antibody (lgG), clone a-IR3 was purchased 
from Oncogene Science (Uniondale, NY, USA). 
The assay buffer in the IGF-I receptor assay consisted of 50 mM Hepes, 50 mM 
Tris,10 mM dextrose, 50 mM MgS04 , 2 mM EDTA, 10 mM CaCl" 45 mM NaCl, 4.5 
mM KCI, and 0.1 % BSA (6). The pH of the assay buffer was adjusted to 8.0 at 
room temperature. The experiments were performed at a pH of 8.0 since it has 
been found in previous experiments that there is optimal binding of insulin to 
erythrocytes at this pH (8). Moreover, Hizuka et at. have demonstrated that binding 
of [12'_lj IGF-I to cells did not change in the pH range between 7.0 and 8.0 (9). In 
order to reduce of the non-specific binding bacitracin was added in a 
concentration of 2 mg/ml to the incubation medium (10). 
Competitive IGF-I receptor assay 
Competitive binding studies were carried out in Eppendorf tubes. For the IGF-I 
receptor assay the methods described by Hizuka et at. (9) and Izumi et at. (6) were 
used with three modifications: The final incubation volume was decreased to 250 
III for measurement of IGF-I binding to erythrocytes, and to 100 III for 
measurement of IGF-I binding to PBMCs. Secondly, bacitracin was added to the 
assay buffer. Thirdly, after 20 h incubation bound and unbound ligand were 
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Erythrocytes: In a final volume of 250 Jil erythrocytes ( > 1.0 x 109 , ml final 
concentration) or 100 Jil PBMCs (> 15 x 10·'ml), were incubated with 1251-IGF-1 
(10-30.000 cpm) in assay buffer and in the absence or presence of increasing 
concentrations of unlabeled hIGF-I, hIGF-II, and insulin at 4 'C for 20 h. Each 
experiment was performed in duplicate. For the competition studies, added 
unlabeled concentrations of hIGF-1 and hIGF-1i ranged from 10-11 to 10-7 M, while 
insulin was added in concentrations ranging from 10-11 to 104 M. 
After 20 h incubation, bound and unbound radioligand were separated by three 
washing steps with saline at 4 'C. In each washing step, the cells were centrifuged 
at 10.000 G during 2 minutes and the supernatant was removed. After the third 
centrifugation step the cell-bound radioactivity was measured in a gamma counter. 
Non-specific binding was defined as the amount of radioligand bound in the 
presence of excess of unlabeled IGF-I (10-7 M). Specific binding of 1251_IGF_1 was 
determined by subtracting the amount of radioactivity bound in the presence of 
excess of unlabeled IGF-I (1O-7M). 
In the experiments with the anti-IGF-I receptor antibody a1R-3 competitive binding 
studies were carried out after preincubation of the cell suspensions during 3 h with 
a1R-3 (final concentration 1Jig IgG,!100 Jil). Gelatine was added to the control 
tubes, because the solution provided by the manufacturer contained 0.2 % (w/V) 
gelatine. After 3 h preincubation the cell suspensions were incubated with 
1125111_ IGF-I and unlabeled IGF-I and the rest of the IGF-I receptor assay was 
performed as described above. 
The binding data were analyzed according to the method of Scatchard (11). The 
number of binding sites is expressed as sites per cell. The dissociation constant 
(Kd) is given in nmol/L. 
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Hormone assays 
Blood samples were taken by venipuncture simultaneously with the IGF-I receptor 
study, and was allowed to coagulate for 60 minutes. All subjects were fasting . 
Subsequently, serum was separated by centrifugation and quickly frozen to -20 DC. 
Free IGF-I was measured with a commercially available two-site 
immunoradiometric assay (Diagnostic System Laboratories Inc., Webster, Texas, 
U.S.A.; intra-assay and inter-assay C.V.: 10.3% and 10.7%, respectively) (12). 
Estimation of free IGF-I typically involves size-exclusion extraction followed by a 
displacement immunoassay. Sample matrix alterations with consequent 
disturbance of the free/bound equilibrium is an inevitable consequence. The used 
free IGF-I assay needs initially no sample extraction as part of the standard 
procedure to measure IGF-1. Samples are added directly to tubes containing a 
dense coating of high-affinity free IGF-I antibody, incubated at 2 hr at room 
temperature, washed, incubated with 1251 labeled antibody directed to a second 
epitope, washed and counted. Assay standards are rhIGF-I: 0.04-2.6 nmol/L, the 
minimal detection limit is 3.9 x 1 O~ nmol/tube. There is no cross-reactivity with 
IGF-II and no residual IGFBP-1 or IGFBP-3 is detectable after the first wash. It is 
likely that the free IGF-I fraction measured with the free IGF-I assay represents a 
combination of the true free and the fraction of IGF-I which can be readily 
dissociated from IGFBPs under the specific assay conditions (12). Total IGF-I was 
determined by a commercially available radioimmunoassay (Medgenix Diagnostics, 
Brussels, Belgium, intraassay and interassay coefficients of variation (C.V.): 6.1%; 
9.9%) after the acid/ethanol extraction method, originally described by Daughaday 
et al.(13).The purpose of this step is to convert the different forms of IGF-I present 
into free IGF-1. Commercially available immunoradiometric assays were also used 
for measurement of IGFBP-1, and IGFBP-3 (Diagnostic System Laboratories Inc., 
Webster, Texas, U.S.A.; intraassay and interassay C.v. for IGFBP-1: 4.0% and 
6.0%, respectively; and for IGFBP-3: 1.8 % and 1.9%, respectively). Insulin was 
determined by a commercially available radioimmunoassay (Medgenix Diagnostics, 
Brussels, Belgium, intraassay and interassay C.V.: 8.0%; 13.7%). 
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Statistical Analysis 
Results are expressed as the mean +/- SEM. Pearson's correlation coefficients 
were calculated to assess the association between variables. A two-sided p value 
of < 0.05 was considered significant. 
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Scatchard analyses of 12'I-IGF-1 binding to human erythrocytes (left) and PBMCs 
(right) show both a linear plot. 
[HJ = concentration of Free IGF-I 
[HRJ = concentration of Bound IGF-I receptor complex 
[HRJ/[HJ = Bound/Free ratio 
The showed linear regression analysis is the mean of one experiment, done in 
duplicate 
Results 
'''I-IGF-I specifically bound to both human erythrocytes and PBMCs and the 
binding linearly increased for both cell types as a function of the number of cells 
(data not shown). Scatchard analyses for IGF-I binding to erythrocytes and PBMCs, 
respectively, showed a linear plot (Figure 1). 
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Specificity of the IGF·I receptor assay was established as follows: 1] unlabeled 
IGF·I, unlabeled IGF·II, and unlabeled insulin were able to displace 125HGF·1 to 
erythrocytes and PBMCs, although with striking differences of more than 100·fold 
between IGF·I and insulin in affinity (Figure 2). Binding of 12'I·IGF·1 to erythrocytes 
and PBMCs was inhibited by the unlabeled peptides in the following order of 
potency: IGF·I>IGF·II»>insulin (Figure 2). 2]After preincubation with a1R·3 
(a specific antHGF·1 receptor antibody) the specific binding of 1251·IGF·1 in the IGF·I 
receptor assay was totally lost (Figure 3). 
Table 1 shows the results of the characteristics of the IGF·I receptor on 
erythrocytes and PBMCs, respectively, as well as the circulating hormone levels. 
The number of IGF·I binding sites was closely positively related to the Kd of the 
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Competition of IGF·I tracer binding by unlabeled IGF·I, IGF·II and insulin. 
Left: Erythrocytes (± 5 x 10 9 per mL) were incubated with tracer plus the 
-+-IGF-I 
-0- JGF-lI 
.... ·rnsu~n 
indicated hormone concentrations at 4 °C for 20 hours. The percentage 1251·IGF·1 
specific bound is plotted as function of the unlabeled concentration. Data are the 
means of one experiment, done in duplicate. 
Right: PBMCs (± 15 x 10 6 per mL) were incubated with tracer plus the indicated 
hormone concentrations at 4 °C for 20 hours. The percentage 125HGF·1 specific 
bound is plotted as function of the unlabeled concentration. Data are the means of 
one experiment, done in duplicate. 
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IGF-I receptor on both erythrocytes and PBMCs in the fasting state (in all cases p 
:5 O.OOI)(Table 2). The Kds of the IGF-I receptor on erythrocytes and PBMCs, and 
the numbers of the IGF-I receptor on erythrocytes and PBMCs, respectively, were 
closely correlated (Kds: p=0.009, numbers: p=0.04)(Table 2). 
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Figure 3 
Effect of preincubation with a-IR-3 (final concentration l/1g IgG, /100/11) on 
competitive IGF-I binding assay of human PBMCs. The percentage ' 25I-IGF-1 
specific bound to PBMCs is plotted as function of the unlabeled IGF-I 
concentration. Solid line: competitive IGF-I binding assay without preincubation 
with a-IR-3. Broken line: competitive IGF-I binding assay with preincubation with 
a-IR-3.0ata are the means of one experiment, done in duplicate. 
IGF-I receptor on both erythrocytes and PBMCs in the fasting state (in all cases p 
:5 0.001 )(Table 2). The Kds of the IGF-I receptor on erythrocytes and PBMCs, and 
the numbers of the IGF-I receptor on erythrocytes and PBMCs, respectively, were 
closely correlated ( Kds: p=0.009 , numbers: p=0.04)(Table 2). 
Free IGF-I was positively related to the Kd of the IGF-I receptor on erythrocytes in 
the fasting state (p=0.03), while no significant correlation was found with the 
52 
IGF-I, IGFBPs and Blood Cells 
Table 1. Characteristics of IGF-I binding to Erythrocytes and PBMCs, circulating IGF-I and IGFBPs, 
and insulin In healthy volunteers in the fasting state. 
Age subjects (years) 
EMhroc~es 
No of specific IGF-I binding sites/ceil 
Kd (nM) 
PBMCs 
No of specific IGF-I binding sites/cell 
Kd (nM) 
TotalIGF-1 (nmol/l) 
Free IGF-I (nmol/l) 
IGFBP-l (nmol/l) 
IGFBP-3 (nmol/l) 
Insulin (mU/l) 
* For used abbreviations, see text 
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Relation between the Kd of the IGF-I receptor on erythrocytes (vertical axis) and 
serum free IGF-I levels (horizontal axis)( left) and relation between IGF-I binding 
sites per erythrocyte (vertical axis) and serum free IGF-I levels (nmol/L) (horizontal 
axis)(right), both in 21 healthy volunteers and in the fasting state. 
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r=-O.46, N:::21 
p=O.038 
Relation between serum IGFBP-3 levels and number of IGF-I binding sites on 
erythrocytes (left) and relation between serum IGFBP-3 levels and the Kd of the 
IGF-I receptor on PBMCs (right). 
number of receptors (Table 2, and Figure 4). IGFBP-3 was inversely related to the 
number of IGF-I binding sites on erythrocytes (p=O.02) and to the Kd of the IGF-I 
receptor on PBMCs (p=O.04) (Table 2 and Figure 5). The relation between free 
IGF-I levels and the Kd of the IGF-I receptor on erythrocytes in the fasting state, 
remained significant after adjustment for IGFBP-3 levels using multivariate analyses, 
and this relation became even stronger. No relations were observed between total 
IGF-I, IGFBP-1, and insulin, respectively, and the number or the Kd of the IGF-I 
receptor on erythrocytes and PBMCs (Table 2) 
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Table 2. Pearson's correlation coefficients between the circulating IGF-I!1GFBP system, insulin, and the IGF-I receptor on erythrocytes and PBMCs in the 
fasting state (21 subjects) 
Erythrocytes PBMCs 
IGF·I IGF-I IGF-I IGF·I 
Total Free IGFBp·1 IGFBp·3 Receptor Receptor Receptor Receptor 
IGF·I IGF·I Binding Kd Binding Kd 
Sites Sites 
Free IGF·I 0.56 § 
IGFBP·1 -0.54 * ·0.31 
IGFBP-3 0.67§ 0.33 ·0.36 
E!y!hro9:1es 
Binding sites -0.02 0.08 0.12 -0.51 * 
Kd 0.21 0.46 * 0.05 -0.32 0.78 # 
PBMCs 
Binding sites -0.03 -0.15 -0.02 ·0.35 0.38 * 0.23 
Kd -0.03 0.12 ·0.13 -0.46 * 0.60 § 0.55 § 0.74# 
Insulin -0.17 0.06 -0.44 * ·0.26 0.04 0.11 0.07 0.24 
* p<0.05, § p<0.01, # p<0.001 
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Discussion 
We have studied whether the characteristics of the IGF-I receptor on erythrocytes 
and PBMCs can be used to investigate the relation between the circulating IGF-I 
and IGFBP levels and the IGF-I receptor characteristics in the fasting state and so 
to get an impression of IGF-I actions on more important target tissues for IGF-I in 
vivo. The methods to measure IGF-I characteristics on blood cells described by by 
Izumi et a/. (6) and by Hizuka et a/. (9) were used for this purpose with a few 
modifications: the volume of the incubation medium was reduced in order to 
reduce the amount of blood and materials needed for each assay, and bacitracin 
at a concentration of 2 mg/mL was added to reduce non-specific binding without 
altering receptor affinity. Thirdly, after 20 h incubation bound and unbound ligand 
were separated by three washing steps with saline in stead of separation with 
dibutylphthalate as described in the original method. 
For both PBMCs as well as erythrocytes, 10% to 90% of the competition of cold 
IGF-I against 1251_IGF_1 occurred over a concentration range of competitor spanning 
two orders of magnitude (see Figure 2). This is the typical result for a simple 
competitive interaction of an unlabeled and labeled ligand for a single class of 
sites. Moreover, for both PBMCs and erythrocytes linear Scatchard plots were 
found in the concentration range of 10'" to 10-9 M IGF-I, which can be considered 
as the physiological range of (free) circulating IGF-I levels (see below). 
We observed a comparable number of IGF-I receptors on erythrocytes in normal 
individuals as has been reported before (6, 9, 10, 14, 15). These previous studies 
reported numbers of high affinity IGF-I receptors on erythrocytes varying between 
2 and 58 sites per cell in the fasting state. The Kd measured for erythrocytes in the 
fasting state was also similar to the values reported by Izumi et al and Hizuka et a/. 
(6, 9). In previous studies, also using competitive binding assays to measure IGF-I 
receptors, the number of high affinity IGF-I receptors on PBMCs varied between 45 
and 4,500 sites per cell (16, 17, 18). The number of IGF-I binding sites and the Kd 
per PBMC, observed in our experiments, were in the same range. 
Measuring free IGF-I levels in serum, may have phYSiological relevance because it 
theoretically represents the biologically active fraction (19). We found in this group 
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of healthy individuals, mean levels of 0.145 (range 0.034-0.257) nmol/L in the 
fasting state. In the past a significant inverse correlation has been demonstrated in 
non-healthy subjects between plasma total IGF-I levels and the number of IGF-I 
receptors on erythrocytes by some (20-21), but not all investigators (22). In 
agreement with the latter study, we did not find such a relation in the fasting state 
in erythrocytes and PBMCs. Most circulating IGF-I is bound to the insulin-like 
growth factor binding proteins (IGFBPs), which titrate the supply of IGF-I to its 
receptors, while a very small component circulates as the free form (23-24). Free 
IGF-I was positively related to the Kd of the IGF-I receptor on erythrocytes in the 
fasting state, but not to the number of IGF-I receptors on erythrocytes. Moreover, 
free IGF-I was not related to the number and the Kd of IGF-I receptors on PBMCs 
in the fasting state. We do not have an explanation for this cell-specific difference, 
but this suggests that findings from erythrocytes and PBMCs could not be 
extrapolated to other cell types, which may be more relevant target tissues for 
IGF-I action. 
It has been suggested that the study of insulin receptors on red cells reflects the 
chronic and long-term insulin receptor status better, whereas the insulin receptors 
on mononuclear cells primarily might reflect the most recent (acute) IGF-I receptor 
changes (25). Our study does not give information whether the study of IGF-I 
receptors on blood cells in this respect is similar to the study of insulin receptors 
on blood cells. 
IGFBP-3 -quantitatively the most important IGFBP- was inversely related to the 
number of IGF-I receptors on the erythrocytes. IGFBP-3 was also inversely related 
to the Kd of the IGF-I receptor on PBMCs. These observations suggest that 
IGFBP-3 may modulate the interaction of IGF-I with the IGF-I receptors on blood 
cells. Our study also suggests that this modulation is celltype-specific. It may 
thereby indirectly control biological actions of IGF-I (21). 
No statistical relationship was observed between circulating insulin levels and the 
characteristics of the IGF-I receptor (number, Kd) or circulating total IGF-I, free 
IGF-I and IGFBP-3 in the fasting state in our study. Only the well known inverse 
relationship between insulin and IGFBP-l was confirmed. It has been suggested 
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that IGF-I receptor regulation by insulin is a complex and dynamic phenomenon 
(26, 27). In addition, insulin can downregulate IGF-I receptors in some tissues and 
upregulate IGF-I receptors in some other tissues (26, 27). 
In conclusion: We have studied the relationships between the IGF-I/IGFBP system 
and the IGF-I receptor characteristics on erythrocytes and PBMCs in healthy 
subjects in the fasting state. The Kd of the IGF-I receptor on erythrocytes in the 
fasting state was positively related to circulating free IGF-I levels. For the IGF-I 
receptor on PBMCs no relation was observed with free IGF-I levels. IGFBP-3 levels 
were inversely related to the number of IGF-I binding sites on erythrocytes and to 
the Kd of the IGF-I receptor on PBMCs. Total IGF-I, insulin and IGFBP-l levels 
showed no relation to the IGF-I receptor characteristics on erythrocytes and 
PBMCs in the fasting state. Our data suggest that IGF-I and IGFBPs may modulate 
the IGF-I receptor status on blood cells celltype-specific. Therefore, studies of 
IGF-I receptor characteristics on erythrocytes and PBMCs in the fasting state 
cannot be extrapolated to other cell types, which may be more relevant target 
tissues for IGF-I action in vivo. 
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Summary 
We studied the relationships between the circulating insulin-like growth 
factor/insulin-like growth factor binding proteins (IGF-I/IGFBP) system, insulin and 
glucose levels in the fasting state and during a 75 g oral glucose tolerance test 
(OGTI) in six healthy volunteers. In three of these volunteers IGF-I receptors on 
peripheral mononuclear blood cells (PBMCs) were also studied at the start and at 
the end of the OGTI. 
Serum insulin increased, while free IGF-I, and IGFBP-3 levels showed no 
significant changes during the first 120 minutes after an oral glucose load. The free 
IGF-I/IGFBP-l ratio, a measurement of IGF-I bioactivity, started to increase 60 
minutes after the glucose load. The number and affinity of IGF-I binding sites on 
PBMCs did not change 120 minutes after an oral glucose load. 
This study suggests that circulating insulin and IGFBP-l playa role in the 
regulation of IGF-I bioactivity In response to an acute glucose load. 
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Introduction 
The hypoglycemic insulin-like effects of IGF-I suggest that the IGF-I/IGFBP system 
is involved in glucose homeostasis (1). There is considerable homology between 
IGF·I and insulin, and between the IGF-I and insulin receptor (2), while insulin-like 
growth factor binding proteins (IGFBPs) form an important difference between 
these systems (3). The binding proteins are important modulators of IGF-I action, 
and exclusively bind IGF·I but not insulin. 
Nevertheless, insulin also influences IGFBPs: IGFBP-1 levels are negatively regula· 
ted by insulin (4) and it has been suggested that insulin plays an important role in 
the regulation of IGFBp·3 protease activity (5). Moreover, insulin stimulates hepatic 
IGF·I production, while IGF-I feeds back to suppress insulin release (4). 
We report here the results of a study in six healthy volunteers into the dynamic 
relation between the circulating IGF·I/IGFBP system and insulin levels in response 
to an oral glucose load, while in parallel in three of these volunteers IGF-I receptor 
characteristics on PBMCs were studied under fasting conditions and after 120 
minutes. 
Methods 
Subject and Methods 
Four healthy non-obese human male volunteers (31, 33, 34 and 39 years) and two 
female volunteers (21 years and 46 years) participated in the study and were 
investigated after an overnight fast and after an oral 75 gram glucose load during 
two hours in the morning. The first sample was drawn in the fasting state in the 
morning between 8.30 am and 9.30 am immediately before the glucose load (=O 
minutes). Blood samples were taken by an indwelling catheter (venflon), and were 
allowed to coagulate for 60 minutes. 
Subsequently, serum was separated by centrifugation and quickly frozen to -20°C. 
After the glucose load, blood was drawn after 30, 60 and 120 minutes. The subject, 
who developed a reactive hypoglycemia during the OGTT was excluded from the 
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statistical analysis, since a hypoglycemia can induce a paradoxical rise of IGFBP-l 
levels by suppression of endogeneous insulin levels (6). The results of this subject 
are presented separately. 
In three subjects (2 men an 1 woman) IGF-I receptors were performed during the 
OGTT. For the IGF-I receptor study a total of 120 mL of blood was drawn. The 
fasting sample and the sample drawn after 120 minutes were used for the IGF-I 
receptor studies (see infra). The study was performed according to the rules of the 
hospital medical ethics committee. All subjects entered the study after informed 
consent. 
Hormone assays 
Free IGF-I was measured with a commercially available two-site immunoradiometric 
assay (Diagnostic System Laboratories Inc., Webster, Texas, U.S.A.; 
intraassayand interassay C.v.: 10.3% and 10.7%, respectively)(7). Total IGF-I was 
determined by a radioimmunoassay (Medgenix Diagnostics, Brussels, Belgium; 
intraassay and interassay coefficients of variation (C.V.): 6.1%; 9.9%). 
Immunoradiometric assays were also used for measurement of IGFBP-l, and 
IGFBP-3 (Diagnostic System Laboratories Inc., Webster, Texas, U.S.A.; intraassay 
and interassay C.V. for IGFBP-l: 4.0 % and 6.7 %, respectively; and for IGFBP-3: 
1.8 % and 1.9%, respectively). Insulin was determined by a radioimmunoassay 
(Medgenix Diagnostics, Brussels, Belgium; intraassay and interassay C.v. 13.7% 
and 8.0%). Blood glucose concentrations were measured in venous whole blood 
by an automatic hexokinase method (Boehringer Mannheim Gmbh, Germany). 
IGF-I receptor study 
PBMCs were isolated from freshly obtained heparinized blood and cell separation 
was performed by density centrifugation on Ficoll-Paque (Pharmacia, Uppsala, 
Sweden) at 400 G for 30 min at room temperature. 
For the IGF-I receptor assay the methods described by Hizuka et al. (8) and Izumi 
et al. (9) were used with three modifications: The final incubation volume was 
decreased to 100 J1L for measurement of IGF-I binding to PBMCs. Secondly, 
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bacitracin was added to the assay buffer (10). Thirdly, after 20 h incubation bound 
and unbound ligand were separated by three washing steps with saline in stead of 
separation with dibutylphthalate as described in the original method. 
In a final volume 100 pL 60 pL PBMCs (> 15 x 10'/mL), were incubated with 1251_ 
IGF-I(10-30.000 cpm) in assay buffer and in the absence or presence of increasing 
conentrations of unlabeled hIGF-1 at 4 'c for 20 h. Each experiment was performed 
in duplicate. For the competition studies, added unlabeled concentrations of hIGF-
I ranged from 10.11 to 10·' M. 
After 20 h incubation, bound and unbound radioligand were separated by three 
washing steps with saline at 4 'C. In each washing step, the cells were centrifuged 
at 10.000 G during 2 minutes and the supernatant was removed. After the third 
centrifugation step the cell-bound radioactivity was measured in a gamma counter. 
Non-specific binding was defined as the amount of radioligand bound in the 
presence of excess of unlabeled IGF-I (10·' M). Specific binding of 12'I-IGF-1 was 
determined by subtracting the amount of radioactivity bound in the presence of 
excess of unlabeled IGF-I (10-'M). 
The binding data were analyzed according to the method of Scatchard (11). The 
number of binding sites is expressed as sites per cell. The dissociation constant 
(Kd) is given in nmol/L. 
Statistical analysis 
Results are given as the mean with ± SE. Changes in variables during the OGTI 
were analyzed by Wilcoxon signed-rank sum test. A p<0.05 was considerd 
statistically significant. 
Results 
Mean serum free IGF-I, IGFBP-3 and GH levels did not significantly change during 
the first 120 minutes after an OGTI, while IGFBP-1 decreased and as a 
consequence the IGF-I/IGFBP-1 ratios increased the last 60 minutes during the 
OGTI (Figure 1, Table 1). 
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Figure 1. The mean results (with SE) from an oral glucose tolerance test during a 
75 g OGTI in five healthy individuals. Measurements were performed after 0 
(fasting), 30, 60 and 120 min during the OGTI. The changes in mean glucose (I, 
left axis), Insulin (I, right axis), Free IGF-I (II, left axis), IGFBP-l (II, right axis), Total 
IGF-I (III, left axis), and IGFBP-3 (III, right axis) are shown for these five subjects. 
Individual data used were the means of one experiment, done in duplicate. 
Table 1. Changes in mean values for free IGF-I, total IGF-I, IGFBP-l, IGFBP-3 and insulin levels during an oral glucose tolerance in 5 
healthy subjects. 
Glucose (mmol/l) 
Insulin (mU/l) 
Free IGF-I (nmol/l) 
IGFBP-l (nmol/l) 
Free IGF-I/IGFBP-l 
ratio 
Total IGF-I (nmol/l) 
IGFBP-3 (nmol/l) 
GH (tLg/l) 
o min 
4.2 (0.2) 
32.0 (23.6) 
0.123 (0.019) 
1.37 (0.56) 
0.14 (0.05) 
24.7 (2.4) 
109.5 (5.8) 
2.3 (2.05) 
30 min 
6.0 (0.6). 
96.6 (57.2). 
0.126 (0.023) 
1.85 (0.69) 
0.12 (0.05) 
25.1 (2.8) 
106.7 (5.7) 
4.8 (5.1) 
Data showed are the means with SE values between brackets 
60 min 120 min 
4.4 (0.3) 3.7 (0.1) t 
56.3 (33.9). t 27.5 (21.5). t :j: 
0.116 (0.021) 
1.79 (0.70) 
0.11 (0.05) 
24.1 (3.1) 
106.3 (7.8) 
1.6 (1.7) 
0.124 (0.019) 
0.93 (0.37) t :j: 
0.25 (0.10) t:I: 
24.5 (3.1) :j: 
106.9 (5.8) 
1.1 (1.0) 
Changes in variables during the OGTT were analyzed by Wilcoxon signed-rank sum test 
• p< 0.05 when compared with baseline value (t=O min) 
t p< 0.05 when compared with t=30 min 
:j: p< 0.05 when compared w~h t=60 min 
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Figure 2. The results from an oral glucose tolerance test during a 75 g OGTT in 
one healthy individual. Measurements were performed after 0 (fasting), 30, 60 and 
120 min during the OGTT. The changes in glucose (I, left axis), Insulin (I, right 
axis), Free IGF-I (II, left axis), IGFBP-1 (II, right axis), Total IGF-I(III, left axis), and 
IGFBP-3 (III, right axis) are shown for this Data are the means of one experiment, 
done in duplicate. Note the reactive hypoglycemia in this subject. 
Table 2. Characteristics of IGF-I binding to PBMCs, circulating IGF-I and IGFBPs, and insulin in three healthy volunteers in the 
fasting state and after an oral glucose load at t=120 minutes 
Fasting After 120 min OGTT 
Mean SE Mean SE p-value 
PBMCs 
No of specific IGF-I binding sites/cell 2389 (868) 2995 (2018) ns 
Kd (nM) 1.86 (0.23) 1.85 (0.14) ns 
TotaIIGF-1 (nmol/l) 24.7 (4.6) 24.5 (5.7) ns 
Free IGF-I (nmol/l) 0.127 (0.037) 0.134 (0.033) ns 
IGFBP-1 (nmol/l) 1.52 (1.08) 0.76 (0.44) ns 
Free IGF-I/IGFBP-1 ratio 0.165 (0.093) 0.295 (0.177) ns 
IGFBP-3 (nmol/l) 108.4 (1.2) 106.7 (10.9) ns 
Insulin (mU/l) 45.1 (43.5) 39.9 (39.9) ns 
Serum glucose (mmol/l) 4.3 (0.3) 3.8 (0.2) ns 
For used abbreviations, see text 
Data are the means from one experiment done in duplicate, standard deviation between brackets 
Changes in variables during the OGTT were analyzed by Wilcoxon signed-rank sum test 
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Serum insulin levels transiently increased after 30 minutes and had returned to 
fasting values after 120 minutes (Table 1, Figure 1). Individual analysis of serum 
free IGF-I levels showed no changes during the OGTT in five subjects, but in the 
subject, who had a reactive hypoglycemia during the OGTT, serum free IGF-I levels 
decreased significantly while serum IGFBP-1 levels simultaneously increased after 
120 minutes (Figure 2). As a consequence, GH level in this latter subject was 
increased after 120 minutes (GH at t=O min: 0.7/1g/L; GH at 30 min: 0.4 /1g/L;GH 
at t=60 min: 0.7/1g/L; and GH at t=120 min: 7.4 /1g/L) while the free 
IGF-I/IGFBP-1 ratio decreased from 0.15 at t=O min to 0.05 at t=120 min. 
The number and affinity of the IGF-I receptors on PBMCs did not change when the 
values in the fasting state and 120 minutes after start of the OGTT were compared 
(see Table 2) 
Discussion 
Mean serum free IGF-I levels did not change significantly in five healthy subjects 
during the first 120 minutes of an OGTT in our study. Mean IGFBP-1 levels 
decreased, while the free IGF-I/IGFBP-1 levels ratios increased after 60 min. 
Also no changes in free IGF-I levels were observed until 4 hours after a morning 
meal in a recent study using the same assay (12). Insulin and IGF-I 
intercommunicate at many levels and act in a dual effector model regulating basal 
and postabsorptive metabolism (13). Under normal conditions acute variations in 
IGFBP-1 levels are inversely related to insulin levels (14), while IGFBP-1 has been 
proposed as an regulator of IGF-I bioactivity (15). It has been demonstrated that 
low IGFBP-1 levels result in high IGF-I activity, and vice versa (14). The increase in 
the mean free IGF-I/IGFBP-1 ratio during the last 60 minutes of the OGTT (Table 1) 
suggests thus an increased IGF-I bioactivity and supports the idea that IGF-I is a 
main modulator of postabsorptive metabolism in the postprandial period (16). 
Previously it has also been suggested that a lowered total IGF-I/IGFBP ratio may 
reflect a lower bioavailability of IGF-I (17). Thus our observation in the subject who 
tended to develop a reactive hypoglycemia after the glucose load, suggests that 
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the increase of IGFBP-1 levels, indeed lowered IGF-I bioactivity acutely in this 
subject in order to counteract the development of hypoglycemia. 
It took about one hour after the glucose load before a significant decrease in 
IGFBP-1 levels was observed in the other five subjects. The transient increase in 
serum insulin levels after a glucose load (peak at 30 min) as observed in our study 
eventually induces this decrease in serum IGFBP-1 levels. Insulin exerts an 
inhibitory effect on m-RNA IGFBP-1 production in the liver (18). The observed 
changes in serum IGFBP-1 levels are in accordance with the estimated half life of 
IGFBP-1 in plasma (30-90 minutes) (19). 
Because of the considerable amount of blood needed, it was investigated only in 
three subjects whether the characteristics of the IGF-I receptor on PBMCs are 
acutely affected by changes in the circulating levels of insulin, GH, IGF-I and its 
IGFBPs. Our study suggests that IGF-I receptors on PBMCs are unaffected after a 
glucose load. IGF-I receptors are subject to up- and down-regulation in the same 
manner as many other peptide hormone receptors, and it has been suggested that 
expression of the IGF-I receptor gene varies inversely with serum levels of IGF-I 
(20, 21). Since the free IGF-I/IGFBP-1 ratios increased at the end of the OGTT, 
however, our observations suggest that no acute changes in the IGF-I receptor 
characteristics occur during 120 minutes after a glucose load. In contrast to these 
findings, a marked increase in the affinity of insulin receptors of PBMCs has 
previously been demonstrated after an oral glucose load, suggesting that changes 
in the insulin receptor characteristics acutely occur as part of the physiological and 
dynamic regulation of target cell sensitivity (22). 
In conclusion: We have studied the reaction of the circulating IGF-I/IGFBP system 
to an oral glucose load. Free IGF-I levels and IGFBP-3 levels did not significantly 
change during the first 120 minutes after the glucose load, despite significant 
changes in insulin, glucose, and IGFBP-1 levels. The free IGF-I/IGFBP ratio, a 
measurement for IGF-I bioactivity, increased 60 minutes after a glucose load. The 
characteristics of the IGF-I binding sites on PBMCs (Kd and number) did not 
change 120 minutes after a glucose load. This preliminary study suggests that 
circulating insulin and IGFBP-1 play a role in the dynamic regulation of IGF-I 
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Summary 
Background: Most previous studies concerning the relationship between IGF-I and 
age used assays measuring total IGF-1. Although free IGF-I is considered of greater 
biological relevance, little is known about its relationship with sex steroids levels in 
elderly healthy subjects. 
Measurements: In a cross-sectional study of 218 healthy persons (103 men, 115 
women) aged 55 to 80 years we measured serum total and free IGF-I, IGFBP-1 and 
IGFBP3 levels and sex steroids. Free androgen index and free oestradiol index 
were used as an indicator for free oestradiol and free testosterone levels, 
respectively. 
Results: Free IGF-I levels did not decline with age in the whole study population. 
Free IGF-I levels even increased in individuals above 70 yrs of age in comparison 
to those aged between 55 and 70 yrs (0.086(SE 0.004) nmol/L vs 0.106 (SE 0.007) 
nmol/L , p=0.009). Total IGF-I and IGFBP-3 decreased with age (r= -0.20, p=0.005 
and r=-0.24, p=0.001, respectively). Total IGF-I levels were positively related with 
free oestrogen index in both sexes. Free IGF-I did not relate to free oestrogen and 
androgen index. In women only, free IGF-I was positively related with DHEAS 
while IGFBP-1 was inversely correlated with DHEAS. 
Conclusions: Free IGF-I levels do not decrease with age and are even higher in 
individuals above 70 yrs. There was no relationship between free IGF-I and free 
androgen and oestrogen indices in both sexes. We hypothesize that higher free 
IGF-I levels in older persons may be the consequence of a selective survival in 
the cohort: subjects with high free IGF-I levels may live longer. The absence of a 
relationship between free IGF-I levels and free androgen and oestrogen indices 
suggests that there is no direct interaction between the biological activity of 
circulating IGF-I levels and sex hormone produc1ion in a healthy aging population. 
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Introduction 
The changes in total circulating insulin-like growth factor-I (IGF-I) with age parallel 
those of growth hormone (GH) (1). After a peak during early adulthood, there 
appears to be a gradual decrease in the serum concentrations of total IGF-I and 
insulin-like growth factor binding protein-3 (IGFBP-3), which is progressive with 
increasing age (2-4). However, IGF-I measured in serum is the total extractable 
IGF-I, which offers only a crude estimate of biologically active IGF-I, due to the 
wide inter-individual variation in Circulating IGFBP (5). Free IGF-I likely has greater 
physiological and clinical relevance than total IGF-I in analogy with sex and adrenal 
steroids and thyroid hormones, and accounts for approximately 1 % of total IGF-I 
(6). The amount of total IGF-I is dependent on the free IGF-I level and on the 
concentrations of the specific insulin-like growth factor binding proteins (IGFBPs). 
IGFBP-3 is quantitatively by far the major binding protein and it is thought to 
function as an intravascular reservoir and buffer for IGF-I (7). IGFBP-l has been 
proposed as an acute regulator of IGF-I bioactivity and might simultaneously both 
inhibit or potentiate IGF-I action at different sites (8). 
Consequently, it seems desirable to distinguish bound and unbound components 
of IGF-I when studying the IGF/IGFBP system (5). Recently a method has been 
developed and validated to measure free IGF-I levels (9,10). The increase in serum 
total IGF-I and IGFBP-3 levels during puberty suggest the influence of estrogens 
and lor androgens on Circulating IGF-I and IGFBP-3 levels (11, 12). This effect 
might be at least partially mediated through stimulated growth hormone (GH) 
secretion (II). 
Little is known about the free IGF-I levels and the relationships of the 
circulating IGF-I/IGFBP system to the circulating sex steroids at older age. We 
investigated the free IGF-I, total IGF-I, IGFBP-l and IGFBP-3 and plasma sex 
steroid levels in a healthy older population. 
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Subjects and methods 
Study population For the present study, a sample of participants from the 
Rotterdam Study was invited for an additional examination. The Rotterdam Study is 
a population-based cohort study of the determinants of chronic disabling 
diseases in the elderly. All approximately 10,000 inhabitants of a suburb of 
Rotterdam, aged 55 years and over were invited to participate as described 
elsewhere (13). Overall 7983 participants were examined in the Rotterdam Study 
(response rate 78 %). 
The population for the present study included 218 persons aged 55 to 80 
years, who had completed the baseline visit of the Rotterdam Study not more than 
six months earlier. Subjects with acute, psychiatric or endocrine diseases including 
diabetes mellitus treated with medications, were not invited. Compared to the other 
participants of the Rotterdam Study of the same age without known diabetes 
mellitus, there were no differences in age and gender distribution. Only 4 women in 
this study population were on hormone replacement therapy. These were (n=4) 
excluded from analysis. The study population was stratified by age in three groups 
of about equal size: group 1 (55·64 yrs old, 73 subjects), group 2 (65·69 yrs old, 
72 subjects) and group 3 (>70 yrs old, 69 subjects). From all subjects informed 
consent was obtained and the study was approved by the medical ethics 
committee of Erasmus University Medical School. 
Measurements Participants were examined in the morning after an overnight fast. 
Fasting blood samples were taken by venipuncture between 8.00 and 9.00 a.m. 
and allowed to coagulate for 30 minutes. Subsequently serum was separated by 
centrifugation and quickly frozen in liquid nitrogen. Free IGF-I was measured with a 
commercially available two-site immunoradiometric assay (Diagnostic System 
Laboratories Inc., Webster, Texas, U.S.A.; intraassay and interassay C.V.:10.3% 
and 10.7%, respectively)(9, 10). Estimation of free IGF-I in other assay systems 
usually involves size-exclusion extraction followed by a displacement 
immunoassay. Sample matrix alterations with consequent disturbance of the 
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free/bound equilibrium is an inevitable consequence. The free IGF-I assay used in 
this study needs initially no sample extraction as part of the standard procedure to 
measure IGF-1. Samples are added directly to tubes coated with IGF-I antibodies, 
washed, incubated with 1251 labeled antibody directed to a second epitope on IGF-I, 
washed and counted. Assay standards are rhIGF-I: 0.04-2.6 nmol/L, the minimal 
detection limit is 4 pmol/L. There is no cross-reactivity with IGF-II and no residual 
IGFBP-l or IGFBP-3 is detectable after the first wash. The free IGF-I fraction 
measured in this assay, is a combination of the true free and the fraction of IGF-I 
which can be readily dissociated from IGFBPs under the specific assay conditions 
(9). Total IGF-I was determined by a commercially available radioimmunoassay 
(Medgenix Diagnostics, Brussels, Belgium, intraassay and interassay coefficients of 
variation (C.V.): 6.1 %; 9.9%). Commercially available immunoradiometric assays 
were also used for the measurement of IGFBP-l and IGFBP-3 (Diagnostic System 
Laboratories Inc., ; intraassay and interassay C.v. for IGFBP-l: 4.0% and 6.0 %, 
respectively; and for IGFBP-3: 1.8 % and 1.9%, respectively). Oestradiol and 
oestrone were assayed with a radioimmunoassay (Diagnostic Products 
Corporation, Los Angeles, U.S.A.; oestradiol: intraassay and interassay C.v. : 7.0% 
and 8.1%; oestrone: intraassay and interassay C.V. : 9.4% and 11.1%, 
respectively). SHBG was assayed with an commercially available 
immunoradiometric assay (Diagnostic Products Corporation; intraassay and 
interassay C.V. : 3.6% and 6.9%, respectively). The ratio of oestradiol to SHBG was 
used as an index of free oestradiol (14). Testosterone was measured with a non-
commercial radioimmunoassay (intraassay and interassay C.V: 5.6%; 9.0%) (15). 
The ratio of total testosterone to SHBG was used as an index of free testosterone 
(16, 17). DHEAS and androstenedione were assayed by radioimmunoassay 
(Diagnostic Products Corporation; DHEAS: intraassay and inter-assay C.V. : 5.3% 
and 7.0%; androstenedione intraassay and interassay C.V. : 8.3% and 9.2%). 
Insulin was determined by a commercially available radioimmunoassay (Medgenix 
Diagnostics, intra-assay and inter-assay C.V.: 8.0%; 13.7%). Serum glucose levels 
were determined, using a standard glucose hexokinase method. Height and weight 
of the subjects were measured while wearing indoor clothes and without shoes. 
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Body mass index was defined as weight divided by the square of height (kg/m'), 
body fat distribution was estimated using the ratio of waist and hip circumferences. 
Statistical Analysis The clinical characteristics of the study population stratified by 
gender are expressed as the mean and standard error (SE). Mean totaIIGF-I, 
free IGF-I, IGFBP-1 and IGFBP-3 levels with SE were also calculated after 
stratification for age. Linear regression analyses were used to calculate differences 
in the baseline characteristics between men and women with adjustment for age. 
Pearson's correlation coefficients were calculated to assess associations between 
the variables. One way ANOVA was used to test for difference in the free IGF-I 
levels across age groups and multiple linear regression analysis was performed to 
adjust for confounding variables. A two-sided p-value of <0.05 was considered 
significant. Analyses in which the values were logarithmically transformed yielded 
results similar to those with untransformed data: the non-transformed results are 
presented. All statistical analyses were performed with the Stata statistical package 
(Computing Resource Center, Santa Monica, Ca, U.S.A). 
Results 
In Table 1 the general characteristics of the study population are 
presented. Men were slightly older than women. BMI, and mean (free or total) 
IGF-I and IGFBP-1 levels did (age-adjusted) not differ between the sexes. Mean 
free over total IGF-I ratio and IGFBP-3 levels were significantly lower in men than in 
women. Mean insulin and glucose levels did not differ between both sexes. As 
expected, serum SHBG levels were significantly lower in men. Although the 
differences in mean serum oestradiol levels did not reach statistical significance, 
mean free oestradiol index and oestrone levels were significantly higher in men 
than in women as were total and free testosterone. Mean DHEAS and 
androstenedione levels were also significantly higher in men. 
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Table 1. General characteristics of the study population 
Men Women 
n=103 n=lll p value' 
mean (SE) mean (SE) 
Age (years) 67.6 (0.56) 65.9 (0.59) 0.05 
BMI (kg/m'j 26.4 (0.29) 26.6 (0.41) 0.70 
Total IGF·I (nmol/L) 19.3 (0.83) 17.9 (0.70) 0.11 
Free IGF·I (nmol/L) 0.088 (0.005) 0.095 (0.005) 0.22 
Percentage 
Free IGF·lrrotal IGF·I 0.51 (0.03) 0.59 (0.04) 0.05 
IGFBp·l (nmol/L) 0.71 (0.07) 0.84 (0.10) 0.21 
IGFBP·3 (nmol/L) 103.5 (2.5) 116.6 (2.5) 0.002 
Insulin (IU/mL) 14.2 (0.8) 13.0 (0.8) 0.47 
Glucose (nmol/L) 6.0 (0.1) 5.8 (0.1) 0.24 
SHBG (nmol/L) 50.9 (2.0) 60.2 (2.7) 0.006 
Oestradiol (pmol/L) 106.4 (2.0) 82.1 (4.8) 0.10 
Free Oestradiol Index 2.26 (0.25) 1.65 (0.13) 0.009 
(pmol/nmol) 
Oestrone (pmol/L) 194.2 (7.1) 126.6 (5.4)) < 0.001 
Testosterone (nmol/L) 20.4 (0.5) 1.4 (0.06) < 0.001 
Free Androgen Index 0.45 (0.02) 0.03 (0.002) < 0.001 
(nmol/nmol) 
DHEAS (umol/L) 4.1 (0.2) 2.6 (0.2) < 0.001 
Androstenedione 6.6 (0.3) 4.6 (0.2) < 0.001 
(nmol/L) 
Values are means with standard error (SE) between parentheses 
• Difference between men and women. adjusted for age 
BMI, body mass index; IGF·I: insulin·like growth factor I; IGFBP: Insulin·like growth 
factor binding protein; SHBG: sex·hormone binding globulin; DHEAS: dehydroepi. 
androsterone sulphate 
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Figure 1. Free IGF-I (Upper left), total IGF-I (Upper right), IGFBp·1 (Lower left) and 
IGFBP-3 (Lower right) levels according to three groups of increasing age (see text). 
Note the different scales on the vertical axes, the increase in free IGF·I levels in 
individuals after 70 yrs in comparison to those between 55 and 70 yrs (# : ANOVA, 
p=0.009), and the comparable decreases in total IGF·I and IGFBP-3 levels with 
increasing age (see text). 
IGF-I, IGFBPs and Aging 
Total IGF-I levels decreased significantly with age in the whole study population 
(r=-0.20, p= 0.005) (Figure I). Free IGF-I levels did not significantly decline with 
age (r=0.12, p = 0.08), but showed a significant increase in individuals above 70 
yrs when compared with those between 55 and 70 yrs (p=0.009) (Figure I). This 
difference remained in multivariate analysis after adjustments for BMI and insulin. 
IGFBP-I levels showed no relation wi;h age and IGFBP-3 levels decreased with 
age (r=-0.24, p= 0.001) (Figure I). 
Serum total IGF-I was positively related with free IGF-I, IGFBP-3, and inversely 
related with IGFBP-I (Table 2). Serum free IGF-I levels were positively correlated 
with IGFBP-3, and inversely with IGFBP-I (Table 2). IGFBP-I was negatively related 
to IGFBP-3, and insulin (Table 2). After adjustment for age and gender these 
relations remained unchanged. 
Table 2. Pearson's correlation coefficients between (total and free) IGF-I, IGFBP-I 
IGFBP-3, insulin and glucose levels for the whole study population 
TotalIGF-1 Free IGF-I IGFBP-l IGFBP-3 Insulin 
Free IGF-I 0.35 # 
IGFBP-l -0.30 # -0.17 * 
IGFBP-3 0.30 # 0.19 § -0.17 * 
Insulin -0.03 0.05 -0.19 § 0.07 
Glucose 0.11 0.09 -0.12 0.03 0.46 # 
* p<O.05, § p<O.01, # p<O.OOl 
Table 3. Pearson's (age-adjusted) correlation coefficients between (total and free) IGF-I, IGFBP-l, 
IGFBP-3, sex steroids and SHBG in men (A) and women (B). 
Total IGF-I Free IGF-I IGFBP-l IGFBP-3 
A. Men 
Oestradiol 0.15 0.10 ·0.08 -0.13 
Free Oestradiol Index 0.24 * 0.13 -0.15 -0.07 
Testosterone ·0.03 0.08 -0.08 ·0.14 
Free Androgen Index 0.20 0_12 -0.35 # 0.28 * 
SHBG -0.20 * -0.05 0.38 # ·0.24 * 
DHEAS 0.13 0.01 -0.05 -0.03 
Androstenedione 0.08 0.01 0.07 0.01 
Oestrone 0.12 ·0.009 -0.03 -0.07 
B. Women 
Oestradiol -0.003 0.08 0.01 0.07 
Free Oestradiol Index 0.26§ 0.16 -0.15 0.38 # 
Testosterone 0.07 -0.009 -0.05 -0.07 
Free Androgen Index 0.29 § 0.12 -0.21 * 0.31 § 
SHBG -0.30 § -0.18 0.31 § -0.43 # 
DHEAS 0.06 0.24 * -0.22 * -0.002 
Androstenedione -0.002 0.Q7 -0.002 -0.02 
Oestrone -0.01 0.15 -0.12 -0.03 
• p<O.05, § p<O.01, # p<O.OO1 
IGF-I, IGFBPs and Aging 
Free IGF-I levels were inversely related to BMI in men (r~-0.23, p~0.03), but not in 
women (r~0.004, p~0.97). No relations were observed between total IGF-I and 
BMI (men: r~-0.03, p~O.77; women: r~0.09, p~0.35). 
IGFBP-1 levels were inversely related with BMI in women(r~·0.20, p~0.004) but not 
in men (r~-0.16, p~0.12), while no relations were observed between IGFBP-3 
levels and BMI in both sexes (men: r~0.12, p~0.24; women: r~0.09, p~0.38). 
Both in men and women serum total IGF-I was positively related to the free 
oestradiol index, and inversely to SHBG (Table 3A and 3B). In women serum total 
IGF-I was also positively related to the free androgen index (Table 3B), while in 
women also serum free IGF-I was positively related to DHEAS (Table 3B). Serum 
IGFBP-1 was positively related to SHBG and inversely to the free androgen index 
both in men and women (Table 3). Only in women IGFBP-1 was also inversely 
related to DHEAS (Table 3). IGFBP-3 was positively related to the free androgen 
index and negatively to SHBG in both sexes, and positively related to the free 
oestradiol index in women only (Table 3). Free oestradiol index was (age-adjusted) 
inversely related to SHBG in women (r~-0.53, p<0.001) while free androgen index 
was inversely related to SHBG in both sexes (M: r~ -0.68, p<0.001; F: r~-0.52, 
p<0.001). 
Discussion 
In this population based study in the elderly total IGF-I and IGFBP-3 levels 
decreased with age, while free IGF-I levels did not. They even tended to be higher 
in subjects over seventy years of age (Figure 1). A close relationship was found 
between total IGF-I and IGFBP-3 levels with free androgen and free oestrogen 
levels both in elderly men and women. No relation was found between free IGF-I 
levels and free sex steroid indices in both sexes. 
Before these findings can be accepted some issues need to be addressed. 
An important, at present insufficiently answered question in this regard remains 
whether the free IGF-I assay used in our study represents a better, more biological-
ly active representation of the IGF-I/IGFBP system, than the currently used total 
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IGF-I, IGFBP-1 and IGFBP-3 assays. The free IGF-I assay used in our study 
measures in the unextracted serum the unbound and readily dissociable IGF-I (the 
so called easily dissociable free fraction) (18). It has become clear that during the 
transport of hormones into cells (e,g. steroid and thyroid hormones) the unbound 
hormone fraction is not the only component of the hormone in the circulation which 
enters the cells (19). This might also be true for IGF-1. Dissociation of IGFBP-bound 
IGF-I might also occur within the capillary bed, suggesting that the active fraction is 
larger than the unbound fraction measured in vitro. Although not yet proven, 
measurement of the easily dissociable free IGF-I fraction probably reflects the "true" 
bioavailable IGF-I (the amount of IGF-I available for entry in most tissues) better 
than the currently used assays. In a previous study three fractions of IGF-I have 
been found to be present in the circulation: the total amount, the ultrafiltrated free 
fraction (measured by an ultrafiltrated centrifuge method) and the easily diSSOCiable 
free fraction (measured by the same free IGF-I assay as used in our stUdy) (10). 
Still, these authors concluded that it remains to be proven to what extent the two 
latter fractions reflect bioavailable IGF-1. 
It should be realized that cross-sectional studies do not reflect the rate of 
change of free IGF-I in an individual. As our study was cross-sectional, the higher 
free IGF-I levels in subjects above 70 years might be the consequence of a 
selective survival in the cohort: subjects with high free IGF-I levels may live longer. 
Alternatively, subjects with lower free IGF-I levels might have been excluded from 
the study because their physical condition (illness, frailty, or other causes) 
prevented a visit to the research centre. 
Apart from these limitations in the study itself, an explanation for our 
observation of higher free IGF-I levels in subjects above 70 years might be that free 
IGF-I levels indeed increase with aging. An age-related increase has also been 
described for IGF-II levels (6). It has become clear that IGF-I levels are not only 
GH-dependent and that there are a number of other factors which influence IGF-I 
production (11). The increase in free IGF-I levels might be due to other age-related 
phenomena, such as a decreased metabolism and clearance of IGF-I, increased 
IGFBP-3 protease activity, increased abdominal adiposity, hyperinsulinemia, and 
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hyperglycaemia, which might modify IGF-I levels independently, despite the 
decrease in GH, totallGF-1 and IGFBP-3 levels during aging (3, 20, 21). 
Alternatively, an Increase in free IGF-I levels may also represent an age·related 
IGF-I receptor or post-receptor defect (22). 
According to previous findings the decline in serum GH concentration with 
age in men and women correlates with changes in gonadal steroid levels (23-25). 
Indeed we confirmed a close relationship between total IGF-I levels and free 
oestrogen levels both in elderly men and women. Total oestradiol levels in our 
study were slightly higher in elderly men than in women, which is in accordance to 
the study reported by Pfeilshifter et al. (25). Mean total IGF-I levels were 
comparable in both sexes in both studies. In neither study a correlation was 
observed between total IGF-I and total oestradiol levels. 
The absence of a relationship between free IGF-I and free androgen and oestrogen 
levels suggests that there is during aging no direct relationship between IGF-I 
bioactivity in peripheral blood and the free sex steroid levels. Such a conclusion 
might have important consequences with regard to therapeutic interventions in the 
elderly, which aim to increase serum IGF-I levels with combinations of IGF-I 
modifying drugs (e.g. GH, growth hormone releasing hormone (GHRH), growth 
hormone binding protein (GHBP 's)) and sex steroids (e.g. androgens and/or 
oestrogens). 
In our study serum IGFBP-l levels were positively related to SHBG in men 
and women. The direction of the associations between IGFBP-l and SHBG were 
the mirror image of the observed associations between IGFBP-l and the free 
androgen index and free oestradiol index. These results suggest a common 
regulatory mechanism for the hepatic production of IGFBP-l and SHBG. Previous 
studies have also reported a positive correlation between SHBG and IGFBP-l 
levels (26-28). In cell cultures of human hepatoma cells both IGF-I and insulin 
inhibit the production of SHBG and IGFBP-l (29, 30). In agreement with this both 
total and free IGF-I levels were negatively related to SHBG levels. 
It has been previously found that DHEA administration increases IGF-I 
concentrations in middle-aged and elderly individuals (31). The relationships 
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between free IGF-I and DHEAS, and between IGFBP-l and DHEAS in women as 
observed in our study, support the view that DHEAS influences free IGF-I levels in 
women via an unknown mechanism. DHEAS might thus exert a direct effect on the 
hepatic production of IGF-I in women. Free IGF-I may also influence DHEA 
production in the adrenals by its previously demonstrated positive effects on the 
number of corticotrophin (ACTH) receptors (32). The absence of a relation between 
serum IGF-I and DHEAS in men might be the consequence of a considerable 
contribution of testicular DHEA to serum DHEAS levels (33), which may have 
masked the relation between free IGF-I and adrenal DHEAS. 
In conclusion, free IGF-I levels did not decrease with age and were even higher in 
individuals above 70 yrs. There was no relation between free IGF-I and free 
androgen and oestrogen indices. We hypothesize that high free IGF-I levels in 
older persons may be the consequence of a selective survival in the cohort: 
subjects with high free IGF-I levels may live 10nger.The absence of a relationship 
between free IGF-I levels and free androgen and oestrogen indices suggests that 
there is no direct interaction between the biological activity of circulating IGF-I 
levels and sex hormone production in a healthy aging population. 
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Summary 
Background: Recently a method to measure free insulin-like growth factor (IGF-I) 
levels has been developed. Free IGF-I levels may have greater physiological and 
clinical relevance than total (bound and free) IGF-1. The associations between the 
circulating IGF-I/ IGF binding protein (IGFBP) system and cardiovascular disorders 
was studied. 
Methods: In a cross-sectional study of 218 healthy persons (103 men, 115 women) 
aged 55 to 80 years, fasting serum (total and free) IGF-I, and IGFBP-l levels, lipid 
profile, insulin, and glucose were measured. In addition blood pressure, body mass 
index (BMI) and waist hip ratio (WHR) were measured. Ultrasonography of both 
carotid arteries was performed to investigate the presence of atherosclerotic 
lesions. A history of angina pectoris, the presence of a possible or definite 
myocardial infarction on the electrocardiogram, and plaques in the carotid arteries 
were used as indicator of presence of cardiovascular signs and symptoms. 
Results: Free IGF-I was inversely related to serum triglycerides (p=0.04, adjusted 
for age and sex). Mean free IGF-I levels in subjects without signs or symptoms of 
cardiovascular diseases were significantly higher than in those with at least one 
cardiovascular symptom or sign (p=O.002, adjusted for age and sex). Free IGF-I 
levels were also higher in subjects who had no atherosclerotic plaques in the 
carotid arterties (p=0.02, adjusted for age and sex) and who had never smoked 
(p=O.02, adjusted for age and sex). 
IGFBP-l showed an inverse relation with insulin, BMI and WHR and a positive 
relation with HDL-cholesterol. The associations between IGFBP-l levels and 
HDL cholesterol, WHR, and BMI remained significant after adjustment for fasting 
insulin levels. 
Conclusions: High fasting serum free IGF-I levels are associated with a 
decreased presence of atherosclerotic plaques, coronary artery disease and lower 
serum triglycerides while high fasting IGFBP-l levels are associated with a more 
favourable cardiovascular risk profile.The findings suggest that the IGF-I/IGFBP 
system is related to cardiovascular risk factors and atherosclerosis. 
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Introduction 
A possible involvement of circulating Insulin-like Growth Factor-I (IGF-I) and 
Insulin-like Growth Factor Binding Proteins (IGFBPs) in the pathogenesis of 
cardiovascular disorders has recently been suggested (1). Total IGF-I levels are 
lower in patients with an atherogenic lipid profile and may contribute to the 
development of atherosclerosis (2). Many in vitro studies have shown proliferation 
of vascular smooth muscle cells after stimulation with IGF-I (3, 4). Moreover, IGF-I 
has also been shown to be an important regulator of vascular function by 
stimulating nitric oxide (NO) release from cultured vascular endothelium (5). 
The commonly measured total extractable IGF-I in serum provides only a 
crude estimate of biologically active IGF-I, due to the wide inter-individual variation 
in IGFBPs (6). Free IGF-I, by analogy with sex and adrenal steroids and thyroid 
hormones, may have greater physiological and clinical relevance and accounts for 
only 1% of total IGF-I (7). Recently a method has been developed to measure free 
IGF-I levels (8). 
The six IGFBPs comprise a family of structurally homologous proteins that 
prolong the half-life of IGF-I in the circulation and modulate IGF-I action at its target 
cells (9, 10). IGFBP-1, one of these IGFBPs, is not restricted to the circulation and 
is considered to function as a transport protein that shuttles IGF-I from the 
intravascular space through the endothelial walls of the capillaries (11, 12). 
IGFBP-1 has been proposed as an acute regulator of IGF-I bioactivity and might 
simultaneously both inhibit or potentiate IGF-I action at different sites (13). Recent 
evidence even suggests that IGFBP-1 has intrinsic mitogeniC and metabolic activity 
(14). Consequently, it seems desirable to distinguish bound and unbound 
components of IGF-I when studying the IGF-I/IGFBP system. 
To broaden our understanding of a possible role of the IGF-I/IGFBP system in the 
development of cardiovasular disorders, we studied the relationships of fasting 
serum circulating levels of (free and total) IGF-I and IGFBP-1 with the presence of 
cardiovascular risk factors and diseases in an elderly population. 
95 
Methods 
Subjects 
Chapter 3 
For the present study, a sample of participants from the Rotterdam Study was 
invited for an additional examination. The Rotterdam Study is a population·based 
cohort study of the determinants of chronic disabling diseases in the elderly. All 
approximately 10,000 inhabitants of a suburb of Rotterdam, aged 55 years and 
over were invited to participate as described elsewhere (15). Overall 7983 
participants were examined (response rate 78 %). 
The population for the present study included subjects aged 55 to 80 years, 
who had completed the baseline visit of the Rotterdam Study not more than six 
months earlier. Subjects with psychiatric or endocrine diseases, including diabetes 
mellitus treated with medication, were not invited. From these subjects a random 
sample of 218 persons was examined. Compared to the other participants of the 
Rotterdam Study of the same age without known diabetes mellitus, there were no 
differences in age and gender distribution, mean blood pressure, use of 
antihypertensive medication, echographic evidence of atherosclerotic plaques in 
the carotid arteries, and electrocardiographic abnormalities. From all subjects 
informed consent was obtained and the study was approved by the medical ethics 
committee of Erasmus University Medical School. 
Cardiovascular assessment Resting standard 12·lead electrocardiogram was made 
with an ACTA Gnosis IV (EsaoteBiomedica) and an automated diagnostic 
classification system of the Modular Electrocardiogram Analysis System (MEANS) 
was used (16, 17). The presence of a possible or definite myocardial infarction on 
the electrocardiogram was used as indicator of presence of coronary artery 
disease (18). 
Information on medical history of myocardial infarction, medical history, drug use 
and smoking was obtained by a trained research assistant using a computerized 
questionnaire, which includes a Dutch version of the Rose questionnaire to 
determine the presence of angina pectoris and intermittent claudication (19). 
To measure carotid artery intima·media thickness ultrasonography of the left and 
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right common carotid artery, carotid bifurcation and the internal carotid artery was 
performed with a 7.5 Mhz linear array transducer (ATl Ultramark IV, Advanced 
Technology laboratories). Following the Rotterdam Study ultrasound protocol, a 
careful search was performed for all interfaces of the near end and far wall of the 
distal common carotid artery (20-22). The actual measurements of the intima-media 
thickness were performed off_line. This procedure has been described previously 
(23). 
The common carotid artery, carotid bifurcation, and internal carotid artery were also 
evaluated for the presence (yes/no) of atherosclerotic lesions on both the near and 
the far wall of the carotid arteries. Plaques were defined as a focal widening relative 
to adjacent segments, with protrusion into the lumen composed of only calcified 
deposits or a combination of calcification and non-calcified material (24). The size 
or extent of the lesions was not quantified. The presence of plaques was used an 
indicator of presence of atherosclerosis. 
Subjects were categorized into groups of current smokers, former smokers and 
those who had never smoked. BMI was defined as weight divided by the square of 
height (kg/m2), and body fat distribution was estimated using the ratio of waist and 
hip circumferences (WHR) in cm. Sitting blood pressure was measured at the right 
upper arm with a random-zero sphygmomanometer. The average of two 
measurements obtained at one occasion was used in the analyses. Hypertension 
was defined as a systolic blood pressure of 160 mm Hg or a diastolic pressure of 
95 mm Hg or the use of antihypertensive drugs (25). 
Biochemical measurements Fasting blood samples were taken by venipuncture 
between 8 and 9 A.M. and allowed to coagulate for 30 minutes. 
Subsequently, serum was separated by centrifugation and quickly frozen in liquid 
nitrogen. Dissociable free IGF-I was measured with a commercially available non-
competitive two-site immunoradiometric assay (Diagnostic System laboratories 
Inc.; intraassay and interassay C.V. : 10.3% and 10.7%, respectively) (8). The free 
IGF-I assay used needs no initial sample exlraction as part of the standard 
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procedure to measure IGF-I, Samples are added directly to tubes containing a 
dense coating of high-affinity free IGF-I antibody, incubated for 2 hr at room 
temperature, washed, incubated with 12'1 labeled antibody directed to a second 
epitope, washed and counted. Assay standards are rhIGF-I: 0.04-2.6 nmol/L, the 
minimal detection limit is 0.004 nmol/L. There is no cross-reactivity with IGF-II and 
no residual IGFBP-1 or IGFBP-3 is detectable after the first wash. It is likely that 
the free IGF-I fraction measured with the free IGF-I assay, is a combination of the 
true free IGF-I and the fraction that can be readily dissociated from IGFBPs under 
the specific assay conditions (8). Addition of pure IGFBP-1 and -3 to an IGF-I 
containing buffer caused a dose-related decrease in measurable free IGF-I (8). 
TotalIGF-1 was determined by a commercially available radioimmunoassay 
(Medgenlx Diagnostics; intraassay and interassay G.V.: 6.1%; and 9.9%) after an 
acidification/neutralization step. The purpose of this step is to convert the different 
forms of IGF-I present into free IGF-I. A commercially available immunoradiometric 
assay was also used for measurement of IGFBP-1 (MW 25.3 kD) (Diagnostic 
System Laboratories Inc.; intraassay and interassay G.V. : 4.0% and 6.0%). Insulin 
was determined by a commercially available radioimmunoassay (Medgenix 
Diagnostics, intraassay and interassay G.V.: 8.0% and 13.7%). Serum glucose, 
creatinine, cholesterol, HDL-cholesterol and triglyceride levels were determined with 
standard laboratory methods. 
Statistical Analysis The clinical characteristics are presented as means (SE). 
Differences between subgroups with or without cardiovascular symptoms and signs 
were analyzed by linear regression after adjustment for age and sex. Multiple linear 
regression analyses were used to further assess the associations of free 
IGF-I, and IGFBP-1 with other parameters. A two-sided propability of p<0.05 was 
considered statistically significant. Analyses in which the values were 
logarithmically transformed yielded similar results to those with untransformed data. 
Because the interpretation of logarithmic data is difficult, the non-transformed data 
are presented. Age-adjusted OR (with 95 % GI) were calculated as an 
approximation of the relative risk of free IGF-I for the presence of atherosclerotic 
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plaques and coronary artery disease. All statistical analyses were performed with 
Stata statistical package (Computing Resource Center). 
Results 
In Table 1, the general characteristics of the study population are presented. The 
percentage free over total serum IGF-I varied between 0.14 and 2.77 "10. Serum 
free IGF-I increased 0.003 nmol/L per nmol/L total IGF-I (SE 0.0004, P<O.OOl, 
adjusted for age and sex) and decreased -0.013 nmol/L per nmol/L IGFBP-1 (SE 
0.004, P=0.003, adjusted for age and sex). Serum total IGF-I levels decreased 
2.766 nmol/L per nmol/L serum IGFBP-1 (SE 0.596), P<O.OOl(adjusted for age 
and sex). Age- and sex adjusted fasting free IGF-I levels were Inversely related to 
serum triglycerides, but showed no relation with most cardiovascular risk factors 
(Table 2). After further adjustment for insulin, the relation between free IGF-I and 
serum triglycerides became even stronger (regression coefficient -3,1 (mmol/L) per 
nmol/L free IGF-I, p=0.01). 
Total IGF-I was positively related to serum glucose (regression coefficient: 0.022 
(SEO.OOB) mmol/L per nmol/L serum IGF-I, p=O.OOB) but not to any of the other 
investigated cardiovascular risk factors mentioned in Table 2 (data not shown). 
IGFBP-1 showed an inverse relation with insulin, glucose, BMI and WHR and a 
positive relation with HDL-cholesterol (Table 2). The associations between IGFBP-1 
and, HDL cholesterol, WHR, and BMI remained significant after adjustment for 
fasting insulin levels (regression coefficients per nmol/L IGFBP-1 were respectively: 
0.06 (SE 0.03) (mmol/L, p=0.03); -0.02 (SE 0.01), p=0.009, and -0.63 kg/m' (SE 
0.27, p=0.02), while the association between IGFBP-1 and serum glucose lost 
statistical significance after this adjustment. 
Free IGF-I and presence of cardiovascular diseases. 
Age- and sex adjusted mean free IGF-I levels were lower in subjects with at least 
one plaque in the carotid arteries compared to those without plaques (difference 
0.017 nmol/L (SE O.OOB), p=0.02). Free IGF-I levels were also lower in subjects 
with coronary artery disease than in those without (difference 0.018 nmol/L 
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Table 1. General characteristics of 218 subjects (103 men, 115 women) 
Mean SE Range 
Age (years) 66.7 (OA) 55.0-82A 
BMI (kg/m') 26.4 (0.2) 16.4-43.1 
WHR (cm/cm) 0.92 (0.006) 0.66-1.12 
TotaIIGF·I* (nmol/l) 18.7 (0.5) 3.1-41.3 
Free IGF·I* (nmol/l) 0.092 (0.004) 0.02-0.28 
Percentage 
Free IGF·I/ TotaIIGF·I* 0.55 (0.02) 0.14-2.77 
IGFBP-l (nmol/l)* 0.77 (0.06) 0.04-6.07 
Insulin *(IU/ml) 13.5 (0.5) 2A-44.2 
Glucose*(mmol/l) 5.9 (0.06) 4.7-11.9 
Cholesterol* (mmol/l) 6.8 (0.08) 2.8-12.5 
HDl·cholesterol* (mmol/l) 1.36 (0.03) 0,70-2.80 
Triglycerides* (mmol/l) 1.96 (0.07) OA7-7A2 
Systolic BP (mm Hg) 139.2 (1.31) 96-185 
Diastolic BP (mm Hg) 74.8 (0.67) 44-97 
Hypertension t (%) 30.1 
Anamneslically Angina Pectoris (%) 7.6 
Anamnestically Myocardial Infarction (%) 20.3 
Myocardial Infarction on ECG (%) 22.1 
Atherosclerotic plaques in carotid arteries (%) 62.8 
Carotid intima media thickness (mm) 0.76 (0.13) OA9-1.49 
Smoking (%) 
Current 24,3 
Former 50.5 
Never 25.2 
Values are means with standard error (SE) between parentheses 
8MI, body mass index; WHR, waist·ta.hip ratio; IGF-I: insulin-like growth factor I; lGFBP: Insulin-like growth fat 
binding protein; BP:::bJood pressure 
Fasting blood samples 
t Hypertension was defined as a systolio BP of 160 mm Hg or over and/or diastolic pressure of 95 mm Hg or 0 
and/or use of antihypertensive drugs 
Table 2. Age~ and gender adjusted associations between fasting free lGF~1 and IGFBP~1, respectively, and several cardiovascular risk factors in 
an elderly population ( aged 55-80 years). 
Regression Regression 
Coefficient (SE) p value Coefficient (SE) p value 
A. Free IGF-I (nmol/L) B. IGFBP-l (nmol/L) 
Systolic BP (mm Hg) -6.3 (24.8) 0.80 -1.9 (1.5) 0.21 
Diastolic BP (mm Hg) 4.5 (13.0) 0.73 -1.0 (0.8) 0.22 
Cholesterol' (mmol/L) -2.1 (1.6) 0.18 -0.01 (0.09) 0.89 
HDL Cholesterol' (mmol/L) 0.16 (0.46) 0.73 0.08 (0.03) 0.004 
Triglycerides' (mmol/L) -2.8 (1.4) 0.04 -0.02 (0.08) 0.85 
Insulin'(IU/mL) 6.0 (10.2) 0.56 -2.0 (0.6) 0.002 
Glucose' (mmol/L) 1.8 (1.2) 0.14 -0.18 (0.07) 0.02 
WHR -0.11 (0.10) 0.29 -0.02 (0.006) 0.001 
BMI (kg/m2) 5.78 (4.89) 0.24 -0.98 (0.29) 0.001 
;, Fasting values, for used abbreviations see legends Table 1 
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(SE 0.009), p=0.04) (Table 3). Age- and gender-adjusted free IGF-I levels were not 
related to the carotid intima media thickness (regression coefficient per 0.01 nmoljL 
IGF-I: 0.0012 (SE 0.0016) mm, p=0.47). Mean free IGF-I levels were lower in 
subjects with a history of angina pectoris, and higher in subjects with hypertension 
but this value did not reach statistical significance after adjustment for age and sex 
(Table 3). Serum free IGF-I levels were significantly higher in subjects who had 
never smoked (p=0.02) than in ever (former and current) smokers. Mean free IGF-I 
levels were higher in subjects without any actual sign of cardiovascular disease 
(i.e. no angina pectoris, no myocardial infarction on the electrocardiogram and no 
atherosclerotic lesions in the carotid arteries), than in subjects with at least one 
symptom or sign of cardiovascular disease (i.e. angina pectoris and/or myocardial 
infarction on the electrocardiogram and/or atherosclerotic lesions in the carotid 
arteries) (0.107 nmol/L (SE 0.008) vs 0.086 nmoljL (SE 0.004), p=0.002 adjusted 
for age and sex; see Figure 1). This association remained significant after further 
adjustment for smoking and hypertension. 
For total IGF-I, lower levels were observed in groups with presence of one 
cardiovascular disease and/or risk factor than in those without. The difference in 
total IGF-I levels was significant for angina pectoris; mean total IGF-I in subjects 
with angina pectoris: 15.0 (SE 2.1) nmol/L and 19.1 (SE 0.6) nmoljL in subjects 
without angina pectoris (adjusted for age and sex, p=0.04). 
Mean IGFBP-l levels were not significantly different in subgroups with or 
without cardiovascular diseases and risk factors, hypertension or smoking(Table 3). 
Age-adjusted multiple logistic regression analysis performed with the 
presence of atherosclerotic plaques and the presence of coronary artery disease 
as dependent variable, respectively, and free IGF-I as independent variable-
showed a significant decreased risk for the presence of plaques per 0.D1 nmol/L 
increase in serum free IGF-I level: OR 0.94 (95 % CI: 0.89·0.99) per 0.01 nmoljL 
(P=0.03), and a decreased risk for the presence of coronary artery disease per 
0.01 nmol/L increase in serum free IGF-I level: OR 0.91 ( 95 % CI: 0.84-0.99) per 
0.01 nmol/L (p =0.02). 
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Table 3. Fasting free IGF-I(A) and IGFBP-1 (B) levels (both expressed in nmol/L) in subjects with vs subjects without 
symptoms and signs of cardiovascular diseases, hypertension, and smoking. 
A. Free IGF-I 
History of Angina Pectoris 
Coronary artery disease 
Atherosclerotic plaques in Carotid arteries 
Hypertension 
Smoking 
B. IGFBP-1 
History of Angina Pectoris 
Coronary artery disease 
Atherosclerotic plaques in Carotid arteries 
Hypertension 
Smoking 
Present 
Mean 
0.084 
0.077 
0.088 
0.096 
Ever 
0.086 
0.657 
0.813 
0.754 
0.846 
Ever 
0.802 
(SE) 
(0.012) 
(0.005) 
(0.004) 
(0.006) 
(0.004) 
(0.102) 
(0.091) 
(0.062) 
(0.080) 
(0.070) 
Absent 
Mean 
0.092 
0.096 
0.101 
0.091 
Never 
0.110 
0.785 
0.813 
0.812 
0.831 
Never 
0.699 
(SE) 
(0.004) 
(0.004) 
(0.006) 
(0.005) 
(0.007) 
(0.065) 
(0.099) 
(0.121) 
(0.077) 
(0.112) 
p-value* 
0.67 
0.04 
0.02 
0.73 
0.02 
0.66 
0.62 
0.45 
0.09 
0.10 
* p value for the differences in free lGF-1 and lGFBP~1 levels, respectively, between subgroup with vs subgroup without cardiovascular diseases, 
hypertension and smoking adjusted for age and gender 
0.3 
:; 
o 
E 0.2 
S 
iI 
!2 
~ 0.1 
Cardiovascular disease 
p<O.002 
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Figure 1. Mean free IGF-I levels (adjusted for age and gender) compared between 
subjects without signs and symptoms of cardiovascular diseases (left) and subjects 
with at least one cardiovascular symptom or sign (right). The line in the middle of 
the boxes represents the 50Jh percentile of the data. The boxes extend from the 
25th percentile to the 75th percentile values, the whiskers extend from the 5th to 
the 95th percentile values of each group (difference 0.026 nmol/L (SE 0.008), 
p=0.002). 
Discussion 
Mean free IGF-I levels were significantly lower in subjects with atherosclerotic 
plaques in the carotid arteries and with coronary artery disease. When subjects 
without symptoms or signs of cardiovascular diseases (i.e. no angina pectoris, no 
myocardial infarction on the electrocardiogram and no atherosclerotic plaques in 
the carotid arteries) were compared with those with at least one symptom or sign 
of cardiovascular disease, mean free IGF-I levels were significantly higher in the 
former group. These findings suggest that lowered free IGF-I levels are associated 
with a higher prevalence of cardiovascular disease. Low circulating IGF-I levels 
have been previously associated with angiographically documented coronary artery 
disease (26). Other investigations have also suggested that low circulating IGF-I 
levels are associated wilh premature atherogenesis, cardiovascular morbidity and 
mortality (27, 28, 29). However, these latter studies need to be considered with 
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caution, because they were retrospective studies, while many subjects in these 
studies showed also deficiencies for other pituitary hormones, which might have 
been suboptimally replaced. 
Serum free IGF-I is considered as an important biologically active IGF-I 
fraction (7). The serum free IGF-I levels in our study lie within the same range as 
previously reported for the affinity of the IGF-I receptor on both vascular 
endothelium as well as vascular smooth muscle cells (3, 30). Because endothelial 
cells are continuously exposed to IGF-I in vivo, it is conceivable that circulating 
(endocrine) IGF-I might be of importance in both the normal physiology of vascular 
endothelium and in disease states (e.g. atherosclerosis) (31). Evidence exists that 
IGF-I does cross vascular endothelium and in this respect might be comparable to 
insulin {3~, 32). The importance of circulating (endocrine) IGF-I has been 
challenged by the autocrine/paracrine concept of IGF-I since most cells implicated 
in the pathogenesis of atherosclerosis are capable of expressing (auto· and 
paracrine) IGF-I, IGF-I receptors, and IGFBPs (I). There are many who even 
believe that there is no role for circulating IGF-I in the development of 
atherosclerosis. Some arguments in favour of this view are: that the expression of 
IGF-I in the vessel wall is independent of pituitary growth hormone secretion (33), 
and endothelial denudation of blood vessels in rats increases the accumulation of 
IGF-I in vascular smooth muscles without concomitant changes in hepatic IGF-I 
mRNA expression and serum total IGF-I levels (34). However, both observations 
can also be explained by an increased proteolysis of circulating IGFBPs by specific 
IGFBP- proteases present in serum (as plasmin and thrombin), contributing to an 
increased delivery of IGF-I at an injury of the vascular endothelium (35, 36). This 
mechanism may then result in increased association of IGF-I with IGF-I receptors 
on vascular smooth muscle cells during repair of injured arterial intima. This 
response to injury might be reflected in (transiently) lower serum free IGF-I levels 
as a consequence of consumption. In addition, the frequently used immunoreactive 
techniques to localize IGF-I ultrastructurally in atherosclerotic plaques do not 
demonstrate the origin of IGF-I (locally produced or endocrine). Other arguments in 
favour of a physiological effect of circulating IGF-I on the vessel wall are: 
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that administration of exogenous IGF-I to human retinal vascular endothelium cells 
in culture causes decreased IGF-I mRNA levels in these cells (37); and finally, 
several studies suggest that the majority of IGF-I secreted by vascular endothelial 
cells (in contrast to IGFBPs) results from IGF-I uptake from serum and not from 
local de novo synthesis (30, 38). These studies suggest that intact endothelium 
serves as a regional storage site for intravascular receptor-bound IGF-I . 
Recent data suggest that IGF-I stimulates the production of NO from both the 
endothelium and vascular smooth muscles (39). Decreased NO production by 
vascular endothelium due to low free IGF-I levels, might be a mechanism, which 
could contribute to the observed relation between free IGF-I levels and the 
presence of cardiovascular symptoms and signs in our study (40). 
In our study free IGF-I levels were inversely associated with fasting 
triglycerides. Indeed, administration of recombinant IGF-I to humans was reported 
to cause a decreasel in triglyceride levels (41). 
Also in our study no relationships were found between (free and total) IGF-I 
and BMI or WHR. The total amount of excess fat on the body is roughly reflected in 
the BMI, wheras WHR is more strongly associated with the amount of abdominal 
fat. Several epidemiological studies suggest that abdominal obesity may especially 
be involved in atherosclerosis (42) and that a decreased growth hormone 
secretion is an endocrine characteristic of obesity (43). Growth hormone 
dependent IGF-I concentrations would thus be expected to be subnormal in 
obesity (44). However, total IGF-I levels have been reported not to be significantly 
different between obese subjects and lean control subjects (44, 45). In this latter 
study free IGF-I levels were reported to be higher in obese males while free IGF-I 
levels were not significantly elevated in obese females (45). The differences 
between these results and our are most likely due to difference in age, sex and 
degree of obesity in the study group as the subjects in our study were older, 
predominantly female and less obese. Moreover, in our study another method was 
used to measure free IGF-I levels. 
Higher fasting age-adjusted IGFBP-l levels were associated with decreased 
BMI, WHR, insulin and glucose levels, and increased HDL cholesterol levels. In a 
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previous study, it was demonstrated that reduced fasting IGFBP-l levels correlate 
with an increased prevalence of cardiovascular risk factors in non-insulin 
dependent diabetes mellitus (46). Our study shows that this relationship Similarly 
exists in a non-diabetic population and that the reverse is also true, i.e. higher 
IGFBP-l levels are associated with an advantageous cardiovascular risk profile. 
Insulin is considered as the main regulator of IGFBP-l levels, while it also 
modulates the action of IGFBP-l (11): it also accelerates IGFBP-l transport from 
the intravascular space through the endothelial walls of the capillaries to the target 
cells (11, 12). However, the associations between IGFBP-l levels and BMI, WHR 
and HDL-cholesterol were independent of insulin levels. This suggests that a low 
IGFBP-l level might be an independent marker for the metabolic disturbances, 
which are all associated with an increased risk of cardiovascular diseases. 
Studies of the biological effect of IGFBP-l have shown conflicting results. IGFBP-l 
is capable of both inhibilion and augmentation of IGF-I bioaclivity (47). These 
conflicling observations may be explained by the recent findings that differential 
phosphorylation of IGFBP-l could significantly alter its affinity for IGF-I, and 
therefore differently modulate IGF-I bioactivity (48). The IGFBP-l assay used in our 
study cannot discriminate phosphorylated and non-phosphorylated IGFBP-l, but 
IGFBP-l normally circulates mainly as a highly phosphorylated form (49). This 
latter form of IGFBP-l would favor sequestration of IGF-I by IGFBP-l resulting in a 
decreased IGF-I release to IGF-I receptors (47). The observed lower IGFBP-I levels 
in subjects with a disadvantageous cardiovscular risk profile, might be thus an 
adaptive mechanism to increase IGF-I bioactivity at the vascular endothelium. 
Although most cells implicated in the pathogenesis of atherosclerosis are 
capable of expressing (autocrine and paracrine) IGF-I, IGF-I receptors, and IGFBPs, 
the results of our study suggest that the measurement of circulating free IGF-I and 
IGFBP-l levels may be of clinical relevance and will help to unravel the role of the 
IGF-I/IGFBP-l system in atherogenesis. 
In conclusion, our findings indicate that low circulating free IGF-I levels are 
associated with an increased risk of presence of atherosclerotic cardiovascular 
disease. In addition, higher IGFBP-l levels are related to a more favourable 
cardiovascular risk factor profile. These findings lend support to the view that the 
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IGF-I/IGFBP-l system is related to cardiovascular risk in the elderly population. 
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Summary 
Oblective: Little is known about the association between free IGF-I levels and bone 
mineral density (BMD). 
Design: Cross-sectional study of 218 healthy subjects (103 men, 115 women, age 
55-80 yrs) 
Methods: fasting serum free, total IGF-I, estradiol and SHBG levels were 
measured. The ratio of estradiol to SHBG was used as an index of free estradiol. 
BMD measurements were performed by dual-energy X-ray absorptiometry (DXA) of 
the lumbar spine and the proximal femur. 
Results: In multivariate analyses with BMD of the lumbar spine as the dependent 
variable and serum free IGF-I, age, BMI and the free estradiol index as 
independent variables- the free IGF-I was positively related to the BMD of the 
lumbar spine in men (p~0.02) but not in women. When the same analyses for the 
lumbar BMD were performed with total serum IGF-I the association also was only 
statistically significant in men (p~0.05). In multivariate analyses with the trochanter 
BMD as the dependent variable and serum free IGF-I, total IGF-I, age, BMI and the 
free estradiol index as independent variables- the associations between (free and 
total) IGF-I and the trochanter BMD in men was borderline significant. 
Conclusions: In elderly men free and total IGF-I were positively related to lumbar 
BMD, while (free and total) IGF-I was borderline positively related to trochanter 
BMD. As these relations were not observed in elderly women, we suggest a weak 
gender-specific anabolic effect of IGF-I on BMD on trabecular bone. 
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Introduction 
Insulin-like growth factor-I (IGF-I) and its specific Insulin-like growth factor binding 
proteins (lGFBPs) are postulated to playa key role in bone metabolism (1)_ It is 
generally agreed that IGF-I has anabolic effects on bone cells (2). It has been 
shown to be an important regulator of bone remodelling and growth (3) and has 
been found to stimulate collagen synthesis in bone, resulting in increased matrix 
production (4). Bone cells synthesize IGF-I and all of the six IGFBPs (1) and 
observations in osteoblast-like cell-lines have suggested that skeletal 
concentration of IGF-I is a reflection of its local synthesis by osteoblasts (3). 
Recently a method was developed to measure free serum IGF-I (5, 6). Free 
IGF-I, analogous to free sex and adrenal steroids and thyroid hormones, is likely to 
be a major biologically active hormonal form of IGF-I (7). 
Estrogens have a protective effect on bone mass and slow bone loss during 
aging (8). Moreover, it has been suggested that the estrogen status in women has 
a complex effect on serum concentrations of IGF-I and therefore has to be taken 
into account when evaluating levels of serum IGF-I (9). 
In order to gain more insight into the relations between systemic IGF-I, 
estrogens and bone mineral density (BMD) in the elderly, we measured serum free 
and total IGF-I levels, estrogens and bone mineral density in 218 healthy elderly 
subjects. 
Materials and methods 
Study population 
The population for the present study included 218 subjects aged 55 to 80 years, 
who had completed the baseline visit of the Rotterdam Study not more than six 
months earlier. The Rotterdam Study is a population based prospective cohort 
study of determinants of chronic disabling diseases in the elderly as described 
elsewhere (10). Briefly, all 10,275 inhabitants of a suburb of Rotterdam, aged 55 
years and over, were invited to participate. From the 9161 independently living 
persons 77% participated in the interview and 71 % also had extensive 
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examinations including bone density measurements. 
The 218 people that took part in the present study were randomly selected from 
the 7983 participants of the Rotterdam Study after exclusion of subjects with acute, 
psychiatric disease or diabetes. Compared to the other participants of the 
Rotterdam Study without known diabetes mellitus, there were no differences in age 
and gender distribution, mean blood pressure, use of antihypertensive drugs, 
echo cardiographic evidence of atherosclerotic plaques in the carotid arteries and 
electrocardiographic abnormalities. Only four women in this study population were 
on hormone replacement therapy. These four women were excluded from analysis. 
From all subjects informed consent was obtained and the study was approved by 
the medical ethics committee of Erasmus University Medical School. 
Measurements 
Biochemical measurement Participants were examined in the morning after an 
overnight fast. Fasting blood samples were taken by venipuncture between 8.00 
and 9.00 a.m. and allowed to coagulate for 30 minutes. Subsequently serum was 
separated by centrifugation and quickly frozen in liquid nitrogen. Free IGF-1 was 
measured with a commercially available two-site immunoradiometric assay 
(Diagnostic System Laboratories Inc., Webster, Texas, U.S.A.; intraassay and 
inter-assay coefficients of variation (C.V). : 10.3% and 10.7%, respectively) (5,6). 
The free IGF-1 assay needs no initial sample ex1raction as part of the standard 
procedure to measure IGF-1. Samples are added directly to tubes containing a 
dense coating of high-affinity free IGF-1 antibody, incubated at 2 hr at room 
temperature, washed, incubated with 12'1 labeled antibody directed to a second 
epitope, washed and counted. There is no cross-reactivity with IGF-1I and no 
residual IGFBP-l or IGFBP-3 is detectable after the first wash. It is likely that the 
free IGF-1 fraction measured with the free IGF-1 assay, is a combination of the true 
free and the fraction of IGF-1 which can be readily dissociated from IGFBP-s under 
the specific assay conditions (5). Total IGF-1 was determined by a 
commercially available radioimmunoassay (Medgenix Diagnostics, Brussels, 
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Belgium, intraassay and interassay C.V.: 6.1 and 9.9%} after an 
acidification/neutralization step. The purpose of this step is to convert the different 
forms of IGF-I present into free IGF-I. Estradiol was assayed with a 
radioimmunoassay (Diagnostic Products Corporation, Los Angeles, California, USA 
; intraassay and interassay C.V. : 7.0% and 8.1%). SHBG was assayed wilh a 
commercially available immunoradiometric assay (Diagnostic Products Corporation; 
intraassay and interassay C.V. : 3.6% and 6.9%, respectively). The ratio of estradiol 
to SHBG was used as an index of free estradiol (11). Height and weight were 
measured wearing indoor clothes and without shoes. Body mass index (BMI) was 
defined as weight divided by the square of height (kg/m'). 
Measurement of bone mineral density (BMD) BMD measurements were performed 
by dual-energy X-ray absorptiometry (DXA), using a Lunar DPX-L densilometer 
(Lunar Radiation Corporation, Madison, WI, USA). Standard positioning was used 
with anterior-posterior scans of the lumbar spine and the right proximal femur. If 
there was a history of hip fracture or prothesis implantation, the left femur was 
scanned. Using standard software the vertebrae L2 to L4, and at the proximal 
femur, the femoral neck, Ward's triangle and the greater trochanter were 
analyzed. Quality assurance included calibration with the standard of the machine 
and was performed routinely every morning. The in vivo coefficient of variation for 
BMD measurements was 0.9 % in the lumbar spine, 3.2 % in the femoral neck, 
3.1% in the Ward's triangle, and 2.5 % in the greater trochanter. 
Statistical Analysis Pearson's correlation coefficients were calculated to assess 
the associations between IGF-I and BMD, after adjustment for age, and other 
confounders when appropriate. Analyses in which the values were 
logarithmically transformed yielded results similar to those with untransformed data. 
Because interpretation of results from logaritmically transformed data is more 
difficult, the non-transformed results are presented. Linear regression analysis was 
used to calculate the statistical significance of differences in general characteristics 
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between men and women, as well as the associations between IGF-I and BMD, 
after adjustment for age, and other confounders when appropriate. A two-sided p-
value of <0.05 was considered significant. All statistical analyses were performed 
with Stata statistical package (Computing Resource Center, Santa Monica, Ca, 
U.S.A). 
Results 
In Table 1 general characteristics of the study population are presented. Men 
were slightly older than women. Mean (free and total) IGF-I levels did not differ 
between the sexes. Bone mineral density was (age-adjusted) higher in men than in 
women at all four measured sites. Mean free estradiol index was significantly higher 
in men than in women. 
Serum free IGF-I was positively associated with total IGF-I (r~0.35, p<O.OOI). 
Serum total IGF-I decreased with age in women, while this relation just missed 
significance in men (Table 2). Free IGF-I was not related to age in both sexes 
(Table 2). Free IGF-I was inversely related to BMI in men, but this latter relationship 
was lost after adjustment for age.Total IGF-I was not significantly related to BMI in 
both sexes (Table 2) .. 
No (age-adjusted) relations were present between serum free IGF-I and the free 
estradiol index in both sexes (men:r~0.13, p~0.21; women: r~ 0.16, p~0.10). 
Total serum IGF-I was (age adjusted) positively related to free estradiol index in 
men and women (men: r~0.24, p~0.02; women: r~0.26, p~0.008). 
No relations were observed in the total study population between free or total IGF-I, 
and the BMD of the lumbar spine, femoral neck, Ward's triangle and the greater 
trochanter, respectively, without further adjustments (to give an impression of the 
distribution of the data the relationships between (total and free) IGF-I and the 
lumbar spine and between (total and free) IGF-I and the greater trochanter are 
showed in Figure 1-2. Only in men free IGF-I and total IGF-I were significantly 
associated with BMD of the lumbar spine after adjustment for BMI and age 
(Table 3) 
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Table 1 Distribution of variables by sex 
Men Women 
n=103 n=111 p value 
Age (years) 67.6 (0.6) 65.9 (0.6) 0.05 
BMI (kg/m~ 26.4 (0.3) 26.6 (0.4) 0.70 ** 
Total IGF-I* (nmol/L) 19.3 (0.83) 17.9 (0.70) 0.11 ** 
Free IGF-I* (nmol/L) 0.088 (0.005) 0.095 (0.005) 0.22 ** 
SHBG* (nmol/L) 50.9 (2.0) 60.2 (2.7) 0.006 ** 
Estradiol*(pmol/L) 106.4 (17.2) 82.1 (4.8) 0.10 ** 
Free estradiol Index* 2.26 (0.25) 1.65 (0.13) 0.009 ** 
(pmol/nmol) 
Bone mineral density (g/cm~ 
Lumbar spine 1.19 (0.02) 1.03 (0.02) < 0.001 ** 
Femoral neck 0.87 (0.01) 0.81 (0.01) 0.003 ** 
Ward· s triangle 0.71 (0.02) 0.73 (0.01) 0.027 ** 
Greater trochanter 0.83 (0.01) 0.73 (0.01) < 0.001 ** 
Values are means with standard error between parentheses 
* Fasting values 
** Difference between men and women, adjusted for age. 
BMI: body mass index; IGF-I: insulin-like growth factor-I; SHBG: sex-hormone binding globulin 
Table 2. Association between fasting total and free IGF-I levels and age and BMI* 
TotalIGF-1 
Age 
Free IGF-I 
Age 
BMI 
TotalIGF-1 
Free IGF-I 
* Dependent variable is underlined 
men 
women 
men 
women 
men 
women 
men 
women 
-0.17 
-0.28 
0.14 
0.10 
-0.003 
0.09 
-0.20 
-0.004 
p value 
0.09 
0.003 
0.15 
0.27 
0.97 
0.35 
0.05 
0.94 
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The relation between both free IGF-I and total IGF-I, respectively, and trochanter 
8MD in men reached borderline significance after the same adjustments. In 
multivariate analyses with 8MD of the lumbar spine as the dependent variable and 
free IGF-I, age, 8MI and the free estradiol index as independent variables- the 
association between free IGF-I and the 8MD of the lumbar spine in men remained 
statistically significant ( r;0.24, p;0.02). When the same analyses for the lumbar 
8MD were performed with total IGF-I rather than free IGF-I, the association was 
statistically significant in men (r;0.21, p;0.05). In analyses with the trochanter 
8MD as the dependent variable and free IGF-I, age, 8MI and the free estradiol 
index as independent variables, the association between free IGF-I and the 
trochanter 8MD in men just missed significance (r;0.19, p;0.06). When the same 
adjustments were performed for the relation between the trochanter 8MD and total 
IGF-I, this association remained of borderline statistical significance (r;0.19, 
p;0.06). 
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Table 3. Associations between bone mineral density at various sites and fasting 
total and free IGF-I levels in men and women' 
Men Women 
p value p 
value 
Lumbar SRine 
TotalIGF-1 0.22 0.03 -0.10 0.35 
Free IGF-I 0.24 0.02 -0.009 0.93 
Femoral Neck 
TotalIGF-1 0.11 0.29 -0.12 0.27 
Free IGF-I 0.09 0.36 -0.05 0.65 
Ward's Triangle 
TotalIGF-1 0.15 0.15 -0.06 0.56 
Free IGF-I 0.15 0.14 -0.04 0.72 
Greater Trochanter 
TotalIGF-1 0.19 0.06 0.007 0.94 
Free IGF-I 0.18 0.08 0.02 0.89 
Dependent variable is underlined 
* adjusted for age and 8MI. 
Chapter 3 
Discussion 
In this population derived sample of elderly subjeots both free and total IGF-I were 
weakly positive related to BMD of the lumbar spine in elderly men, but not in 
women. In men also the relation between both total and free IGF-I and troohanter 
BMD reaohed borderline signifioanoe. 
These findings suggest that IGF-I levels do not play a major role in proteoting 
elderly from bone loss with aging. Serum free IGF-I levels are considered to be the 
major biologioally active hormonal form of IGF-I (7). However, the assessment of 
serum free IGF-I levels in our study did not give muoh additional information than 
total IGF-I, since the relationships between free IGF-I and total IGF-I and bone 
mineral density were almost identical. 
Previous studies have shown an age-related deorease in the serum level of total 
and free IGF-I (7, 12). Aging is also oharacterized by a decrease in bone density 
and a decrease in the IGF-I content of bone (13). Studies on osteoporosis in men 
have shown a relation between low bone mass and lower serum IGF-I levels as a 
oonsequenoe of deoreased growth hormone seoretion (14, 15). Other observations 
suggest that changes in the IGF-I oontent of bone may be related to ohanges in 
serum IGF-I conoentration (16), which raises the possibility that the skeletal 
conoentration of IGF-I reflects deposition from serum IGF-I, rather than local 
production (3). However, the relation between oiroulating (free and total) IGF-I 
levels and the lumbar and troohanter BMD in men, as observed in our study, 
oontributes little to the issue whether skeletal IGF-I is predominantly derived from 
looal produotion or from the oirculation. This is still a very complex issue as 
oiroulating IGF-I is a marker of growth hormone activity and may simply reflect the 
direot effects of growth hormone on local skeletal IGF-I production. Moreover, 
growth hormone and circulating IGF-I may have indireot effects on bone mass, 
whioh may have nothing to do with skeletal IGF-I produotion. For example, there 
are many interaotions between growth hormone/IGF-I and estradiol in men and 
women and between calcium and growth hormone. The issue is even more 
complex if one oonsiders that the interindividual differences in skeletal IGF-I 
ooncentrations in old age may have already existed in young age and correlations 
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concentrations in old age may have already existed in young age and correlations 
between IGF-I and bone mass may be due to mixtures of genetic and/or 
environmental influences (17). It is therefore possible that any association between 
IGF-I and bone mass in elderly individuals may be due to events which occurred 
long before the actual measurements were performed. 
No relations could be disclosed between free and total IGF-I and BMD in women. 
This latter relationship is similar to that reported in postmenopausal women by 
Kassem et al. (18), Bennett et al. (19) and Rosen et al.(20}. Although there are 
some studies which have shown a positive relationship between BMD and IGF-I in 
women (21, 22), the patients in the study of Pun et al. (21) had also a concomitant 
vitamin D deficiency, while in the study of Wuster et al. (22) both pre- and postme-
nopausal women were included in the study. In this latter study there also was a 
considerable difference in age and body weight between patients and controls. 
Finally, both these studies were not population based. 
The above mentioned associations between (free and total) IGF-I and (lumbar and 
trochanter) BMD in men turned out to be present only after adjustment for BMI. It 
has previously been demonstrated that weight and BMI are some of the strongest 
predictors of bone mass at all ages in both sexes (23, 24), and this effect is 
especially present at weight-bearing sites such as the lumbar spine and the femur. 
We observed strong associations between BMD and BMI in both sexes. In men 
this result might be related to the contribution of lean body mass to BMI, as it has 
been suggested that lean body mass is the principal determinant of BMD in men 
(25). 
In conclusion, a weak positive relation between serum IGF-I and BMD was 
observed in men but not in women, possibly indicating a gender-specific anabolic 
effect of IGF-I on trabecular bone. 
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Summary 
Background: Little is known about the influence of the free insulin-like growth 
factor-I/insulin-like growth factor binding protein (lGF-I/IGFBP) system on the 
quality of health and on disability in the elderly population. 
Design: In a cross-sectional population based study of 218 healthy elderly subjects 
(age 55-80 yrs) fasting free and total Insulin-like growth factor (IGF-I), insulin-like 
growth factor binding protein-1 (IGFBP-1) and insulin-like growth factor binding 
protein-3 (IGFBP-3) levels were measured. 
Subjective quality of health was assessed by asking all partiCipants whether they 
judged the quality of their health as better, the same or worse than that of their 
peers. Disability was determined by the Disability Index of the Stanford Health 
Questionnaire. 
Results: Mean serum free IGF-I levels were significantly lower in the 21 subjects, 
who experienced their health as worse, than that of their peers, compared to the 
181 subjects who experienced their health as better or the same as their peers 
0.069 nmol/L (SE: 0.009) vs 0.093 nmol/L (SE: 0.004) ) (p=0.04). Mean IGFBP-1 
levels were significantly higher in subjects, who felt less healthy than their peers 
1.23 nmol/L (SE: 0.26) vs 0.73 nmol/L (SE: 0.82) (p=0.01). 
Free and total IGF-I, IGFBP-1 and IGFBP-3 levels, were not different in subjects 
with the lowest and the highest Disability Index Score. 
Conclusion: Low free IGF-I and high IGFBP-1 levels are associated with a 
decreased self-reported quality of health, but are not related to physical disability in 
the elderly. 
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Introduction. 
Pituitary secretion of growth hormone (GH) and circulating levels of total insulin-
like growth factor-I (IGF-I) decline physiologically with age (1}.This gradual age-
related decline in IGF-I levels has been related to loss of lean body mass, atrophy 
of muscles, accumulation of body fat, loss of bone mass and reduced aerobic 
work activity, as they occur during natural aging (2,3). 
No population-based data are available in elderly adult individuals about the 
relationship between the IGF/IGFBP system and psychological well·being. 
Non·elderly adult patients with pathological GH deficiency are also characterized 
by loss of lean body mass, atrophy of muscles, loss of bone mass, and low IGF-I 
levels (4). Studies of adults with GH·deficiency, a state characterized by low total 
IGF-I levels, have indicated a decreased psychological well being (5). Replacement 
therapy of GH deficient patients with GH results in normalisation of total IGF-I levels 
and improved psychological well-being in most patients (6}.These data together 
suggest that low total IGF-I levels contribute or are related to decreased physical 
and psychological well-being during aging. In all these studies only the link 
between total serum IGF-I levels and physical and psychological well-being was 
investigated. Recently a well-validated method has been developed to measure 
free serum IGF-I levels (7, 8, 9). Serum free IGF-I level, analogous to sex and 
adrenal steroids and thyroid hormones, is likely to be a more biological active 
hormonal form of IGF-I (4). Measurement of serum free IGF-I levels may thus give 
more information on the biological effects of the GH-IGF-I axis than serum total 
IGF-1. 
Since little is known about the relationships between the IGF-I/IGFBP system and 
the quality of health and disability in the healthy aging elderly population, the 
current population based study was designed to investigate whether in healthy 
elderly men and women serum circulating levels of total and free IGF-I and IGFBPs 
are associated with the self-reported level of perceived health and with disability. 
Subjects and methods 
Study population For the present study, a sample of participants from the 
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Rotterdam Study was invited for an additional examination. The Rotterdam Study is 
a population-based cohort study of the determinants of chronic disabling diseases 
in the elderly. All approximately 10,000 inhabitants of a suburb of Rotterdam, aged 
55 years and over were invited to participate as described elsewhere (10). Overall 
7983 participants were examined in the Rotterdam Study (response rate 78 %). 
The population for the present study included subjects aged 55 to 80 years, who 
had completed the baseline visit of the Rotterdam Study not more than six months 
earlier. Subjects with acute, psychiatric or endocrine diseases, including diabetes 
mellitus treated with medication, were not invited. From these subjects a random 
sample of 218 persons was examined. Compared to the other participants of the 
Rotterdam Study without known diabetes mellitus, there were no differences in 
age and gender distribution, mean blood pressure, use of antihypertensive drugs, 
echocardiographic evidence of atherosclerotic plaques in the carotid arteries and 
electrocardiographic abnormalities. From all subjects informed consent was 
obtained and the study was approved by the medical ethics committee of Erasmus 
University Medical School. 
Measurements Information on self assessed heallh was obtained by a trained 
research assistant using a computerized questionnaire, who was unaware to the 
blood results. Participants were asked if they experienced their health as better, the 
same or worse than subjects of their own age. Sixteen subjects did not answer 
this question. Disability was assessed by the Disability Index of the Stanford Health 
Assessment Questionnaire (11). The disability index was composed of the mean 
score (0 indicating no impairment, 3 unable to perform) for six component 
questions on arising, walking, bending, and getting in and out of a car. 
Serum samples Participants were examined in the morning after an overnight fast. 
Fasting blood samples were taken by venipuncture between 8.00 and 9.00 a.m. 
and allowed to coagulate for 30 minutes. Subsequently serum was separated by 
centrifugation and quickly frozen in liquid nitrogen. Free IGF-I was measured with a 
commercially available two-site immunoradiometric assay (Diagnostic System 
Laboratories Inc., Webster, Texas, U.S.A.; intraassay and interassay C.V.: 10.3% 
and 10.7%, respectively) (7,8). Total IGF-I was determined by a commercially 
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available radioimmunoassay (Medgenix Diagnostics, Brussels, Belgium, intraassay 
and interassay coefficients of variation (C.V.): 6.1 %; 9.9%). Commercially available 
immunoradiometric assays were also used for measurement of IGFBP-l and 
IGFBP-3 (Diagnostic System Laboratories Inc; intraassay and interassay C.V. for 
IGFBP-l: 4.0% and 6.7 %, respectively; and for IGFBP-3: 1.8 % and 1.9%, 
respectively). Serum glucose levels were determined, using a standard glucose 
hexokinase method. Height and weight were measured wearing indoor clothes and 
without shoes. Body mass index was defined as weight divided by the square of 
height ( kg/m2). 
Statistical Analvsis Linear regression analyses were used to calculate gender 
differences in the baseline clinicical characteristics between men and women, after 
adjustment for age. Linear regression analysis was also used to test for trends in 
the IGF-I/IGFBP system index across groups with differences in quality of health 
adjusting for confounding variables. In this latter analysis the self-reported quality of 
health was used as independent variable in the model. The free IGF-I levels of 
those who scored zero on the Disability Index were compared with those of the 
remainder of the sample. Pearson's correlation coefficient was calculated to 
assess the association between self-reported quality of health and the Disability 
Index score. A two-sided p-value of <0.05 was considered significant. Analyses in 
which the values for the IGF-I/IGFBP system were logarithmically transformed 
yielded results similar to those with untransformed data. Because interpretation of 
results from logarithmically transformed data is difficult, the non-transformed results 
are presented. All statistical analyses were performed with the Stata statistical 
package (Computing Resource Center, Santa Monica, Ca, U.S.A). 
Results 
In Table 1 the general characteristics of the study population are presented. Men 
were slightly older than women. Mean (free and total) IGF-I and IGFBP-l levels did 
not differ between the sexes. IGFBP-3 levels were (age-adjusted) significantly lower 
in men, than in women 103.5 nmol/L (SE: 2.5) vs 115.7 nmol/L (SE: 2.4), p=0.002. 
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There were no sex- and age-specific differences in subjectively perceived health 
and disability score. 
Fasting total IGF-I and IGFBP-3 levels decreased with age {total IGF-I: 0.23 nmol/L 
per year (SE 0.09), p=0.04; IGFBP-3: 0.95 nmol/L per year (SE 0.29), p=0.001), 
while free IGF-I and IGFBP-1 levels remained stable. 
Mean serum free IGF-I levels were significantly lower in the 21 subjects (12 men, 9 
women) who felt less healthy than subjects of their own age, compared to the 181 
subjects (85 men, 96 women), who perceived their health as better or the same 
0.069 nmol/L (SE:0.009) vs 0.093 nmol/L (SE:0.004), p=0.04 (Figure 1 A). This 
difference remained significant after adjustment for gender, age, BMI, WHR, fasting 
insulin and glucose levels. Mean total IGF-I and IGFBP-3 levels did not differ 
between these two groups. Mean IGFBP-1 levels were significantly higher in 
subjects who felt less healthy than their peers {1.23 nmol/L (SE: 0.26) vs B: 0.73 
nmol/L (SE: 0.82), p=0.01 (Figure 1 B). This difference remained significant after 
adjustment for gender, age, BMI, WHR, fasting insulin and glucose levels. 
Free IGF-I levels were not significantly different in subjects with or without any 
disability 0.091 nmol/L (SE: 0.005) vs 0.093 nmol/L (SE: 0.005 ). For total 
IGF-I, IGFBP-1, and IGFBP-3 levels also no differences in serum levels were 
present in this respect (data not shown). There also was no relationship between 
free IGF-I, total IGF-I, IGFBP-1, and IGFBP-3 levels and Disability Index score when 
only subjects were analyzed who scored higher than zero for the Disability Index. 
The self-reported quality of health was (age-adjusted) significantly correlated with 
the Disability Index score (r=0.39, p<0.001) 
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Table 1. Distribution of variables in 218 elderly subjects (115 women and 
103 men) 
mean (SE) 
Age (years) 66.7 (0.4) 
BMI (kg/m) 26.4 (0.2) 
WHR 0.92 (0.006) 
Total IGF-I* (nmol/L) 18.7 (0.5) 
Free IGF-I* (nmol/L) 0.092 (0.004) 
IGFBP-1 * (nmol/L) 0.77 (0.06) 
IGFBP-3* (nmol/L) 110.0 (1.8) 
Insulin* (mIU/L) 13.5 (0.5) 
Glucose* (mmol/L) 5.9 (0.06) 
Subjectivel~ exgerienced 
Qualitv of Health 
Better than peers (%) 55.3 
Comparable to peers (%) 34.5 
Worse than peers (%) 10.2 
Disabili!¥ Index Score 
No disibality (no of subjects) 97 
With any disability (no of subjects) 115 
Values are means with standard error (SE) between parentheses, 
* Fasting blood samples 
8MI, body mass index; WHR, waist·to-hip ratio; IGF·J: insulin-like growth 
factor I; IGFBP: Insulin-like growth factor binding protein; See Methods for 
Disability Index Score 
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Figure lA Free IGF-I levels (vertical axis) divided by self-reported perceived 
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significant (p=O.OI). 
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Discussion 
Mean free IGF-I levels were lower in subjects who reported a decreased quality of 
general health compared to their peers. This relation was independent of age and 
gender. Although there was much overlap in the actual range of free IGF-I levels 
between the three categories of perceived quality of general health, our study 
indicates that free serum IGF-I levels tend to be lower in elderly, who feel 
unhealthy. Increases in IGFBP-1 levels result in increased binding of free IGF-I, 
thereby decreasing the amount of IGF-I available at the target cells (12). Our 
observation of increased IGFBP-1 levels in subjects who felt less healthy, is 
interesting in this context as these changes may be the cause of the lowered free 
IGF-I levels. Catabolism is generally characterized by low IGF-I and high IGFBP-1 
levels (13). This might indicate that subjects who feel less healthy are in a more 
catabolic state, or vice versa. However, at present it is not clear, whether the 
observed changes in free IGF-I and IGFBP-1 levels reflect cause, effect, or are 
mere correlates of (as yet undiagnosed) disease in this study population. 
In an earlier intervention study of elderly individuals, dehydroepiandrosterone 
administration induced an increase in the bioavailability of IGF-I (14). This increase 
in bioavailable IGF-I was accompanied by a an improvement of self-reported 
physical and psychological quality of health in both sexes (14). Studies of adult 
patients with GH deficiency, a state characterized by low free IGF-I levels (4), have 
indicated a decreased self-reported quality of health (5). Replacement therapy of 
GH deficient patients with GH results in normalisation of free IGF-I levels (15) and 
improved self-reported quality of health in most patients (6). These data, together 
with our observations suggest that low free IGF-I levels contribute or are related to 
decreased self-reported physical and psychological quality of health with aging. 
In our study, free and total IGF-I levels were not associated with physical disability. 
The quality of life of elderly individuals is more determined by their level of 
cognitive functioning and their ability to remain independent than by specific 
disability (16). This may explain for the observed difference between free IGF-I, 
disability and (self-rated) perception of health status. In accordance with our 
observation, it was recently reported that an age-related decline in IGF-I secretion 
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is not responsible for functional decline with age (16). 
In conclusion, low free IGF·I and high IGFBp·1 levels in both sexes are associated 
with a decreased perceived quality of health, but are not related to physical 
disability in the elderly. 
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Introduction 
As most if not all of the circulating growth hormone (GH) is produced by the 
pituitary gland, it is most likely that growth hormone deficiency (GHD) must be 
present in any patient without an anterior pituitary. The problem is however, that 
many patients still have some pituitary remnant after selective pituitary surgery, 
while GHD is often incomplete in those diagnosed during childhood. In these 
patient-groups, one therefore needs more information in order to determine 
whether GHD does exist. This has become more important after human GH 
became available for long-term treatment of adult GHD patients. Simultaneously, 
the role of GH as an important metabolic regulator during life is being gradually 
unraveled. Many studies have demonstrated that GH replacement therapy to GHD 
adults has significant beneficial effects on the quality of life, body composition, 
metabolic status and lipid spectrum (3, 5, 7, 30, 31, 50, 52, 58, 60, 61, 66, 94). 
However, the costs of this therapy remains an important problem. It is therefore 
mandatory to treat only those patients with proven GHD. The procedure of making 
the diagnosis of GHD remains controversial, however in the following pages we will 
try to formulate the most important practical tests and parameters, which can be 
used as diagnostic tools for GHD in adult patients. 
What Is GHD? 
Now the important regulatory role of GH for many tissues and metabolic processes 
has been revealed, it is not surprising that the signs and symptoms of GHD are 
versatile (See figure 1). According to the available literature and based upon 
clinical experience, the signs and symptoms of a typical patient with GHD have 
their origins in the following characteristics (7, 26, 47, 76, 79, 89): 
Increased fat mass (mainly localized around the hip) 
Reduced lean body mass, muscle mass and muscle strength 
Decreased extracellular water 
Lowered bone mineral density 
Impaired cardiac function 
Poor physical performance 
GHRH~C 
Yt\ GO 
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Circulation f GH-BP 
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Time 
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Figure 1 Overview of metabolic pathways of GH 
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Many of these features are also present in patients with other diseases. However, 
there are also many patients with a defect in anterior pituitary function after pituitary 
surgery, who do not have the clinical signs and symptoms related to long-standing 
GHD. The discriminatory value of these characteristics is therefore limited in the 
diagnosis of GHD. Apart from this, most patients with anterior pituitary insufficiency 
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are on replacement therapy with other pituitary hormones. A variety of symptoms 
encountered in GHD patients might be related to over or undertreatment with 
corticosteroids, thyroxine or sex-steroids. The clinical picture described above is 
important however for the selection of those patients in whom it will be necessary 
to perform a biochemical test to prove the presence of GHD. As GH secretion and 
insulin-like growth factor-I (IGF-I) levels decrease with increasing age, it is crucial 
to have available carefully collected age-and sex-specific control data both for GH 
stimulation tests, as well as for IGF-I levels in the circulation (99). This is especially 
true for elderly patients with a history of pituitary disease but with a normal 
production of the anterior pituitary hormones other than GH. These factors all 
together did raise the need for the development of reliable sensitive and specific 
tests to assess GH reserve. 
Growth Hormone reserve tests. 
As shown in Figure 2, both physiological and pharmacological GH secretion 
stimulatory tests have been developed, which can be used to distinguish between 
normal and GHD patients. These tests can be divided into tests which act directly 
GH: physiological 
• 12 or 24 h profiles 
• exercise stimulation 
• sleep 
• urinary GH 
• GH-binding protein 
pharmacological stimulation 
• insulin 
• glucagon 
• arginine 
• GHRH 
• clonidine 
• L-DOPNpropranolol 
• Pyridostigmine 
IGF-I and/or IGFBP-3 
Figure 2 Biochemical methods of diagnosis of GHD in adulthood 
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upon the pituitary gland, such as the GHRH test and tests which act via 
supra-pituitary mechanisms, such as the Insulin Tolerance Test (lIT). There are 
reports that peak GH concentrations after provocative testing correlate poorly with 
24-h mean concentrations in GHD, which suggests that provocative GH testing 
frequently does not correlate with endogenous GH secretion (10). 
Insulin Tolerance Test 
In the early seventies the first reports about GH stimulatory test methods, using 
insulin became available (32, 33). In 1986, Kaplan et a!. described the changes in 
hGH levels during insulin-induced hypoglycemia in a large group of short and 
normal children (68). The lIT remained the golden standard for the diagnosis of 
GHD. Rahim et a!. (109) compared the GH response to insulin·induced 
hypoglycemia, intravenous arginine administration, oral clonidine administration 
(100 and 200 /-Ig) and intramuscular glucagon in normal individuals. They found 
that the peak GH response in the lIT was significantly greater than for any other 
agent, followed by glucagon, arginine, clonidine 200 and 100 /-Ig and placebo 
respectively. Hoffman et al reported that hypopituitary subjects have significantly 
lower stimulated peak GH levels, mean 24 h. GH, IGF-I and insulin-like growth 
factor binding protein-3 (IGFBP-3) concentrations than normal subjects. Only the 
lIT however could separate GHD patients from normal individuals, while the other 
parameters (spontaneous GH secretion, IGFI and IGFBP-3) did show considerable 
overlap with normals (49). One has to keep in mind, however, that the 
reproducibility of the lIT (and other tests) is limited (48). The cut-off value of the 
maximal GH concentration after appropriate hypoglycemia is considered to be < 3 
/-Ig/L for "absolute" and ~ 5 /-Ig/L for relative GHD. The lIT is an uncomfortable test 
to the patient and whether it is a safe test when used in adult patients with 
hypopituitarism is still a matter of debate. The fact that these patients frequently 
also lack the increase in cortisol secretion as counteracting mechanism during 
hypoglycemia makes this test contra-indicated in patients with coronary heart 
disease, while it should only be carried out in experienced endocrine units under 
close supervision. seems not to be a major problem in every day practice. 
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Arginine and pyrldostigmine 
The intravenous administration of arginine stimulates pituitary GH secretion (1). The 
GH-releasing effect of both arginine and pyridostigmine is mediated via the same 
mechanism, namely, by suppression of endogenous somatostatin release. 
Combined administration of either arginine or pyridostigmine with GHRH has a 
striking powerful GH-releasing effect, which is considerably higher than that after 
GHRH alone (38, 39, 42, 43, 70). These test methods have been used for many 
years, especially in pediatric centers, mainly because they have been proven to be 
safe (55, 87, 95,101,105-107). Masuda et a!. suggested that some factor (or factors) 
other than GHRH and somatostatin are involved in the mechanism by which the 
ITT stimulates GH secretion, because the effect of insulin was not fully blocked in 
the presence of a somatostatin analog (75). 
GHRH and GHRP tests 
In normal man, several analogues of GHRH have been developed, which are safe, 
sensitive and specific stimuli to GH release. Continuous infusion of GHRH leads to 
a decrement in responsiveness, due at least in part to changes in hypothalamic 
somatostatin. The GH response to GHRH is also modulated by obesity, blood 
glucose levels, free fatty acids, and GH itself. (2, II, 12,37,44,45,80,84,97,100). 
The GH-releasing activity of hexarelin (GHRP-6), a new synthetic hexapeptide, 
after i.v. administration has a low variability and has been shown to be superior to 
the GH response to GHRH. The GH-releasing activity appeared to be dose 
dependent. Thus, hexarelin can be clinically useful to stimulate GH secretion in 
humans (36, 80). Especially if the ITT is contraindicated, or cannot be carried out 
under experienced and close supervision a combined arginine + GHRH or a 
combined arginine + pyridostigmine stimulation test are excellent and probably 
equally valuable alternatives. 
IGF-I 
As mentioned above, a decrease in circulating IGF-I levels occurs. This is the 
reason that the assessment of IGF-I alone is of limited value in elderly patients, as 
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long as one does not have carefully collected control values for all ages, as well as 
both sexes. If lowered IGF-I levels are found in a patient with otherwise disturbed 
anterior pituitary function, chances that this patient has GHD are high. IGF-I 
concentrations within the normal range do not rule out GHD, however. This 
necessitates further biochemical investigation, especially if other factors make GHD 
likely. Recently it has become possible to determine serum free IGF-I 
concentrations. Whether or not this free IGF-I plays a major metabolic role, or only 
reflects just a small non-significant amount of unbound IGF-I is not yet known. 
Hasegawa et al. demonstrated that patients with complete GH deficiency had low 
levels of both free IGF-I and total IGF-I, with 94% and 100% of the levels below the 
5ht percentile for age, respectively. They concluded that in the evaluation of 
childhood GHD the clinical utility of plasma free IGF-I measurements is similar to 
measurements of total IGF-I (46). Important confounders in the evaluation of serum 
IGF-I levels are malnutrition, cirrhosis of the liver, poorly controlled diabetes 
mellitus and hypopituitarism. 
IGFBP-3 
GH and e.g. sex-steroids, but not IGF-I, stimulate IGFBP-3 production. GHD 
therefore results in decreased IGFBP-3 levels. Serum levels of total IGF-I and 
IGFBP-3 reflect endogenous GH secretion in healthy children and exhibit little 
diurnal variation, which makes them good diagnostic markers for screening of GHD 
in short children, although some controversy still exists. The IGFBP-3 
concentrations in adult GHD, however, demonstrate a considerable overlap with 
values that are found in the lower ranges of IGFBP-3 levels in normal individuals 
(17, 18,22,63,64). In our study involving 173 patients with GHD IGF-I and 
IGFBP-3 levels were lower than the 5th percentile in 86 % and in 74 % of those 
patients with childhood onset GHD, while this was the case in 73 % and 45 % of 
the 99 patients with adult onset GHD (Figure 3). For this reason, the assessment of 
IGFBP-3 levels in adult GHD seems of limited value. Juul et al. reported however 
that in childhood onset GHD, both IGF-I and IGFBP-3 determinations predict the 
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outcome of GH provocative tests in adults suspected of GHD and these authors 
suggest that IGF-I, as well as IGFBP-3 serum concentrations are valuable 
diagnostic parameters in the evaluation of GHD in adults with childhood-onset 
disease (67). 
Other test methods 
Other ways to assess GH reserve in patients are e.g. the administration of clonidine 
(95) and the measurement of GH secretion during sleep (34), but these test 
methods have not been widely used in the diagnostic work-up of GHD in adult-
hood. Recently, highly sensitive assays for the detection of GH have become 
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Figure 3 Baseline correlation between serum IGF-I and IGFBP-3 in untreated 
adult·onset GHD. Note that a relatively large number of patients have normal 
IGFBP-3 concentrations in comparison with IGF·I levels. 
available. Reutens et al. did demonstrated that a sensitive Enzyme Linked Immuno-
sorbent Assay (ELISA), used to quantify 24 hr. integrated GH concentrations in 
normal and hypopituitary subjects did not clearly separate GHD patients from 
normal individuals, however, despite their impaired GH responses to In (85,86). 
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One might therefore conclude that the highly- and ultra sensitive assays have no 
additional value over the conventional Radio Immuno Assay (RIA's) and Immuno 
Radiometric Assay (IRMA's), despite their superior sensitivities. However, one 
should keep in mind that the cut·off values of GH responses to In mentioned 
above, refer to the use of polyclonal RIA for GH determination; these values should 
be amended if ultrasensitive GH assays are used. 
The optimal biochemical diagnosis of GHD. 
Hoffman et. al. reported that the In was the only test method, when compared to 
spontaneous GH secretion, IGFI and IGFBP-3, that was able to provide a 100 % 
diagnostic accuracy in defining GHD (49). The risk of inducing severe 
hypoglycemia in hypopiluitaristic patients because of their enhanced sensitivity for 
insulin however, remains an actual danger. Ghigo et al. reported extensively about 
the applicability of pyridostigmine (PO; a muscarinic cholinergic agonist), arginine 
and GHRH alone or in combination (38,41,74). PO + GHRH and arginine + GHRH 
tests are reliable tests for the diagnosis of primary GHO in childhood (25,40). 
The same group of investigators recently confirmed in a study in 45 patients with 
GHO and 326 healthy controls that IGF·I measurements had no value in the 
diagnosis of GH deficiency in adults aged over 40 years. IGF-I assessment was 
reliable however, in the group of young adults of 20·40 years of age. The ranges of 
peak GH responses to PO + GHRH and ARG + GHRH tests were clearly different 
between GHO patients and normal individuals. They concluded that both PO + 
GHRH and ARG + GHRH testing should be considered as reliable biochemical 
measurements of GH deficiency in adults. In the same study, both combinations of 
tests were slightly better than the In in stimulating GH secretion. In contrast to the 
PO + GHRH test, the ARG + GHRH test turned out to be reliable throughout the 
adult lifespan and appeared to be the most appropriate for palient compliance and 
safety (35). 
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Body composition 
Chapter 4 
There are many reports which demonstrated that untreated adult patients with GHD 
have an increase in total body fat mass (both in visceral and subcutaneous fat). 
Their lean body mass is decreased, as well as their bone mineral density, their 
muscle strength and exercise performance (6, 8, 9, 15, 19, 23, 26, 28, 59, 62, 72, 
88, 90, 92, 93). There are many techniques to measure body composition. Widely 
used are Bioelectric Impedance Analysis (BIA) , isotope dilution techniques, total 
body potassium assessment by 40K• total body water (TBW) by tritium dilution, total 
body nitrogen (TBN) by neutron activation, sum of skinfold assessment and finally 
dual-energy X-ray absorptiometry (DEXA), which has become more or less the 
golden standard. Apart from this multitude of methods for measuring body 
composition, one has to take into account that for mathematical purposes there are 
two-compartment and multicompartment body composition models. In a study by 
Bosaeus et. al. a comparison of several methods to estimate body fat in 25 
patients with known GHD was made. At baseline and at group level, the results of 
DEXA fat mass measurements correlated well with measurements based on TBW 
or TBK alone, in a four-compartment model based on TBK and TBW, and a 
mUlti-compartment model based on bone mineral (by DEXA), TBN and TBW. The 
frequently used body fat measurement by BIA agreed less well. They repeated 
these measurement after 12 months of GH treatment and found that body fat 
decreased by all methods used. This decrease was smaller by DEXA than by the 
other methods. The four-compartment model based on TBK and TBW, and TBW 
alone, showed the best agreement with changes in DEXA fat. They concluded that 
all methods demonstrate a decrease of body fat with GH replacement therapy, but 
variation between methods is considerable (19). On the average, total body fat in 
GHD adults is 7 kg higher in GHD patients than in normal controls (15, 88). 
Computer Tomography (CT) studies have revealed that muscle mass is decreased 
in GHD (24, 28, 65). GH significantly affects body water homeostasis: TBW content 
in GHD is decreased, while GH treatment, using the D20 dilution method induces 
an increase in TBW, with a maximal Increase within 4-6 weeks after start of 
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therapy (9). 
Although at present the role of GH in maintaining bone mineral density (BMD) 
during adult life is not completely understood, results obtained from many 
controlled and uncontrolled studies show that BMD in (adult) GHD is significantly 
reduced. Changes in BMD with GH replacement therapy can be observed. After a 
transient decrease in BMD, many studies reported an increase in BMD when 
patients are treated longer than 6 months (4, 5, 13, 14, 16, 20, 27, 29, 31, 50-52, 
56,57,61,69,82,102). 
Quality of Life (QOLl 
As GHD patients frequently complain about fatigue, lack of energy, social and 
sexual problems, validated questionnaires were developed that could quantify the 
degree of loss of quality of life. Frequently used are e.g. Nottingham Health Profile, 
the Self-Esteem scale, the Hospital Anxiety and Depression scale, the mental 
Fatigue Questionnaire, while nowadays more and more disease specific 
questionnaires are being developed (21, 53, 54, 73, 77, 78, 83, 90, 96, 104,108). 
Almost all questionnaires demonstrate that GHD and loss of QOL go hand in hand. 
In figure 4, the QOL score measured by the Nottingham Health Profile in GHD 
patients in comparison to other invalidating diseases is shown. This clearly shows 
that GHD is a true invalidating entity and needs treatment if possible. 
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Figure 4 Comparison between QOL scores (Nottingham Health Profile 
Questonnaire) for several chronic diseases. Note that GHD is an incapacita-
ting condition. From left to right per parameter: rheumathoid arthritis, breast 
cancer, coronary heart disease, diabetes, adult·onset GHD, childhood-onset 
GHD. 
Childhood onset GHD 
Several reports indicate that in childhood onset adult GHD patients, especially 
those with idiopathic GHD, the GH status has to be reinvestigated to confirm GHD 
(71,81,91,103). Clearly Nicolson et al. demonstrated, using the ITT as stimulatory 
test, that childhood onset adult GHD patients, due to previous irradiation of the 
skull showed an increase in the incidence of GHD during adulthood (48.8 versus 
55.8%). Patients diagnosed in the past as idiopathic GHD, however, did show a 
decrease in incidence of GHD during adulthood (78.1 versus 53.1%). Roughly 47 
% of these patients with an initial maximal GH concentration of less than 5 I'g/L in 
the ITT showed a maximal GH level of higher than 5 I'g/L during a second test in 
adulthood (81). 
Another important factor is the number of other concomitant anterior pituitary 
insufficiencies that is present in a patient, suspected to have GHD. Toogood et al. 
demonstrated in a group of 190 patients with pituitary disease that GHD was 
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present in 91 % of the patients with two or three other anterior pituitary insufficien-
cies. When one pituitary hormone insufficiency was present, only 55% of these 
patients had also GHD. When no pituitary insufficiencies were found, only 24% of 
these individuals turned out to be GHD (98). 
Recommendations 
Even more important than to decide which test, or which parameter to use when 
GHD is suspected, is the issue of whom should be tested in the first place. 
We propose the following guide-lines: 
In the absence of other signs and symptoms of hypothalamic or pituitary 
dysfunction, or previous GH therapy during childhood persons do not need to 
undergo tests for GHD. For this purpose, some sort of score has to be developed, 
which gives the physician an indication whether a patient is at risk for GHD. This 
will lead to a more uniform approach of the diagnostic work-up of GHD. 
This score must preferentially include data obtained from a (disease specific) 
QOL questionnaire, the assessment of the number of other pituitary insufficiencies 
present in the patient and the clinical signs and symptoms, which are known to 
frequently occur after long-term GHD. Also helpful at this stage of the diagnostic 
process is the measurement of body composition of the patient. 
If this score indicates that the chances of a given patient having GHD is high, 
an assessment of total (or free) IGF-I concentrations should be performed in 
patients younger than 40 years of age. An IGF-I level less than 2 standard 
deviations « - 2SD) below the age specific normal value should be considered 
as proof for the existence of GHD. Only in cases when absolute evidence must be 
obtained (for example for health care authorities, authorizing the prescription of 
GH), one single stimulatory test to assess GH reserve could be performed. 
Patients older than 40 years of age and younger patients with a IGF-I 
concentration higher than - 2 SD below the age specific normal value should 
undergo at least one, but preferentially two stimulatory tests. It is antiCipated that 
the combined arginine + GHRH test (or combined arginine + pyridostigmine test), 
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promoted by Ghigo et al. will proof itself as a test method with sufficient potency to 
be used as a single test (35). Figure 5 shows this proposed diagnostic route. 
At present the post-marketing studies carried out by the major GH 
producing companies, include at least one QOL scale, some body composition 
measurement and at least one GH stimulatory test. Hopefully these studies will 
enable us to eventually manufacture an easier diagnostic flowchart, which can be 
used in future patients. 
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Figure 5 Proposal for a flow chart for diagnosing GHD. Preferentially, a 
quantitative score must first be developed, consisting of at least three para-
meters: QOL, body composition and number of other pituitary insufficiencies. 
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Chapter 4 
Summary 
Objective: Elevated serum IGF-I and IGF binding protein-3 (IGFBP-3) levels have 
been found in patients with active acromegaly. We have studied the relative 
diagnostic merits of measurements of IGFBP-3 over IGF-I as a parameter of 
disease activity in these patients. 
Design/Patients: Thirty untreated patients with acromegaly were compared with 30 
healthy adults. 
Measurements: 24 h sampling for serum GH in patients with acromegaly, serum 
IGF-I and IGFBP-3. 
Results: Mean IGF-I levels amounted to 22.0 nmol/L (range: 6.5 - 38.4 nmol/Lj in 
the healthy adults and to 118.7 nmol/L (range: 67.7 - 206.0 nmol/L) in patients with 
acromegaly. Mean IGFBP-3 levels amounted to 3.5 mg/L (range: 2.1 - 4.8 mg/L) in 
controls and to 5.4 mg/L (range: 4.2 - 6.6 mg/Lj in patients with acromegaly. Mean 
IGF-I/IGFBP-3 ratios amounted to 6.5 nmol/mg (range: 1.9 - 14.5 nmol/mg) in the 
healthy adults and to 22.0 nmol/mg (range: 14.3 - 32.7 nmol/mg) in patients with 
acromegaly. There was a considerable overlap for IGFBP-3 levels between normals 
and acromegalics, but not for IGF-I levels. Also, the IGF-I/IGFBP-3 ratio showed 
overlap between normals and acromegalics. There was a significant correlation 
between the mean 24 h GH and IGFBP-3 levels (p = 0.036) and between the IGF-I 
and IGFBP-3 levels (p < 0.002) in acromegaly. In patients with acromegaly, the 
IGFBP-3 levels showed a decrement, but the IGF-I/IGFBP-3 ratio did not change 
significantly with age. 
Conclusions: IGFBP-3 has no additional discriminitative value over IGF-I 
measurements for the assessment of clinical activity in acromegaly. In acromegaly, 
IGFBP-3 decreases with increasing age. In acromegaly, IGFBP-3 levels significantly 
correlate with mean 24 h GH levels and IGF-I levels. 
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Introduction 
Acromegaly is a disorder caused by an excessive GH production, most commonly 
from a somatotroph adenoma located within the pituitary gland. Under normal 
conditions, GH regulates circulating IGF·I levels (1). However, unlike GH levels, 
IGF-I levels do not exhibit pulsatility or circadian patterns. Serum IGF-I levels 
correlate well with the 24 h GH secretion and, therefore, are usually elevated in 
active acromegaly (2-5). However, serum total IGF-I concentrations do not reflect 
disease activity in some cases of acromegaly. IGF-II levels remain in the normal 
range in active acromegaly, which is in agreement with the contention that GH is 
not a major regulator of IGF-II in adulthood (6-8). Most of the IGF-I and IGF-II in the 
circulation and throughout the extracellular space is bound to members of a 
recently characterized family of high affinity binding proteins (IGFBPs)(9). Under 
normal conditions, the 264-amino acid, 46-53-kOa glycoprotein IGFBP-3 is the most 
abundant IGFBP in human serum. After complexing with the IGF, this protein binds 
an additional 80-88-kOa acid-labile subunit (ALS), and the thus constituted 150-kOa 
ternary complex is the major storage form of IGFs in the circulation. When 
associated with the ternary complex, the IGFs do not readily leave the vascular 
compartment and their half lifes are prolonged from less then 10 min to 12-15 h. 
Subsequently, the IGFs can be released after cleavage of the ternary complex by 
specific proteases. The production of IGFBP-3 is increased in response to an 
increase in GH, insulin, IGF-I, or a change in nutritional status (9-10). Therefore, 
elevated IGFBP-3 levels have been found in patients with active acromegaly (7, 8, 
10-12). 
The aim of our study was to evaluate the relative diagnostic merits of 
measurements of IGFBP-3 over IGF-I as a parameter of disease activity in 
acromegaly. 
Patients and Methods 
Patients with active acromegaly 
Thirty previously untreated patients (14 females, 16 males; mean age 50.6 years) 
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with newly diagnosed active acromegaly were studied. The diagnosis of 
acromegaly had been based on a typical clinical presentation, persistently elevated 
GH levels over 24 h, elevated IGF-I levels and nonsuppressible GH following oral 
glucose loading. A pituitary tumor was demonstrated in all patients by computed 
axial tomography, or T1-weighted MR images of the sellar region in the coronal or 
sagital plane. Patients were euthyroid and none of the patients had disturbed renal 
function. All patients had a somatotroph pituitary adenoma removed at subsequent 
surgery. Serum GH was sampled from 0800 h to 1800 h at hourly intervals, 
followed by 2 hourly sampling to 0600 h and a final sample was taken at 0700 h. 
A single non-fasting blood sample was drawn for IGF-I and IGFBP-3. 
Healthy adults 
Thirty healthy adults (14 females, 16 males; mean age 56.6 years) were studied as 
controls. A single non-fasting blood sample was drawn for IGF-I and IGFBP-3. 
Immunoassays 
Serum GH was measured by immunoradiometric assay (IRMA) supplied by CIS Bio 
International, Gif-sur-Yvette Cedex, France (intraassay CV, 2.8%; interassay CV, 
4.4%). Total serum IGF-I was determined by radioimmunoassay (RIA), using kits 
obtained by Medgenix Diagnostics, Fleurus, Belgium (intraassay CV, 6.1%; interas-
say CV 9.9%). Serum IGFBP-3 levels were determined by IRMA supplied by 
Diagnostic System Laboratories, Webster, Texas (intraassay CV 3.9%, interassay 
CV 1.9%). 
Statistics 
Differences between the sexes were calculated using a one way ANOVA. Results 
are given as means. Correlations were made by the Pearson two-tailed bivariate 
correlation test. All statistics were prepared using the commercial available software 
program SPSS for Windows, release 6.0 (SPSS Inc., USA). Statistical significance 
was defined as p < 0.05. 
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Results 
Table 1 shows shows the individual parameters as sex, age, mean 24h GH, IGF-I 
and IGFBP-3 levels and the calculated ratio between serum levels of IGF-I and 
IGFBP-3 in the 30 patients with acromegaly_ There were no statistical significant 
differences between the sexes with regard to mean GH, IGF-I and IGFBP-3 levels, 
or the IGF-I/IGFBP-3 ratio. Mean IGF-I levels were 22.0 nmol/L (range: 6.5 - 38.4 
nmol/L) in the healthy adults (Table 2) and were 118.7 nmol/L (range: 67.7 - 206.0 
nmol/L) in patients with acromegaly. Mean IGFBP-3 levels were 3.5 mg/L (range: 
2.1 - 4.8 mg/L) in controls and 5.4 mg/L (range: 4.2 - 6.6 mg/L) in patients with 
acromegaly. Mean IGF-I/IGFBP-3 ratios were 6.5 nmol/mg (range: 1.9 - 14.5 
nmol/mg) in the healthy adults and 22.0 nmol/mg (range: 14.3 - 32.7 nmol/mg) in 
patients with acromegaly. 
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Table 1 Characteristics and bIochemical parameters of 30 patients with acromegaly 
Mean Basal Basal 
Patient Age 24-h GH IGF-I IGBP-3 IGF-I/IGFBP-3 
number Sex (years) (mU/l) (nmol/L) (mg/l) (mmol/mg) 
39 157 134_7 5.3 25.4 
2 43 51 147.3 5.6 26.3 
3 65 50 107.0 6.0 17.8 
4 37 32 206.0 6.4 32.2 
5 68 56 178.0 5.7 31.2 
6 59 44 87.0 5.4 16.1 
7 51 55 175.0 6.5 26.9 
8 59 176 159.7 6.1 26.2 
9 58 48 129.7 6.4 20.3 
10 77 14 67.7 4.6 14.7 
11 40 108 121.6 5.3 22.9 
12 58 30 83.1 4.7 17.7 
13 33 34 108.0 5.8 18.6 
14 47 56 101.7 4.4 23.1 
15 m 73 98 137.3 4.2 32.7 
16 m 55 52 93.7 4.6 20.4 
17 m 70 82 98.0 4.7 20.9 
18 m 59 36 126.6 5.1 24.8 
19 m 54 84 97.0 5.7 17.0 
20 m 47 42 91.8 5.2 17.7 
21 m 46 26 101.9 4.5 22.6 
22 m 49 22 103.6 4.8 21.6 
23 m 40 17 111.6 5.7 19.6 
24 m 51 71 117.5 5.9 19.9 
25 m 41 325 142.6 6.6 21.6 
26 m 29 222 140.7 6.0 23.5 
27 m 55 16 71.7 5.0 14.3 
28 m 52 39 94.5 5.0 18.9 
29 m 30 95 101.9 4.9 20.8 
30 m 34 41 123.4 5.2 23.7 
Mean 50.6 74 118.7 5.4 22.0 
Range 29-77 14-325 67.7- 4.2-6.6 14.3-32.7 
-.-_ .. ---_. 
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Table 2 General characteristics and biochemical parameters of 30 healthy controls 
Basal Basal 
Age IGF-I IGFBP-3 IGF-I/IGFBP-3 
(years) (nmol/L) (mg/L) (mmol/mg) 
56_6 22.0 3.5 6.5 
53-61 6.5-38.4 2.1-4.8 1.9-14.5 
In Figures 1a, band c, the IGF-I and IGFBP-3 levels and the IGF-I/IGFBP-3 ratios in 
the individual healthy adults and patients with acromegaly are shown. These 
figures show that there was a considerable overlap for IGFBP-3 levels between 
normals and acromegalies, but not for IGF-I levels. Also, the IGF-I/IGFBP-3 ratio 
showed overlap between normals and patients with acromegaly. 
Figure 1 a, IGF-I; b, IGFBP-3 and c, IGF-I/IGFBP-3 ratio in 0, 30 healthy adults and 
+, 30 patients with acromegaly 
Figures 2a and b show the relationships between IGFBP-3 and mean 24-hour GH 
levels and between IGFBP-3 and IGF-I in acromegalics. There was a significant 
correlation between the mean 24-hour GH and IGFBP-3 levels (p=0.036) and 
between IGF-I and IGFBP-3 levels (p<0.002) in these patients_ 
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Figure 2 Relationships between IGFBp·3 and mean 24 h GH levels ( Figure 2a), 
between IGFBp·3 and IGF·I levels (Figure 2b), between IGFBP·3 levels and age 
(Figure 2c), between the IGF·I/IGFBp·3 ratio and age (Figure 2d) and between 
IGF·I and mean 24 h GH levels (Figure 2e) in 30 patients with acromegaly. To 
convert GH values from J.lg/L to mUll multiply by 2.0. 
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Figures 2c and d show the relationships between age and IGFBP-3 and the 
IGF-I/IGFBP-3 ratio in acromegalics. The figures show that the IGFBP-3 levels 
decrease with increasing age, but the IGF-I/IGFBP-3 ratio does not change 
significantly with age in these patients. Figure 2e shows the relationship between 
IGF-I and mean 24 h GH levels in our patient group. The correlation between the 
mean 24 h GH and IGF-I levels was not statistically significant (p ~ 0.089). 
Discussion 
Using a specific IGFBP-3 Radioimmunoassay (RIA), Grinspoon et at. recently 
demonstrated that IGFBP-3 is a sensitive physiological marker of somatotroph 
hyperplasia, because there was no overlap between the IGFBP-3 levels in 18 
patients with untreated acromegaly and age-comparable controls or the age-
adjusted normative range (12). Even though the mean age in our control group 
was slightly higher than in our acromegaly patients, there was a considerable 
overlap of IGFBP-3 but not of IGF-I levels between the patients and normals. In 
normal healthy adults, IGFBP-3 levels decrease with increasing age, which is in line 
with a decline in GH secretion (6, 11, 13). Therefore, our data suggest that IGFBP-3 
has no additional value over IGF-I estimations for the assessment of GH excess in 
adults. 
Elevated serum IGF-I and IGFBP-3 levels normalize after successfull therapy in 
acromegaly (8). In acromegaly, serum IGF-II levels are within the normal range (6-
8). As IGFBP-3 binds both IGF-II and IGF-I, the ratio between (IGF-I (+ IGF-II)) and 
IGFBP-3 has been proposed as an index of free, biologically active IGF-I (7, 8). 
Juul et at. have recently shown that the IGF-I/IGFBP-3 ratio is significantly higher in 
acromegalics than in controls (7). They could also demonstrate a Significant 
correlation between this ratio and urinary GH secretion or serum GH levels. 
However, Jorgensen et at. observed that the (IGF-I + IGF-II)/IGFBP-3 ratio was 
similar when comparing active and succesfully treated acromegaly and control 
subjects (8). In our study, the IGF-I/IGFBP-3 ratio in patients with acromegaly was 
generally higher than in controls. However, as compared to the individual IGF-I 
levels, we could not demonstrate an additional discriminitative value of this ratio for 
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the diagnosis of acromegaly. 
In acromegalic patients, IGF-I levels tend to decrease with aging, which is In line 
with a decline in GH secretion (14). We could also demonstrate a decrease in 
serum IGFBP-3 levels with aging in these patients. In normal adults, the 
IGF-I/IGFBP-3 ratio decreases with increasing age (7). We could not demonstrate a 
decrease in the IGF-I/IGFBP-3 ratio with increasing age in our group of acromegalic 
patients. This might be explained by an in parallel decrement of IGF-I and IGFBP-3 
in these patients. 
We have found a significant correlation between the mean 24 h GH levels and 
IGFBP-3 and between the IGF-I and IGFBP-3 levels in patients with untreated 
acromegaly. In our study, all patients presented with elevated IGF-I levels. 
Grinspoon et al. found a correlation only between IGF-I and IGFBP-3, but not 
between random GH levels and IGFBP-3 in their group of acromegalic patients 
(12). Their series included 2 out of 18 patients with clinical acromegaly and 
elevated IGFBP-3 levels, but normal IGF-I levels and GH suppression to 2 Jig/L or 
less with glucose. These authors concluded that GH stimulation of IGFBP-3 is at 
least partially mediated through its effects on IGF-I (12). 
In conclusion, our data suggest that IGFBP-3 alone, or in a IGF-I/IGFBP-3 ratio has 
no additional discriminitative value over IGF-I measurements for the assessment of 
clinical activity in acromegaly. IGFBP-3 levels, like IGF-I levels tend to decrease 
with increasing age in acromegaly. In acromegaly, IGFBP-3 levels significantly 
correlate with mean 24 h GH levels and IGF-I levels. 
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Summary 
We have studied the physiological and clinical relevance of measurements of 
serum total and free IGF-I, and IGFBP-3 in 57 previously untreated patients with 
active acromegaly (32 males, 25 females; mean age 47 years) as compared to sex 
and age-matched normal healthy controls. Serum total and free IGF-I, but not 
IGFBP-3 are suitable biochemical parameters for screening for acromegaly. In 
acromegalics, the mean 24-hour serum GH, total IGF-I and IGFBP-3 levels tend to 
decrease with aging. However, in our series of patients, mean 24-hour serum GH 
levels, IGFBP-3, total and free IGF-I do not correlate with disease activity in 
acromegaly. 
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Introduction 
In normal healthy adults, spontaneous GH secretion shows a diurnal pattern and is 
influenced by age and sex. More than 99% of growth hormone (GH) is secreted in 
a pulsatile fashion. In patients with active acromegaly, only 50% of GH secretion is 
excreted in a pulsatile manner, but the GH pulse frequency is increased as 
compared to normal healthy adults (1). Because of the variability in GH secretion 
over the day and the short half-life of GH (approximately 20 min.) in the circulation, 
random GH measurements have only limited value for the differential diagnosis of 
acromegaly. Generally, "undetectable" GH levels measured with a standard 
commercially available radioimmunoassay (RIA) or immunoradiometric assay 
(IRMA) in a patient suspected of having acromegaly exclude the diagnosis. 
However, it should be noted that the actual GH level in this situation may not really 
be zero, but below the sensitivity level of the assay. In contrast, spontaneous, 
exercise-induced, or postprandial GH pulses during the day may occasionally 
result in an abnormally high random GH determination in a normal subject. Using 
24-hour GH levels, a good separation can be made between patients with active 
acromegaly and normal subjects, but only after matching for age (2). In normal 
subjects, serum GH levels (measured with a commercially available RIA) are 
suppressed to < 2 pg/l « 4 mUll) within 1-2 hours following the administration of 
an oral load of 75-100 g glucose after overnight fasting. However, in acromegaly 
there is a failure to suppress GH levels to < 2 pg/l « 4 mU/I) during oral glucose 
tolerance testing (OGIT) or even shows a paradoxical rise (3, 4). 
Insulin-like growth factor I (IGF-I), formerly known as somatomedin-C, mediates 
many of the growth hormone actions. GH induces IGF-I synthesis and release, 
especially from the liver. In contrast to serum GH levels, serum (total) IGF-I levels 
show little fluctuation during the course of the day. Serum (total) IGF-I levels are 
invariably elevated in active acromegaly (5). Pregnancy and late puberty are also 
associated with elevated serum (total) IGF-I levels. A highly significant correlation 
exists between serum (total) IGF-I levels and the area under the serum GH curve 
estimated during OGTT (r = 0.66) (6). A positive correlation has also been 
demonstrated between the mean 24-hour serum GH levels and serum (total) IGF-I 
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levels. The relationship between mean serum GH levels during either OGTT, or in 
24-hour profile and serum (total) IGF-I levels shows a curvilinear pattern. A linear 
relationship exists between GH levels < 10 pg/L « 20 mUlL) and serum (total) 
IGF-1. Serum (total) IGF-I levels reach their maximum at serum GH levels > 20 pg/L 
(> 40 mUlL) (6, 7). 
The majority of IGF-I (and IGF-II) in the serum are complexed with binding proteins 
(IGFBPs). In the circulation, about 75% of the IGFs are complexed with IGFBP-3 
and an acid-labile subunit (ALS) in a 150-200 kDa ternary complex. The remainder 
of the circulating IGFs is either bound to lower molecular mass IGFBPs or circulate 
in the free form. IGFBP-3 appears to be the primary regulator of IGF bioavailability 
in response to changes in circulating GH levels (8). The ternary complex does not 
cross the vascular endothelium and, therefore, serves as a reservoir for IGFs. When 
associated with the ternary complex, the half-life of the IGFs is prolonged. 
Breakdown of the IGFBPs is regulated by IGFBP proteases. An increase in IGFBP-3 
proteolysis will lead to increased formation of lower molecular mass IGF-IGFBP 
complexes, which are capable of crossing the endothelium. Elevated IGFBP-3 
levels have been found in patients with active acromegaly (9, 10). The 28 kDa 
IGFBP-1 appears to be the primary regulator of IGF bioavailability in response to 
the changes in the circulating insulin level (8). Serum levels of IGFBP-5, but not 
IGFBP-4, show significant positive correlation's with the IGFs. IGFBP-1 and 
IGFBP-4 in serum have predominant IGF-I inhibitory activities, whereas IGFBP-5 in 
serum has IGF-I stimulatory activities (11). 
By analogy with steroid and thyroid hormones, the unbound fraction may be the 
dominating fraction for the biological activity of IGF-I. Frystyk et al have shown that 
fasting serum free IGF-I levels are increased in acromegaly and showed no overlap 
with levels found in healthy controls (12). 
We have studied the physiological and clinical relevance of measurements of 
serum total and free IGF-I and IGFBP-3 in acromegaly as compared to normal 
healthy adults. 
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Patients and Methods 
Fifty-seven previously untreated patients (32 males, 25 females; mean age 47 
years) with active acromegaly were studied. Disease activity was scored according 
to 5 clinical parameters: excessive sweating, headaches, fatigue, paresthesias and 
arthralgias (see Table 1). Fifty-seven sex and age-matched adults were studied as 
controls. 
Table 1 ClinIcal activity score in acromegaly. Total score: <3, mild; 3-5, moderate; >5, severe 
Headaches Fatigue Perspiration Parestheslas Arthralgia 
Score 
0 None None None None None 
1 Mild Mild Mild Mild Mild 
2 Moderate Moderate Moderate Moderate Moderate 
3 Severe Severe Severe Severe/CTS Severe 
CTS, carpal tunnel syndrome 
In patients with acromegaly, serum GH was sampled from 0800 to 1800 h at hourly 
intervals, followed by 2-hourly sampling to 0600 h. A final sample was taken at 
0700 h. Fasting samples for measurements of IGF-I, IGFBP-3 and free IGF-I were 
taken from acromegalics and healthy controls. Serum GH was measured by IRMA 
supplied by CIS Bio International, Gif-sur-Yvette Cedex, France (intraassay CV, 
2.8%, interassay CV, 4.4%). Serum total IGF-I was determined by RIA using kits 
obtained by Medgenix Diagnostics, Fleurus, Belgium (intraassay CV, 6.1 %, 
interassay CV, 9.9%). Serum free IGF-I was measured by IRMA supplied by 
Diagnostic Service Laboratories, Webster, Texas (intraassay CV 10.3%, interassay 
CV, 10.7%). Serum IGFBP-3 levels were determined by IRMA supplied by 
Diagnostic Service Laboratories, Webster, Texas (intraassay CV, 3.9%, interassay 
CV,1.9%). 
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Results 
In figures 1a, band c, serum total IGF-I, free IGF-I and IGF8P-3 levels in normal 
healthy controls and patients with active acromegaly are shown. The figures show 
that there was a considerable overlap for serum IGF8P-3 levels between normals 
and acromegalies, but not for serum total and free IGF-1. Figures 2a, b, c and d 
show the relations between age and mean 24-hour serum GH, total IGF-I, free IGF-I 
and IGF8P-3 levels in patients with active acromegaly. Mean 24-hour serum GH, 
serum total IGF-I and IGF8P-3 levels decrease with increasing age. However, there 
is no relation between serum free IGF-I levels and age in acromegaly. 
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Figure 2 Relations between (A) serum IGF8P-3 and age (r=-O.25, p=O.02), (8) 
mean 24 h serum GH and age (r=-O.29, p=O.002), (e) serum totallGF-1 and age 
(r=-O.30, p=O.02) and (0) serum free IGF-I and age (not significant) in 57 patients 
with active acromegaly, (non-parametric correlation (Spearman). Statistical 
significance was defined as p<O.05. 
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In Table 2, the correlations between mean 24-hour serum GH levels and serum 
total IGF-I, free IGF-I and IGFBP-3 are shown. There was a significant correlation 
between mean 24-hour serum GH levels and serum total IGF-I levels (r ~ 0.38, P ~ 
0.005, non-parametric correlation (Spearman)). There was no significant 
correlation between mean 24-hour serum GH and serum free IGF-I, or serum 
IGFBP-3 levels. There was a significant correlation between serum total IGF-I and 
serum IGFBP-3 levels (r ~ 0.55, P < 0.001, non-parametric correlation 
(Spearman)), but not between serum total and free IGF-I levels. Also, no significant 
correlation was found between serum free IGF-I and IGFBP-3 levels. 
Table 2 Correlations between the various clinical and biochemical parameters in 57 patients with ac! 
acromegaly (non-parametrio correlation (Spearman», Statistical significance was defined as p < Q,Q5.{NS, 
significant) 
TotalIGF·1 
Age ·0.28 (p=0.04) 
TOlaIIGF-1 
IGFBp·3 
Free IGF-I 
Disease Activity 
IGFBP-3 
·0.28 (p=0.04) 
0.55 (p <0.001) 
Free IGF·I 
·0.13 (NS) 
0.12 (NS) 
0.01 (NS) 
Disease activity Mean 24 h GI 
·0.46 (p<O.OOl) ·0.40 (p=O.OO 
0.18 (NS) 0.38 (p=O.OO 
0.06 (NS) 0.21 (NS) 
0.01 (NS) 0.26 (NS) 
0.10 (NS) 
Figures 3a, b, c and d show the correlation's between disease activity and mean 
24-hour serum GH, free and total IGF-I, and IGFBP-3 levels. These figures show 
that mean 24-hour serum GH, free and total IGF-I, and IGFBP-3 levels did not 
correlate with disease activity. 
Discussion 
By comparing a large series of patients with untreated acromegaly with sex and 
age-matched controls, the present study has shown a considerable overlap of 
serum IGFBP-3 levels, but not of free and total IGF-I levels between the controls 
and acromegalics. This is in line with our previous findings in a smaller group of 
patients with acromegaly (10). 
Therefore, IGFBP-3 is not a marker for the assessment of GH excess in adults. 
Both serum free and total IGF-I measurements can serve better for this purpose. 
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Figure 3. Relations between (A), serum free IGF·I and clinical activity (not significant), (6) serum 
totallGF·1 and clinical activity (non slgnlftcant), (C) serum IGF6P-3 and clinical activity (non 
significant). (0) mean 24-hour serum GH and clinical activity (non significant) in 57 patients with 
active acromegaly (non-parametrio correlation (Spearman». Statlstloal slgnifioance was defined as 
p < 0.05. 
Our results show that in acromegalics, mean 24-hour serum GH, total IGF-I and 
IGFBP-3 levels tend to decrease with aging. This is also in line with our previous 
observations (10, 13). We could not demonstrate a decrease in serum free 
IGF-I with age. This might be explained by a parallel decrement of total IGF-I and 
IGFBP-3. We have shown that mean 24-hour serum GH levels, IGFBP-3, total and 
free IGF-I does not correlate with disease activity in acromegaly. 
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Conclusions 
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Serum total and free IGF-I, but not IGFBP-3 are suitable biochemical parameters 
for screening for acromegaly. 
In acromegalies, mean 24-hour serum GH, total IGF-I and IGFBP-3 levels tend 
to decrease with aging. 
Mean 24-hour serum GH, total and free IGF-I and IGFBP-3 levels do not 
correlate with disease activity in acromegaly. 
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Chapter 5 
Summary 
The existing literature on serum insulin-like growth factor I (IGF-I) levels in insulin 
dependent diabetes mellitus (IDDM) is conflicting. Free IGF-I may have greater 
physiological and clinical relevance than total IGF-I. Recently a validated method 
has been developed to measure free IGF-I levels in the circulation. 
Serum free and total IGF-I, insulin-like growth factor binding protein-l (IGFBP-l) 
and insulin-like growth factor binding protein-3 (IGFBP-3) levels were measured in 
56 insulin-treated IDDM patients and 52 healthy sex- and age-matched controls. 
Diabetic retinopathy was established by direct fundoscopy. In 54 IDDM patients 
glomerular filtration rate (GFR) and effective renal plasma flow (ERPF) were 
calculated from the clearance rate of 125I-iothalamate and 131 1_. iodohippurate 
sodium. 
Fasting free IGF-I, total IGF-I and IGFBP-3 levels were significantly lower in IDDM 
patients than in age- and sex-matched healthy controls (free IGF-I: P<O.005; total 
IGF-I: P<O.OOI; IGFBP-3: P=O.OOI), while IGFBP-l levels were higher (P<O.OOI). 
In IDDM subjects a decrease of free IGF-I, total IGF-I and IGFBP-3 levels with age 
was observed (free IGF-I: r=-O.27, P=O.05; total IGF-I: r=-O.52, P<O.OOI; IGFBP-3: 
r=-O.37 P=O.005). Free IGF-I was inversely related to fasting glucose in IDDM 
subjects (r=-O.35, P=O.OI) whereas the relationhip between total IGF-I and fasting 
glucose did not reach significance ( r=-O.27, P=O.06). 
Age-adjusted free IGF-I levels were significantly higher (P<O.05) in IDDM subjects 
with retinopathy than in subjects without retinopathy after adjustment for age. 
Total IGF-I and IGFBP-3 levels were positively related to GFR (Total IGF-I: r=O.35 
and P<O.05; IGFBP-3: r=O.28 and P<O.05). Both of these differences lost 
significance after adjustment for age. 
Free IGF-I, total IGF-I levels and IGFBP-3 levels were lower and IGFBP-l levels 
were higher in insulin-treated IDDM subjects when compared to age- and sex-
matched controls. Free IGF-I, total IGF-I and IGFBP-3 levels decreased significantly 
with age in IDDM subjects. Age-adjusted free IGF-I levels in subjects with diabetic 
retinopathy were higher than those in subjects without diabetic retinopathy. Total 
IGF-I and IGFBP-3 levels were positively related to GFR in IDDM subjects, but 
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these relations were lost after adjustment for age. Measurement of free IGF-I levels 
in IDDM subjects did not have clear advantages compared that of total IGF-I, 
IGFBP-1, and IGFBP-3 levels. Serum IGF-I and IGFBPs reflect their tissue 
concentrations to a various degree. Consequently, extrapolations concerning the 
pathogenetic role of the IGF-I/IGFBP system in the development of diabetic 
• complications at the tissue level remain speculative 
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Introduction 
The literature on insulin-like growth factor-I (IGF-I) in patients with diabetes is 
conflicting. Flyvbjerg reported that in IDDM patients the serum levels of IGF-I were 
within the normal range for the entire population (age 20·80 years) compared with 
age- and sex-matched controls (1). Therefore, Lamberton et al. have concluded 
that serum IGF-I, measured as total IGF-I levels, probably do not play an important 
role in the pathogenesis of diabetic microvascular disease (2). On the other hand 
Merimee et al. have reported a transient rise in total serum IGF-I levels in patients 
with diabetes mellitus in the early phase of neovascularisation of the retina (3). 
These findings could not be confirmed by Hyer et al. (4) or Wang et al. (5). 
Blood-born IGF-I may also contribute to the glomerular hyperfillration (GFR) 
observed in early diabetic nephropathy (6). However, circulating levels of total 
IGF-I do not closely correlate with renal hypertrophy, and there is a lack of 
correlation between kidney size and the progressive decline in GFR in diabetic 
patients, suggesting that factors which are important for growth might not 
necessarily be involved in renal hemodynamics (7, 8). 
Part of the controversy on serum IGF-I levels in IDDM may be explained by 
methodological problems in the IGF-I assay. Until recently the assay methods used 
to measure IGF-I in serum were not able to distinguish among unbound, free 
IGF-I, and IGF-I bound to insulin-like growth factor binding proteins (IGFBPs) (9). 
IGFBP-3 appears to be the primary regulator of IGF levels in response to changes 
in circulating GH levels and serves as a storage pool for IGF-I (10) whereas 
IGFBP-1 appears to be the primary regulator of IGF-I levels in response to changes 
in circulating insulin levels (11). 
Determination of free IGF-I in stead of total IGF-I might be an important step 
to get more insight in the concentrations and the role of the IGF-I/IGFBP system in 
IDDM (7). Free IGF-I, by analogy with sex and adrenal steroids and thyroid 
hormones, may be the major biological active hormonal form of IGF-I(12). 
Here we report the resulls of a study, in which we investigated the relations-
hips of circulating free IGF-I, total IGF-I, IGFBP-1 and IGFBP-3 levels and with the 
presence of diabetic retinopathy and renal hemodynamics in patients with IDDM. 
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Subjects and Methods 
Subjects 
The study group consisted of 56 consecutive patients with 100M which visited our 
outpatient-clinic. Inclusion criteria were: 100M. age18 yr or above at the time of the 
study. age at diagnosis below 40 years and insulin dependency within 6 months of 
diagnosis. no other medication than insulin. glycosylated hemoglobin (HbA 1 oJ less 
than 11 %. normal serum creatinine (50-110 pmol/I) and no overt nephropathy 
(albuminuria less than 300 mg/24 h in two out of three measurements). About half 
of these patients were part on a previous study in which the dynamics of GH 
secretion were studied (13). All patients were on an insulin-dosing schedule of 2-4 
times daily. using combinations of short-acting and intermediate long-acting insulin. 
Fifty-two. age- and sex-matched. controls without evidence of disease were 
recruited from the normal urban population and staff members of our hospital to 
measure free and total IGF-I levels. The study was approved by the hospital ethical 
review committee and all patients and volunteers gave their informed consent. 
Methods 
Blood sampling 
Blood was collected between 0800-0900 h in the morning after an overnight fast in 
both 100M patients as well as in the control group. The last insulin injection on the 
day before blood sampling was adminstered at 2200 h by 100M subjects on 
intensive insulin therapy (4 daily injections. injection of an intermediate long-acting 
insulin at 2200 h) and at 1800 h by 100M subjects on conventional therapy (2 
daily injections of a mixture of short and medium acting insulins). 
Hemodynamic and renal function tests 
In 54 of 56 subjects with 100M the renal and hemodynamic function tests were 
performed. The glomerular filtration rate (GFR) and effective renal plasma 
flow (ERPF) were calculated from the clearance of 1251-iothalamate and 
131I-iodohippurate sodium. respectively. as described in detail previously (14). 
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Blood glucose measurements were performed every 30 min. Glucose (50 mg/kg 
per hour) and insulin (daily dose in U divided by 100/hour) was given iv. 
To maintain the blood glucose concentration between 6.0-10 mmol/L the rate of 
glucose infusion was adjusted according to the blood glucose levels. The mean 
GFR in a group of normal persons (n=18,10 men and 8 women, mean age 39 yr; 
range, 25-61) yr) was 107 (range, 88-130) ml/min.1.73 m'. A GFR greater than 130 
ml/min.l.73 m' indicated hyperfiltration. 
Blood pressure was measured every 5 min during a 60-min period in the supine 
position using an automatic device (Datascope, Accutor la, Parasmus, NJ). The 
mean of at least six values between 30-60 min was calculated. 
Analytical methods 
The free IGF-I immunoradiometric assay (Diagnostics System Laboratories Inc, 
Webster, TX) used in the present study needs no sample extraction. The assay has 
been previously described (15, 16). In short, serum samples (100 pi) or 
recombinant human IGF-I standards are added to tubes containing a dense 
coating of the primary high-affinity IGF-I antibody, incubated at 2 h at room 
temperature. No residual IGFBP-l or IGFBP-3 is detectable after the first wash 
according to the manufacturer's data (15).The tubes were washed, and incubated 
for 2 h at room temperature with the secondary radiolabeled antibody, washed 
three times with deionized water and counted. The lower limit of detection is 4 
pmol/L. There cross-reactivity with IGF-II is less than 0.01 %. The Intra-assay and 
inter-assay coefficients of variation (CVs) for the free IGF-I assay are 10.3 and 10.7 
%, respectively at a plasma level of 0.01 nmol/L (n=8). 
Total IGF-I was determined by a commercially available RIA (Medgenix 
Diagnostics, Brussels, Belgium, intra-assay and interassay CVs: 6.1 % and 9.9%). 
Immunoradiometric assays were used for measurement of IGFBP-l and IGFBP-3 
( Diagnostics System Laboratories Inc, Webster; intra-assay and inter-assay CVs for 
IGFBP-l 5.2 and 6.0 %; intra-assay and inter-assay CVs for IGFBP-3: 0.56 and 1.9 
%). HbA,c was measured by HPLC (normal values: 5.0-6.3 %) (Variant HPLC-
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Biorad, Veenendaal, The Netherlands), and blood glucose concentrations were 
measured in venous whole blood by an automatic hexokinase method (Boehringer 
Mannheim Gmbh, Mannheim, Germany). Urinary albumin was measured with a 
radial immunodiffusion on agarose gel that contained 0.4 III anti-albumin antiserum 
(Dako A 001, Dakopatts, Copenhagen, Denmark) (17). The lower limit of detection 
was 2 mg/l and the interassay variability 8%. The means of the results of three 
collection periods are presented. 
Diabetic retinopathy 
Diabetic retinopathy (DRP) was established by direct funduscopy as judged by an 
experienced opthalmologist and was graded as no DRP, background DRP, or 
proliferative DRP (18). 
Statistical Analysis. 
Baseline clinical characteristics are presented as mean and range. Free 
IGF-I, total IGF-I, IGFBP-1, IGFBP-3, and urinary albumin excretion have a log 
normal distribution and are therefore presented as the geometric mean. IDDM 
subjects were compared with healthy controls. For the healthy control group we 
did not match on individual basis but performed frequency matching, id est 
selecting our controls in such a way that age- and sex distribution were similar in 
cases and controls. For diabetic subgroups mean and 95 % confidence intervals 
are presented. Baseline differences between variables were analyzed with one way 
ANOVA. Pearson's partial correlation coefficients were calculated to analyze the 
associations between variables and to test significance. Free IGF-I, total IGF-I, 
IGFBP-1, and IGFBP-3 did not met the criteria for normality and were logarilhmic 
transformed before analysis. After this transformation, a normalization of the 
distribution was achieved. The results presented in Table 3 were adjusted for age 
by using linear regression analysis with IGF- I(etc.) as dependent and age and 
retinopathy (yes/no) as independent variables. The results presented in Table 4 
were adjusted for age by using linear regression analysis with IGF-I(etc.) as 
dependent and age and hyperfiltration (yes/no) as independent variables. A two 
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sided P-value of <0.05 was considered significant. All statistical analyses were 
performed with Stata statistical package (Computing Resource Center, Santa 
Monica, Cal. 
Results 
General characteristics 
The baseline clinical characteristics of 56 100M subjects (23 women, 33 men) are 
presented in Table 1. In the 52 sex- and age-matched controls the female/male 
ratio was 21/31 and not significantly different from the 100M patients; The mean 
age in the control group was 34.5 yrs (SO 13.8, range 18-64) and did not differ 
from the 100M group. 22 out of the 54 100M patients had a GFR above 130 
mL/min/1.73 m' and were classified as hyperfillrators. 
Serum free and total IGF-I levels in the 100M patients and control subjects are 
shown in Figure 1 and Table 2. Serum free and total IGF-I levels were significantly 
lower in the 100M patients than in the control group. The ratio between free IGF-I 
and total IGF-I levels was lower but not statistically different between 100M patients 
and heallhy controls. Serum IGFBP-3 levels were significantly lower and IGFBP-1 
significantly higher in the 100M patients than in the control group (Fig 1 and Table 
2). 
Free IGF-I serum levels were posllively related to total IGF-I concentration (100M: 
r=0.52 and P<O.OOl; control group: r=0.47 and P<O.OOl) and IGFBP-3 (100M: 
r=0.33 and P<0.05; control group: r=0.19 and P=0.17) and inversely related to 
IGFBP-1 concentration (100M: r=-0.40 and P<0.005; control group: r=-0.47 and 
P<O.OOl).The plasma concentration of total IGF-I was positively related to IGFBP-3 
(100M: r=0.72 and P<O.OOl; control group: 0.47 and P<O.OOl) and inversely to 
IGFBP-1 levels (100M: r=-0.42 and P<0.005; control group: r=-0.56 and P<O.OOl). 
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Table 1. Clinical characteristics of patients with insulin·dependent diabetes mellitus 
Age (yrs) 
BMI (kg/m2) 
Duration Diabetes (yrs) 
Fasting glucose (mmol/l) 
HbAlc (%) 
Serum creatinine (f1moI/L) 
Albuminuria' (mg/24 hr) 
Systolic blood pressure (mm Hg) 
Diastolic blood pressure (mm Hg) 
Insulin dose (IU/day) 
GFR (mLJmin/l.73 m2) 
ERPF (mL/min/1.73 m2) 
Retinopathy (number of patients) 
None 
Background 
Proliferative 
Mean 
36.3 
23.8 
17.6 
10.5 
8.7 
79 
12 
130 
75 
53 
126 
554 
29 
13 
14 
Range 
(18·63) 
(16.1·37.9) 
(3·44) 
(3.2-19.6) 
(5.4-10.5) 
(50-119) 
(2-167) 
(100-197) 
(60-101) 
(30-78) 
(59-206) 
(298-917) 
, Results are presented as arrythmic mean and range between brackets; 
albumin is expressed as geometric mean and range 
BMI: body mass index was defined as weight divided by the square of height 
(kg/m2); 
GFR: glomerular filtration rate; ERPF: effective renal plasma flow 
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(left) and healthy controls (right). Note the logarithmical scale of the vertical axes. 
The bar represents the median value in each group. 
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Table 2. Comparison of fasting total and free IGF-I, IGFBP-1, and IGFBP-3 levels between 
100M patients and (age- and sex-matched) healthy controls 
IDDM Controls 
Mean Range Mean Range P-value'" 
Free IGF-I (nmol/L) 0.09 (0.01-0.57) 0.15 (0.04-0.58) <0.005 
TotalIGF-1 (nmol/L) 19.4 (6.9·44.3) 27.6 (13.3-51.4) <0.001 
Free IGF-I over TotalIGF-1 0.59 (0.11-1.99) 0.67 (0.13-2.37) ns 
ratio x 100% 
IGFBp·l (nmol/L) 4.1 (0.4-35.3) 0.78 (0.08-5.46) <0.001 
IGFBP·3 (nmol/L) 99.0 (50.2-163.3) 114.6 (79.6-170.7) =0.001 
Results are expressed as geometric mean and range between brackets. The results of the free IGF-I/tota[ IGF-I 
are presented as the mean. 
II By Anava 
Both free IGF-I, as well as IGFBP-3 levels decreased significantly with age in 
diabetic patients, whereas IGFBP-1 levels did not change with age (Fig 2, A and 
C). In the normal individuals such a decrease in free IGF-I and IGFBP-3 with age 
was statistically not significant (Fig 2, A and C), while total IGF-I levels were 
inversely related with age in both 100M and healthy controls (Fig. 2 B). Free IGF-1 
and IGFBP-3 levels tended to be disproportionately lower in 100M than heallhy 
controls with increasing age (Fig 2, A and C). 
Free IGF-I was inversely related to fasting glucose in 100M subjects, but not to 
HbA,. (Fig 3). The relation between total IGF-I and fasting glucose did not reach 
significance( r=-0.27, P=0.06) and fasting IGFBP-1 levels were positively related to 
fasting glucose levels in 100M subjects (Fig 3). Fasting glucose levels were 
positively related to HbA,. (r=0.36, P=0.01). 
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Table 3, Serum free IGF·I levels and other clinical characteristics of diabetic patients with and without clinically manifest 
diabetic retinopathy 
No Retinopathy (N=29) Retinopathy" 
Mean 95% CI Mean 95 % CI P·valueb 
Free IGF·' (nmol/L)C 0,09 (0,04,0,20) 0,10 (0,04,0,23) ns 
TotalIGF·' (nmoVL)c 21.2 (10,0,45,1) 17,6 (8,3·37,3) ns 
IGFBP·1 (nmollL)C 3.98 (2,85·5,57) 4.22 (2,86,6,22) ns 
IGFBp·3 (nmol/L)' 104.4 (94,8·115.1 ) 93,5 (84,6'103,3) ns 
Age (yr) 29.1 (25,3,33,0) 44.1 (39.7-48,5) <0.001 
Duration Diabetes (yr) 12.4 (10.4·14,5) 23,2 (19.4·27,0) <0.001 
Systolic blood pressure (mm Hg) 125 (120·130) 134 (127·143) <0.06 
Diastolic blood pressure (mm Hg) 73 (69·77) 77 (73·81) ns 
Serum creatinine (umol/L) 75 (70·80) 83 (74,91) ns 
GFR (mtJmin/1,73 m~ 140 (131·148) 111 (102·121) <0.001 
ERPF (mtJmlnJ1.73 m~ 594 (557,831) 514 (473·555) <0.006 
Albuminuria {mg/24hr)C 10 (4'23) 16 (6,41) ns 
Fasting Glucose (mmoVL) 10,67 (8,87,12.48) 10.27 (8,24·12,29) ns 
Hemoglobin Ale (%) 8,77 (8,21·9,33) 8,57 (8.07·9,06) ns 
Insulin dose (IU/day) 55 (50·60) 52 (46·58) ns 
BMI (l<glm~ 24.0 (21.9·26,2) 24.5 (22.7·26,3) ns 
For abbreviations, see Table 1 
• n=27; 13 background and 14 proliferative 
b By Anova, comparing subjects with and without retinopathy. P<O.05 was considered stattstlcally significant 
C Geometrio mean 
Table 4. Serum free IGF-Ilevels and other clinical characteristics of diabetic patients with glomerular hyperfiltralion (GFR 
>130 ml/mln/1.73 m~ vs subjects without glomerular hyperfiftraUon (GFR<130 mLjmln/1.73 m~. 
A. Subjects (N:32J without B. Subjects (N:22) with 
hyperfiftratlon hyperfiltraUon 
Mean 95%CI Mean 95%CI P-value$ 
Free IGF·' (nmolJL)b 0.08 (0.03·0.18) 0.11 (0.05-0.26) ns 
Total IGF-I(nmol/L)b 17.7 (8.4-37.4) 21.9 (10.2·46.8) 0.06 
IGFBP-1 (nmol/L)b 5.04 (3.66'6.93) 3.51 (2.42-5.09) ns 
IGFBP-3 (nmollL)b 95.5 (87.6-103.8) 103.8 (92.0-117.2) ns 
Serum creatinine (umol/L) 83 (76-90) 73 (67-79) < 0.05 
ERPF (mlJmin/1.73 m~ 515 (481-550) 610 (567-653) < 0.001 
Albuminuria (mg/24hr)b 13 (5-32) 12 (5-29) ns 
Systolic blood pressure (mm Hg) 132 (124-139) 127 (123-131) 
.ns 
Diastolic blood pressure (mm Hg) 75 (72-79) 74 (70-79) ns 
Age (yr) 41.1 (36.7-45.5) 30.0 (25.6-35.8) <0.005 
Duration Diabetes (yr) 19.6 (16.2-23.0) 15.0 (11.2-18.7) ns 
Fasting Glucose (mmol/L) 10.25 (8.43-12.07) 11.59 (9.79-13.39) ns 
Hemoglobin Ale (%) 8.50 (8.00-8.99) 8.90 (8.33-9.48) ns 
Insulin dose {IU/day} 51 (46-56) 57 (51-62) ns 
BM! (kglm~ 23,9 (22.1-25.7) 24,8 (22.5-27.0) ns 
For abbreviations, see Table 1 
9 Anova comparing subjects with and without hyperfiltration, p<0.05 was considered statistically sIgnificant 
b Geometric mean 
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IGF-I/IGFBP system in 100M patients with retinopathy 
The 27 100M patients with retinopathy were older than the 29 patients without 
retinopathy, the duration of diabetes was longer, blood pressure was higher, and 
the GFR and ERPF were lower (Table 3). Free and total IGF-I, IGFBP-l, IGFBP-3, 
HbA" and fasting glucose levels were not different between the 2 groups. When 
adjusted for age the patients with retinopathy tended to have higher free IGF-I 
levels (P=0.04). 
Renal hemodynamics 
Using 130 mL/min/1.73 m2 as a cut-off, 22 patients had hyperiiltration and 32 had 
a normal GFR (Table 4). The patients with hyperiiltration were younger, and the 
blood pressure was not different between the two groups. In 100M subjects, GFR 
decreased significantly with age (r=-0.53, P<O.OOI). Free IGF-I, IGFBP-l and 
IGFBP-3 levels tended to be higher in the 100M patients with hyperiiltration than in 
subjects with a glomerular filtration below 130 mL/min/1.73 m2 (Table 4), but the 
differences were not significant. 
Total IGF-I and IGFBP-3, but not free IGF-I levels were positively related to GFR. 
(r=0.35 and P<0.05, and r=0.28 and P<0.05, respectively). The relationships 
between total IGF-I and IGFBP-3 levels and GFR were lost after adjustment for age. 
After adjustment for fasting glucose IGFBP-l levels were inversely related to GFR 
(r=-0.30, P<0.05). Total and free IGF-I levels were not related to ERPF. 
Discussion 
There are many contradictory studies on IGF-I in patients with diabetes and 
used methodologies are highly variable even between studies showing similar 
findings. Some studies have previously found low to lowered total IGF-I and 
IGFBP-3 levels and high fasting IGFBP-l levels in 100M, despite hypersecretion of 
GH (19-21). Our study shows that the fasting serum levels of total IGF-I (the sum 
of free IGF-I and IGF-I bound to an array of IGF-binding proteins) and IGFBP-3 are 
lower and IGFBP-l levels are higher in insulin-treated 100M patients than in an 
age- and sex-matched healthy control group. We observed also lower fasting free 
200 
IGF~/, IGFBPs and Insulin 
IGF-I levels in adult IDDM patients, despite insulin treatment. It is likely that the 
measured free IGF-I levels in our study, represent a combination of the true free 
IGF-I levels and a fraction of IGF-I which can be readily dissociated from IGFBPs 
under the specific assay conditions (15). Recently, free IGF-I concentrations were 
found to be low in untreated IDDM children using the same assay, but these 
concentrations tended to normalize after start of insulin treatment (22). 
We observed a significant decrease of free IGF-I and IGFBP-3 levels during 
aging in IDDM subjects, but not in healthy controls. Therefore free IGF-I and 
IGFBP-3 levels tended to be disproportionately lower in IDDM than healthy 
controls. A similar difference between IDDM subjects and healthy controls was not 
observed for total IGF-I levels with increasing age. In accordance with this, 
Graubert et al. reported that in the streptozocin·induced diabetic rat serum free 
IGF-I concentrations were more depressed than total IGF-I(23). Reduced free IGF-I 
concentrations probably account for reduced IGF-I bioactivity in diabetic serum, 
as has been reported in earlier studies (24). 
Free IGF-I levels were inversely related to fasting glucose levels in IDDM 
subjects while fasting glucose levels were positively related to HbA,c' IGF-I exerts a 
tonic hypoglycemic effect in the circulation (25) and decreased IGF-I effect may 
induce an increase in serum glucose levels. Since we observed a significant 
decrease of free IGF-I levels during aging in IDDM subjects, this decrease might 
contribute to gradually higher serum glucose levels and thereby to the 
development of diabetic microvascular complications (26). 
IGFBP-1 levels were positively related to fasting glucose levels. A previous 
study in IDDM subjects reported also a positive relationship between IGFBP-1 and 
fasting plasma glucose levels (27). IGFBP-1 administration causes an acute rapid 
increase in plasma glucose levels (25), which suggest that increased IGFBP-1 
levels results in a decreased availability of free IGF-I levels (28). IGFBP-1 is thought 
to modulate the free fraction of IGF-I. The inverse relationship between free IGF-I 
and IGFBP-1 in our study supports the hypothesis that circulating free IGF-I levels 
are low(er) when IGFBP-1 levels are high (15). 
Free IGF-I levels tended to be higher in IDDM patients with retinopathy after 
201 
Chapter 5 
adjustment for age. However, this result needs to be interpreted with caution since 
retinopathy scoring was performed with direct ophtalmoscopy, a technique that 
may result in some misclassification of subjects and could, therefore, materially 
alter the results and the conclusions of our study. 
An increased GFR is considered as an early symptom in diabetes mellitus 
(29). We observed lower values for total serum IGF-I in 100M patients than in sex-
and age-matched controls, which suggests at first glance no important role for 
IGF-I in the pathogenesis of hyperfiltration in 100M. Nevertheless, in our study total 
IGF-I levels were positively related to the GFR of the kidney. The observed 
correlation coefficient between total IGF-I and GFR is in agreement with previous 
data showing, that IGF-I leads to an augmentation of GFR by 10 - 20 % (30, 31). 
In an experimental animal model of diabetes which was characterized by an 
increased GFR, an increased binding of IGF-I to its renal IGF-I receptors was found 
in comparison to controls (32). Increased binding of IGF-I to the IGF-I receptor in 
the 100M subjects, despite low serum total IGF-I levels, might also give an 
explanation for the observed relationship between total IGF-I and GFR in our 
study. However, this relationship was lost after adjustment for age, which suggest 
that the relationship between GFR and serum total IGF-I levels is age-dependent 
and lost with the physiological age-dependent decrease of serum total IGF-I levels 
during aging. 
In conclusion, free and total IGF-I and IGFBP-3 levels are lower and IGFBP-1 
levels are higher in 100M subjects than in controls. Free IGF-I and IGFBP-3 levels 
decrease significantly with age in 100M subjects between 20 and 65 years. Higher 
(age-adjusted) free IGF-I levels were observed in 100M subjects with diabetic 
retinopathy than in subjects without retinopathy. Total and IGFBP-3 levels were 
related to glomerular filtration rate in 100M subjects but this relation was lost after 
adjustment for age. 
Measurement of serum free IGF-I levels in 100M subjects did not provide clear 
advantages compared to that of total IGF-I, IGFBP-I, and IGFBP-3 levels. Serum 
free IGF-I and IGFBPs reflect their tissue concentrations to various degrees. 
Consequently, extrapolations concerning the pathogenetic role of the IGF-I/IGFBP 
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system in the development of diabetic complications at the tissue level remain 
speculative. 
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Summary 
Background & Objectives: Insulin and IGF-I interact at many levels. Little is known 
about the insulin-like growth factor-I/insulin·like growth factor binding proteins 
(IGF-I/IGFBP) system in congenital partial lipodystrophy, a syndrome characterized 
by insulin resistance, hyperinsulinemia and absence of truncal and limb 
subcutaneous fal. Some cases have acromegaloid features with thick skin and 
large hands and feet in association with normal levels of circulating growth 
hormone. 
Methods: In four females known with congenital partial lipodystrophy, 
hyperinsulinemia with acromegaloid features, the number and affinity of the IGF-I 
receptors on peripheral blood mononuclear cells (PBMCs), and the concentration 
of circulating insulin, total and free IGF-I, IGFBP-1 and IGFBP-3 levels were 
measured in the fasting and the fed state. 
Cultures of PBMCs of the patients with lipodystrophy were also used to study the 
effect of IGF-I stimulation on thymidine uptake in vitro. 
Measurements: In 1he subjects with lipodystrophy the affinity and the number of the 
IGF-I receptors on peripheral mononuclear cells (PBMCs) and erythrocytes did not 
significantly differ from controls in the fasting state. Insulin levels were significantly 
higher in subjects with lipodystrophy both in the fasting as well in the fed state. 
Total IGF-I, free IGF-I and IGFBP-3 levels did not differ but serum IGFBP-1 levels 
were lower in lipodystrophy subjects than in healthy controls. The free 
IGF-I/IGFBP-1 ratio was increased in lipodystrophy subjects both in the fasting and 
fed states.The effects of IGF-I stimulation on thymidine uptake by PBMCs of 
lipodystrophy subjects in the absence of IGFBP-1 were not different from healthy 
controls cultures in vitro. When a combination of IGFBP-1 (in a concentration 
comparable to the fasting serum IGFBP-1 levels in lipodystrophy patients found in 
our study) and IGF-I was added to PBMC cultures from lipodystrophy patients no 
decrease in thymidine uptake by PBMCs was found. 
Conclusions: In the four subjects with lipodystrophy hyperinsulinemia, lowered free 
IGF-I and IGFBP-1 levels, but increased free IGF-I/IGBP-1 ratios were observed. 
Low IGFBP-1 concentrations in culture media did not reduce the stimulating 
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Our data suggest that the obseNed increased IGF-I/IGFBP-l ratio in 
lipodystrophy patients contributes to an unopposed biological effect of IGF-I on 
IGF-I receptors, thereby inducing the development of acromegaloid features, 
acanthosis nigricans and polycystic ovaries in some patients with congenital partial 
lipodystrophy. 
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Introduction 
The acromegaloid features in type A insulin resistance have been suggested to 
result from excessive insulin action (hyperinsulinemia) because the levels of growth 
hormone (GH) and total IGF-I seemed too low to explain these features (1). There 
are striking similarities between the clinical features of the acromegaloid variant of 
type A insulin resistance and congenital partial lipodystrophy (2). Congenital partial 
lipodystrophy (K6berling-Dunningan syndrome) is a syndrome, that is characterized 
by the absence of subcutaneous fat from the trunk and limbs (3). The faces of 
affected subjects often shows broad and acromegaloid features (2). Associated 
clinical features which are variably expressed are severe hyperlipidemia, acanthosis 
nigricans, hepatosplenomegaly, tubero-eruptive xanthomata, elevated basal 
metabolic rate (especially in the postprandial state), insulin-resistant diabetes 
without ketoacidosis and carpal tunnel syndrome (2, 4, 5). Polycystic ovaries and 
menstruat irregularity are common in affected females, while in the majority of 
cases essential hypertension is also present (6). An X-linked dominant mode of 
inheritance has been suggested, which explains the female predominance (7). 
Hyperinsulinism and insulin resistance are striking features of congenital partial 
lipodystrophies (8). The cause of lipodystrophy is unknown. While it is apparent 
that insulin action is diminished in congenital partial lipodystrophy, only a few 
isolated case studies have addressed the potential role of defects at the level of the 
insulin receptor. Recently a homozygous mutation of the insulin receptor gene has 
been described in an extremely insulin·resistant subject with partial lipodystrophy 
(9). In partial lipodystrophy, it has been demonstrated that, using in vitro 
clonogenic assays of primary cultures of erythrOid progenitors, there is a blunted 
response to insulin stimulation, while there is a normal response to insulin-like 
growth factor-I (lGF-I) (10). The insulin receptor and the IGF-I receptor are 
structurally similar. Each is a heterotetrameric glycoprotein comprising two alpha 
and two beta subunits. The latter subunits contain tyrosine kinase activity in their 
cytoplasmic portion (11). Under normal physiological conditions insulin stimulates 
the insulin receptor, but insulin might also stimulate the IGF-I receptor at higher 
concentrations (12, 13). tGF-1 in serum is mainly bound to circulating IGF-binding 
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proteins. These binding proteins are an important regulatory system and modulate 
the action of IGF-I at its target cells (14). As there is little known concerning the 
IGF-I/IGFBP system in partial lipodystrophy, the aim of the present study was to 
investigate the relationships between serum (total and free) IGF-I, IGFBP-1, and 
IGFBP-3 levels and the number and affinity of the IGF-I receptors on blood cells in 
four known subjects with partial lipodystrophy, hyperinsulinemia and insulin 
resistance, and acromegaloid features. 
Subjects and Methods 
Subjects 
Patients with partial lipodystrophy 
Since partial lipodystrophy is a rare disease we were only able to study four 
patients which were visiting our outpatient clinic. All four female patients with partial 
lipodystrophy showed absence of subcutaneous fat on their trunk and limbs, and 
broad faces with short thick necks. Patient A was 27 yrs old, patient B 36 yrs old, 
patient C 47 yrs old, and patient D 26 yrs old. Patient C, the mother of patient A 
and D, had a recent history of precordial angina and intermittent claudication. 
Patient B was not closely related to the other three subjects. Patient A and D had 
known acanthosis nigricans, hirsutism, polycystic ovaries, and menstrual 
irregularities. All four subjects have acromegaloid features as well as soft tissue 
swelling of their hands and feet. Patient A had complaints of paresthesiae due to a 
bilateral carpal tunnel syndrome. All four subjects had hyperlipidemia (fasting 
cholesterol: range 5.8-7.8 mmol/L, HDL cholesterol: range 0.42-0.72 mmol/L and 
triglycerides range 3.6-12.8 mmol/L) and three of them were treated for essential 
hypertension. 
No lipodystrophic patient showed symptoms or signs of liver disease. 
Patient A had developed NIDDM, the other three subjects were normoglycemic. 
For the IGF-I receptor studies two lipodystrophic subjects (A and B) were 
investigated in the fasting state; Three lipodystrophic subjects (A, C and D) were 
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investigated in the fed state. The measurement of thymidine uptake by PBMCs after 
addition of IGF-I and/or IGFBP-l to the cell culture were performed on fasting 
blood samples. 
Healthy Controls 
For the experiments performed in the fasting state, eighteen healthy human 
volunteers (15 men and 3 women, aged 23-47 yr) entered the study, while for the 
experiments in the fed state, fourteen healthy human volunteers (10 men and 
4 women, aged 26-47 yr) were investigated. 
The measurement of thymidine uptake by PBMCs after addition of IGF-I and/or 
IGFBP-l to the cell culture were performed on fasting blood samples both in the 
patients with partial lipodystrophy as well as the healthy controls. 
The study was performed according to the rules of the hospital medical ethics 
committee. All subjects entered the study after informed consent. 
Blood 
For the fasting experiments blood was obtained between 08.00-10.00 after an 
overnight fast started at midnight. 
For the experiments in the fed state blood was obtained between 09.00-11.00 am 
after a non-standardized breakfast between 07.30 and 8.00 am. 
Cells 
Human erythrocytes were isolated from freshly taken heparinized blood from each 
subject. Isolation was performed by density centrifugation on Ficoll-Paque 
(Pharmacia, Uppsala, Sweden) at 400 G for 30 min at room temperature. The 
interphase containing the mononuclear cells and granulocytes was collected, and 
prepared as described below. The pellet containing the erythrocytes was 
resuspended in 0.9 % saline and centrifuged again on Ficoll-Paque under the same 
conditions. Erythrocytes were recovered from the pellet after the second centrifuga-
tion, and washed with two volumes of ice-cold assay buffer (For composition see 
Peptides and Medium). Next the erythrocytes were centrifuged at 400 G for 10 min 
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at 4 ·C. After this centrifugation step the erythrocytes were resuspended in ice-cold 
assay buffer (two volumes cells, one volume assay buffer). This resulted in a cell 
concentration above 5 x 109 celis/mL. The remaining part of the IGF-I receptor 
assay was performed at 4 ·C. The number of cells was determined with the aid of 
an electronic cell counter model AD-260 (Sysmex, Kobe, Japan). 
Human peripheral blood mononuclear cells (PBMCs) were isolated from the same 
freshly taken heparinized blood from all subjects. Isolation was performed by 
density centrifugation on Ficoll-Paque as already described above. The 
centrifugation on Ficoll-Paque yields an interface of mononuclear cells in which 95 
+/- 5 % are mononuclear lymphocytes. Mononuclear cells were recovered from the 
Ficoll medium interface, washed twice with 0.9% saline and after each washing, 
centrifuged during 5 minutes at 670 G at room temperature. The cells were 
resuspended in 1.75 mL assay buffer, which resulted in a cell concentration above 
15 x 10' /mL. The number of cells per ml was counted with the aid of a 
hematocytometer. After resuspension in assay buffer cells were kept at 4 • C. 
Peptides and Medium 
3-[f25IJiodotyrosyl IGF-I was purchased from Amersham International Inc. 
(Amersham, Buckinghamshire, United Kingdom) and used as radioligand in the 
competitive IGF-I receptor assay.The radiolabeled IGF-I had a specific activity of 
2000 Ci/mmol. Competitive binding studies were performed with approximately 
0.05 nM '''I-Iabeled hIGF-1 and, without and with increasing concentrations of 
unlabeled purified human recombinant IGF-I (hIGF-I). hIGF-1 was purchased from 
Saxon Biochemicals GmBH (Hannover, Germany).The assay buffer in the IGF-I 
receptor assay consisted of 50 mM Hepes, 50 mM Tris,10 mM dextrose, 50 mM 
MgS04 , 2 mM EDTA, 10 mM CaCl" 45 mM NaCl, 4.5 mM KCI, and 0.1% BSA (15). 
The pH of assay buffer was adjusted to 8.0 at room temperature. For reduction of 
non-specific binding, bacitracin was added in a concentration of 2 mg/mL to the 
incubation medium (16). 
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Competitive IGF-I receptor assay 
Competitive binding studies were carried out in Eppendorf tubes. For the IGF-I 
receptor assay the methods described by Hizuka et al. (17) and Izumi et al. (15) 
were used with three modifications: Firstly, the final incubation volume was 
decreased to 250 Ill, for measurement of IGF-I binding to erythrocy1es, and to 100 
Ill, for measurement of IGF-I binding to PBMCs. Secondly, bacitracin was added 
to the assay buffer. Thirdly, after 20 h incubation bound and unbound ligand were 
separated by three washing steps with saline in stead of separation with 
dibutylphthalate as described in the original method. 
Erythrocy1es: In a final volume of 250 Ill, 200 III erythrOCy1es ( > 1.0 X 10' 
erythrOCy1es / ml final concentration), were incubated with 1251_IGF_1 (10-30,000 
cpm) in assay buffer and in the absence or presence of increasing concentrations 
of unlabeled hIGF-1 at 4 'C for 20h. Each experiment was performed in duplicate. 
For the competition studies, added unlabeled concentrations of hIGF-1 ranged from 
10.11 to 10" M. 
PBMCs: In a final volume of 100 III 60 III PBMCs (cell concentration > 15 
million mononuclear cells/ml), were incubated with 12'I-IGF-1 (10-30.000 cpm) in 
assay buffer and in the absence or presence of increasing concentrations 
unlabeled recombinant hIGF-1 at 4 'C for 20h. Each experiment was performed in 
duplicate. For the competition studies, the same added unlabeled concentrations 
of hIGF-1 were added, as earlier described for the IGF-I receptor assay of 
erythrocy1es (see above). 
After 20 h incubation, bound and unbound radioligand were separated by three 
washing steps with saline at 4 'C. In each washing step, the cells were centrifuged 
at 10,000 G during 2 minutes and the supernatant was removed. After the third 
centrifugation step the cell-bound radioactivity was measured in a gamma counter. 
Non-specific binding was defined as the amount of radioligand bound in the 
presence of excess of unlabeled IGF-I (10" M). Specific binding of 1251_IGF_1 was 
determined by subtracting the amount of radioactivity bound in the presence of 
excess of unlabeled IGF-I (10·'M). 
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The binding data were analyzed according to the method of Scatchard (18). The 
number of binding sites is expressed as sites per cell. The dissociation constant 
(Kd) is given in nmol/L. Specificity of the IGF-I receptor assay was established as 
follows: 1] unlabeled IGF-I, unlabeled IGF-II, and unlabeled insulin were able to 
displace labeled and bound IGF-I to erythrocytes and PBMCs, although with 
striking differences in affinity. 2] Binding of 1251_IGF_1 to erythrocytes and PBMCs 
was inhibited by the unlabeled peptides in the following order of potency: 
IGF-I > IGF-II> > > insulin. 3] after preincubation with a1R-3 (a specific anti-IGF-I 
receptor antibody) the specific binding of 1251_IGF_1 in the IGF-I receptor assay was 
totally lost. 
Hormone assays 
Blood samples were obtained at the same time as those for the IGF-I receptor 
study and allowed to coagulate for 60 minutes. Subsequently serum was separated 
by centrifugation and quickly frozen to -20°C. Free IGF-I was measured with a 
commercially available two-site immunoradiometric assay (Diagnostic System 
Laboratories Inc., Webster, Texas, U.S.A.; intra-assay and inter-assay C.V. : 10.3% 
and 10.7%, respectively) (19, 20).Total IGF-I was determined by a commercially 
available radioimmunoassay (Medgenix Diagnostics, Brussels, Belgium, intra-assay 
and inter-assay coefficients of variation (C.V.): 6.1%; 9.9%) after an 
acidification/neutralization step. 
Commercially avalaible immunoradiometric assays were also used for 
measurement of IGFBP-l, and IGFBP-3 (Diagnostic System Laboratories Inc., 
Webster, Texas, U.S.A.; intra-assay and inter-assay C.V. for IGFBP-l: 6.0% and 
3.5%, respectively; and for IGFBP-3: 3.9% and 1.9%, respectively). Insulin was 
determined by a commercially available radioimmunoassay (Medgenix Diagnostics, 
Brussels, Belgium, intra-assay and inter-assay C.V.: 8.0%; 13.7%). For plasma GH 
an immunoradiometric assay was used (CIS bio international, Gif-sur Yvette Cedex, 
France, detection limit 0.4 /lg/L, intra-assay and inter-assay CV 2.8 and 4.4%, 
respectively; normal value < 5/lg/L). 
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Thymidine Uptake of PBMCs in culture. 
hIGF-1 was purchased from Saxon Biochemicals GmBH (Hannover, Germany). 
RPMI-1640 (nr 042-02511) was purchased fom Gibco BRL (Life Technologies BV, 
Breda, the Netherlands). Bovine Serum Albumin (BSA) was from Sigma 
(Instruchemie BV, Hilversum, the Netherlands), The BSA did not contain any 
detectable IGF-I activity as determined by radioimmunoassay 
(Medgenix diagnostics, Brussels, Belgium). ['Hl radiolabeled thymidine, (['Hl-
dTd], TRK 686, 1 mCi/mL) was obtained from Amersham International (Amersham, 
UK). 48 well cell culture flat-bottom plates (catalog number 3548) were obtained 
from Costar (Cambridge, USA). 
IGFBP-l was purified from midgestational human amniotic fluid using an 
ammonium-sulphate precipitation. The pellet was discarded and the supernatant 
adjusted to 40% methanol. Using hydrophobic interaction chromatography with 
methanol gradient, the IGFBP-l was eluted as a single peak. At that point, using 
gel analysis, no impurities can be detected. 
For the thymidine assay we primarily used mostly male controls for our female 
patients because we could only obtain permission to study a small number of 
healthy controls (less than 30 subjects) to perform this sort of study. 
We were very careful in reaching an optimal match for age between the 
lipodystrophic subjects and the healthy controls. Age is to our knowledge a far 
more important factor than gender when studying IGF-I effects on thymidine uptake 
(own unpublished observations and 21-23). 
Cell Culture Medium 
The culture medium contained RPMI 1640 with 4 mM glutamine, 0.1 % BSA, 100 
U/mL penicillin, 100 pg/mL streptomycin, 0.1% BSA. The pH of the medium was 
adjusted to 7.4. 
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Cell culture 
For the cell culture experiments blood was drawn in the fasting state. Human 
peripheral blood mononuclear cells (PBMCs) were isolated from 
heparinized blood. Blood was initially taken for this purpose from four subjects with 
congenital partial lipodystrophy and from five healthy subjects. Isolation was 
performed by density centrifugation on Ficoll-Paque as above already described. 
PBMCs were cultured in flat-bottom 48-well polystyrene plates. To each well 
320,000 PBMCs were added. PBMCs were cultured in a final volume of 250 IlL 
medium in combination with IGF-I (range 0_10'7 M). After 96 h culture at 37 'C in 
5% CO" 100% relative humidity, the cells were pulsed with 0.5 /lCi ['HI thymidine 
and then cultured for another 4 h. The cells were then harvested using standard 
scintillation procedures and ['HI thymidine radioactivity was measured in a liquid 
scintillation counter. Blood was taken from two subjects with congenital partial 
lipodystrophy and from two healthy subjects on a second occasion to investigate 
the effect of IGF-I on thymidine uptake by PBMCs in the presence of IGFBP-l. 
These latter experiments were performed under the same conditions and using the 
same procedures as described above. IGFBP-l was added in this last experiment 
at a concentration of 0.15 x 10" M (a concentration of IGFBP-l comparable to 
fasting serum IGFBP-l levels observed in lipodystrophy patients in vivo). 
Statistical Analysis 
Results are expressed as the mean +/- SE. The Mann-Whitney test was used to 
test for differences between groups. Partial Pearson's correlation coefficients were 
used to calculate the correlations between Kd and number of IGF-I receptors. A 
two-sided p value of < 0.05 was considered significant. 
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Results 
125I-1GF_1 specifically bound to human erythrocytes and PBMCs of the healthy 
volunteers and the binding increased linearly as a function of the number of cells 
(data not shown). Scatchard analysis for IGF-I binding to erythrocytes and PBMCs 
showed in both instances a linear plot (data not shown). Table 1A shows the 
results of IGF-I receptor assays carried out on erythrocytes and PBMCs from 18 
healthy subjects in the fasting state. Table 1 B shows these results In the two 
subjects with partial lipodystrophy. The IGF-I receptor characteristics (number and 
Kd) on erythrocytes and PBMCs from subjects with lipodystrophy did not differ 
from those of normal healthy volunteers (Figure 1). 
In the fasting state there were no differences in mean total and free IGF-I levels, 
insulin levels were significantly higher in the patients with lipodystrophy in 
comparison to healthy controls, while IGFBP-1 levels were lower and the free 
IGF-I/IGFBP-1 ratio was significantly higher in lipodystrophy patients than in healthy 
controls (Table 1). 
In the fed state the IGF-I binding sites and the Kd of the IGF-I receptor on blood 
cells were lower in lipodystrophy patients than in healthy controls (Table 2). Free 
IGF-I and IGFBP-1 levels were significantly lower in lipodystrophy patients than in 
healthy controls while insulin levels and the free IGF-I/ IGFBP-1 ratio were 
significantly higher in lipodystrophy patients than in healthy controls (Table 2) .GH 
values in the subjects with partial lipodystrophy were normal (maximal 0.6 /lg/L). 
Thymidine uptake by PBMCs after 100 nmol/ L IGF-I (10.7 M) stimulation in the 
absence of IGFBP-1 in the culture medium was not significantly different in subjects 
with lipodystrophy compared to healthy controls (Figure 2). When basal thymidine 
uptake was set at 100%, the maximal percentage stimulation of thymidine uptake 
after IGF-I (10'7 M) stimulation was for lipodystrophy subjects (n=4): 46, (-1-91)% 
(mean, (range» and in healthy controls (n=5): 51, (29·88) % (Mann-Whitney test: 
not significant) (Figure 2). Also the baseline incorporation of radioactivity did not 
differ between both groups. 
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Table 1. Characteristics of IGF~I binding on Erythrocytes and PBMCs, circulating IGF~I and IGFBPs. and insulin in the fasting state in 18 healthy volunteers 
(A) and 2 patients with partial lipodystrophy (8). 
A B 
mean ±SE (range) mean ±SE (range) p~vaIue* 
Age subjects (years) 32.6 ±1.8 (23-47) 31.5 ±1.8 (29-34) ns 
E!Y!;hroQy!es 
No of specific IGF~l binding sites/cell 34.3 ±4.0 (11-57) 30 ±2.1 (27-33) ns 
Kd (nM) 2.26 ±0.29 (0.42-4.75) 1.90 ±0.12 (1.73-2.07) ns 
PBMCs 
No of specific IGF~I binding sites/cell 3631 ±524 (430-8774) 6779 ±1101 (5222-8336) ns 
Kd (nM) 1.98 ±0.26 (0.22-3.73) 2.38 ::!::0.08 (2.26-2.50) ns 
TotalIGF-1 (nmollL) 28.6 ±1.7 (13.3-46.4) 26.6 ::!::2.8 (22.7-30.5) ns 
Free IGF-I (nmol/L) 0.14 ::!::0.02 (0.03-0.26) 0.09 ::!::0.01 (0.07-0.11) ns 
IGFBP-1 (nmollL) 1.38 ±0.30 (0.17-5.46) 0.11 ±0.001 0.11 0.02 
Free IGF-I/IGFBP1 ratio 0.22 ±0.07 (0.008-1.42) 0.80 :±:0.10 (0.66-0.93) 0.04 
IGFBP-3 (nmol/L) 100.9 ±2.7 (80.0-121.7) 113.1 ±18.4 (87-139.1) ns 
Insulin (mUlL) 13.1 :±:1.1 (5.2-21.8) 65.7 :±:35.3 (30.3-101.0) 0.02 
For used abbreviations, see text 
* Statistics by Mann~Whitney test comparing mean values of variables in healthy subjects vs variables in subjects with lipodystrophy. 
ns not significant 
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The relationships between Kd and number of IGF-I binding sites per erythrocyte 
(Top panel) and per PBMC (Bottom panel) did not differ between lipodystrophy 
patients and healthy controls. The Pearson's partial correlation coefficients are 
calculated from the data of the healthy controls. 
Table 2. Characteristics of IGF-1 binding on Erythrocytes and PBMCs, circulating IGF-1 and IGFBPs, and insulin in the fed state in 14 healthy volunteers (A) 
and 3 patients with partial lipodystrophy (B). 
A B 
mean ±SE (range) mean ±SE (range) p-value 
Age subjects (years) 34.4 ±1.9 (26-47) 34 ±S.3 (27-47) ns 
EMhro2Yles 
No of specific IGF-l binding sites/cell 9.2 ±1.34 (5-25) 4.7 ±O.S (4006) 0.02 
Kd (nM) 0.62 ±O.11 (0.19-1.6) 0.26 ±O.O1 (0.23-0.29) ns 
PBMCs 
No of specific IGF-1 binding sites/cell 1057 ±161 (402-2135) 779 ±62 (691-867 ) ns 
Kd (nM) 0.53 ±O.O8 (0.19-1.23) 0.185 ±O.OO4 (0.18-0.19) 0.03 
TotaIIGF-I (nmol/L) 28.8 ±2.0 (17.9-40.9) 26.1 ±1.8 (23.5-30.5) ns 
Free IGF-I (nmol/L) 0.33 ±O.O3 (0.13-0.60) 0.16 ±O.OS (0.10-0.27) ns 
IGFBP-1 (nmol/L) 1.01 ±O.O3 (0.18-4.75) 0.02 ±O.OO4 (0.02-0.03) 0.02 
Free IGF-I~GFBP1 ratio 2.25 ±6.64 (0.05-25.3) 10.68 ±3.24 (5.41-13.82) 0.02 
IGFBP-3 (nmol/L) 107.5 ±S.6 (70.6-137.4) 123.6 ±SA6 (110.3-131.1) ns 
Insulin (mUlL) 14.0 ±3.2 (3.5-55.5) 132.5 ±43.0 (32.2-210.7) 0.01 
For used abbreviations, see text 
• Statistics by Mann-Whitney test comparing mean values of variables in healthy subjects vs variables in subjects with lipodystrophy . 
ns not significant 
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Figure 2 Effect of IGF·I stimulation (range 10·"·10·' M) stimulation on ['HI thymidine uptake by 
320,000 PBMCs during 96 h culture at 37 0 C and 5% CO, in RPMI·1640·0.1% BSA. left: effect in 
healthy controls, Right: effect In IIpodystrophic patients. The mean and SEM values of quadruplo 
wells are presented. Basal thymidine uptake was set at 100 %. Results are expressed as percentage 
stimulation of thymidine uptake by 320,000 cells per culture (vertical axis).The mean basal thymidine 
uptake and thymidine uptake after stimulation with IGF-I did not differ between healthy controls and 
lipodystrophy patients (See also text). 
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Figure 3 From left to right, basal thymidine uptake, effect of IGF·I (10"' M), and the combination of 
IGF·I (10" M) and IGFBP·l (0.15 x 10·' M) on thymidine uptake by PBMCs In two healthy controls 
(Sub) 1 and 2) and two lipodystrophy patients (Pat A and D). Basal thymidine uptake (= PBMCs 
cultured during 96 h culture at 37 0 C and 5% CO2 in RPMI-1640-0.1% eSA) was put equal to 100 
%. The Mann-Whitney test was used to test for statistical significant differences In thymidine uptake 
comparing the results of experiments in which only IGF·I was added with the experiments after 
addition of the combination of IGFBp·l and IGF·1. (See also text) 
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When IGFBP-l was added to cultures in a concentration of 0.15 x 10.9 M, no 
statistically significant effect on thymidine uptake in comparison to basal 
(=unstimulated) thymidine uptake was seen in either lipodystrophic subjects or 
healthy controls (data not shown). When both IGF-I (10" M) as well as IGFBP-l 
(0.15 X 10.9 M; a concentration comparable to the fasting serum IGFBP-l 
concentrations observed in lipodystrophy patients in vivo) were added to cell 
cultures, no fall in thymidine uptake was observed in lipodystrophic subjects (in 
comparison to thymidine uptake after stimulation with IGF-I (10" M)), while such an 
effect could be observed in one of the two healthy controls under the same 
culture conditions (Figure 3, Sub] 2). 
Discussion 
Our patients showed acromegaloid features, large hands and feet. In patients with 
partial lipodystrophy acromegaloid features along with thick skin and large hands 
and feet have been described in association with normal levels of circulating 
growth hormone (8, 24). As in other syndromes of insulin resistance, the 
occurrence of acromegaloid features, acanthosis nigricans and polycystic ovaries 
in the (partial) lipodystrophy syndrome has been previously attributed to cross 
stimulation of the IGF-I receptors by the existing hyperinsulinemia (25, 26). 
However, the affinity constant of insulin to the normal IGF-I receptor is about 10 
I1mol/L, a concentration which even under conditions of extreme insulin resistance 
is not reached in human subjects under physiological conditions (e.g. even at 
circulating levels of 2,000 lUlL insulin, the insulin concentration in blood is not 
higher than 12 nmol/L). 
Total IGF-I and IGFBP-3 levels in lipodystrophy patients were comparable to the 
values observed in healthy controls, while fasting insulin levels were significantly 
elevated both under fasting and fed conditions. IGFBP-l levels were lower in 
lipodystrophy patients than in healthy controls both in the fasting as well in the fed 
state. Free IGF-I in lipodystrophic tended to be lower in the fed state. Despite the 
lower levels of free IGF-I and IGFBP-l in lipodystrophy subjects, the free 
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IGF-I/IGFBP-1 ratio was higher than in the healthy controls. Variation in serum IGF-I 
bioactivity appears to be largely due to variations in IGFBPs (27). It has previously 
been suggested that a higher total IGF-I/IGFBP-1 ratio may reflect a higher 
bioavailability of IGF-I (28). The elevated free IGF-I/IGFBP-1 ratio found in our 
lipodystrophy patients therefore suggests that the occurence of acromegaloid 
features, acanthosis nigricans and polycystic ovaries in the (partial) lipodystrophy 
syndrome is mediated by a direct effect of IGF-I on the IGF-I receptor. Untreated 
acromegalic subjects also show an increased free IGF-I/IGFBP-1 ratio (unpublished 
observations). 
At present the relevance of studying the IGF-I receptor on erythrocytes and PBMCs 
is unclear. We know of only one paper from a Japanese group which has studied 
IGF-I receptor characteristics on erythrocytes and liver microsomal membranes in 
one patient with typical leprechaunism (29). The IGF-I receptors on erythrocyte and 
microsomal membranes in this patient showed a lower affinity and a higher 
capacity on both cell types than that observed in infants of the same age (28). We 
do not have own data or other data from the literature in which IGF-I receptor 
numbers have been compared on blood cells and on other tissues. Recently we 
have published about the relationships of IGF-I receptors. IGF-I and IGFBPs on 
erythrocytes and PBMCs in another study (30). One of the conclusions of this 
paper was that studies of IGF-I receptor characteristics on erythrocytes and 
PBMCs in the fasting state are cell specific and cannot be extrapolated without 
restrictions to other cell types. This latter phenomenon might be due to the fact 
that IGF-binding proteins, which are considered important modulators of IGF-I 
action, are synthesized in a tissue- and cell-specific pattern (31). 
Although the lowered serum IGFBP-t levels in lipodystrophy subjects may be the 
consequence of an increased inhibitory effect of insulin on m-RNA prod uction of 
IGFBP-1 in the liver (32), chronic hyperinsulinemia might also have caused a 
permanent increased movement of IGFBP-1 from the vascular compartment to 
extravascular tissues (33). Thus chronic hyperinsulinemia in lipodystrophy subjects 
may result in an increased extravascular transport of IGFBP-1. As IGFBP-1 is also 
considered a "shuttle" for IGF-I (34), this will result in an increased IGF-I effect on 
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the IGF-I receptor in lipodystrophic subjects secondary to the increased availability 
of IGF-I in the extracellular space to interact with the IGF-I receptor. 
We did not observe an additional effect of IGF-I on the increase in thymidine 
uptake of PBMCs drawn from lipodystrophy patients during experiments performed 
in the absence of IGFBP-l. The lack of normal IGF-binding proteins in vitro may 
alter the biological activity of IGF-I. Under these circumstances in vitro, all the IGF-I 
would have been present as free IGF-I. After addition of both IGFBP-l (in a 
concentration which was comparable to the serum IGFBP-l levels observed in 
lipodystrophy patients in vivo) and IGF-I to the PBMCs cultures, no decrease in 
thymidine uptake by PBMCs was observed in lipodystrophy subjects, while at this 
IGFBP-l concentration a significant decrease in thymidine uptake could be 
observed in PBMCs cultures of one healthy subject. Normally the addition of 
IGFBP-l to in vitro cell cultures has been reported to result in the inhibition of 
IGF-I within these experimental systems (35, 36). However, one of the requirements 
for this effect is that IGFBP-l must be added in molar excess to IGF-I (31). 
Therefore, our study suggests no inhibiting action of IGFBP-l on IGF-I in subjects 
with partial lipodystrophy as a consequence of the lowered serum IGFBP-l levels. 
In conclusion, we observed in lipodystrophy subjects normal to lowered serum free 
IGF-I levels, as well as lowered serum IGFBP-l levels, but an increased free 
IGF-I/IGFBP-l ratio in the fasting and the fed state. In addition, the lipodystrophy 
subjects showed normal functioning IGF-I receptors in vitro and no decrease in 
thymidine uptake by PBMCs after addition of a combination of IGF-I and low 
concentations of IGFBP-l to the PBMCs cultures. 
We hypothesize that increased free IGF-I/IGFBP-l ratios may result in an 
unopposed effect of IGF-I on IGF-I receptors, contributing to the development of 
acromegaloid features, acanthosis nigricans and polycystic ovaries as seen in 
congenital partial lipodystrophy. 
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Conclusions and General Discussion 
The aim of this thesis was to investigate the (patho)physiologic role of the 
IGF-I/IGFBP system in adult subjects in health and disease under several 
conditions like aging, GH deficiency, acromegaly, diabetes mellitus and congenital 
partial lipodystrophy. 
In chapter 2 we have studied whether it is possible to measure IGF-I receptors on 
blood cells in vitro and what its (clinical) importance might be. We have adapted 
and further developed a method to measure the IGF-I receptor characteristics on 
blood cells in vitro. The observed affinity constants for the IGF-I receptor on blood 
cells using this method showed a concentration range that was in the same range 
as that measured for serum free IGF-I levels. In the fasting state the Kd of IGF-I 
receptors on erythrocytes was positively related to circulating free IGF-I levels while 
for the IGF-I binding sites on PBMCs no relation with free IGF-I levels were found. 
Serum IGFBP-3 levels were inversely related to the number of IGF-I binding sites 
on erythrocytes and to the Kd of the IGF-I receptor on PBMCs. These observations 
suggest that studies of the IGF-I receptor characteristics are cell-specific, and 
cannot be extrapolated without restrictions to other cell types in the body. We 
therefore concluded that measurement of IGF-I receptors on blood cells does not 
give a good impression of the action of IGF-I on other (relevant) target tissues in 
the body. 
In Paragraph 2.4 we have studied whether in vivo changes occur in the 
IGF-I/IGFBP system and the IGF-I receptor characteristics on blood cells during an 
oral glucose load. The circulating free IGF-I levels and the IGF-I receptors on 
PBMCs showed no changes during a period of 120 minutes after the oral glucose 
load. Serum IGFBP-1 and serum IGFBP-3 levels also did not change significantly 
during this period, despite the observation of a transient increase of serum insulin 
levels after the glucose load. The absence of changes in the IGF-I receptor 
characteristics after an oral glucose load suggest that the changes in circulating 
Insulin and IGFBP-1 levels acutely regulate IGF-I bioactivity. 
The '1ree hormone hypotheSiS" has been a basic tenet of endocrine physiology for 
many decades (1). The assumptions of this hypothesis can be summarized as 
follows (1): 1] hormones are physiologically active only in the unbound, free state, 
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2J measurements of free hormone levels are more reliable indicators of biological 
action than measurements of total hormone levels, and 3J normal, physiologic 
mechanisms preferentially regulate concentrations of the free, rather than total, 
hormone. IGF-I is present in body fluids in association with specific IGFBPs, which 
regulate and, for the most part, inhibit the bioactivity of IGF-I. Measurement of free 
IGF-I, theoretically the bioactive fraction of IGF-I, seems an important step to get 
more information on the biological actions of the IGF-I/IGFBP system in vivo. Free 
IGF-I concentrations reported in the literature vary widely and range from < 1 % to 
19% of total IGF-I in the circulation (2). Several assay methods to measure free 
IGF-I exist, many of which utilize a chromatographic or filtration step prior to the 
assay (1). Matrix changes in the sample matrix using these both methods, could 
change the dynamic equilibrium between the free and bound IGF-I fractions (1). 
We have used an IRMA to measure free IGF-I levels in our studies. This latter assay 
can be used directly on unaltered serum samples and the sample matrix is not 
disturbed. Recently, it was suggested that the free IGF-I assay used in our study, is 
the best that is available at present and appears to generate experimental data that 
were similar to "expected" free IGF-I concentrations (2). This supports the view that 
the free IGF-I levels measured in our studies reflect indeed the majority of the 
biologically active fraction of IGF-I. Free IGF-I levels might in this respect be 
comparable to free thyroxine and free cortisol levels. However, free IGF-I levels 
need to be interpreted with more caution, since the biological action of IGF-I 
presumably is far more complex than observed previously for thyroxine and cortisol 
levels. The bioactivity of IGF-I is modified by at least six binding proteins, many of 
which are modified in their activity by protease activity. Another methodological 
reservation of our free IGF-I assay is that the amount of free IGF-I measured 
depends on the affinities of the IGFBPs vs. the affinities of the IGF-I antibodies 
used in this assay. The effect of this latter phenomenon may be that our free IGF-I 
assay actually measures a combination of the true free IGF-I and a portion of IGF-I, 
which is capable of being competitively dissociated from the IGFBPs. On the other 
hand, this may also be the strength of this assay since one can argue that the free 
IGF-I fraction, which is measured in our assay, may represent the free IGF-I fraction 
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that is available to the tissues. 
As judged from the observed affinity of the IGF-I receptor for IGF-I (Kd ± 1-2 
nmol/L) serum free IGF-I levels as determined by our assay may elicit biological 
effects via the IGF-I receptor. Cross-reaction with the insulin receptor is unlikely 
because of its low affinity for IGF-I at this concentration. Besides receptor affinity 
and the concentration of free IGF-I, IGF-I receptor abundance determines the 
cellular response (3). Tissues with more abundant IGF-I receptors may therefore 
respond to lower IGF-I levels than tissues with a lower number of IGF-I receptors. 
The question whether the measurement of serum free IGF-I levels gives additional 
and/or other information than the total IGF-I assay was studied in Chapter 3. 
In Chapter 3 (Paragraph 3.1) we observed that free IGF-I levels did not decrease 
with age in a healthy elderly population (studied age range 55-80 yrs). In the same 
study population and age range we observed the expected physiologically 
occurring decrease in total IGF-I levels during aging. These results suggest that 
changes in serum free IGF-I levels do not always parallel those of total IGF-I and 
that the measurement of free IGF-I levels might give other information than total 
IGF-I levels. 
The free IGF-I levels were actually even higher in individuals above the age of 70 
years when compared with subjects between 55 and 70. However, one needs to 
realize that a cross-sectional study as we carried out in Chapter 3 has limitations. 
For example the actual rate of change of IGF-I during aging within one individual 
was not measured. Nevertheless, we hypothesize that the higher free IGF-I levels in 
the subjects above 70 years observed in our study may be the consequence of a 
selective survival of the members of this subgroup. This may imply that subjects 
with higher free IGF-I levels live longer. Long-term prospective and population 
based studies are needed to confirm this intriguing possibility. If in such 
prospective studies subjects with the highest free IGF-I levels demonstrate a 
selective survival, this would be the mirror-image of previous findings in growth-
hormone deficient adults (a condition characterized by low IGF-I levels), that 
showed an increased total and cardiovascular mortality (4-6). 
We did not observe a relationship between free IGF-I levels and free androgen and 
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free oestrogen indices in this healthy aging population. This suggests that the 
changes in the biological activity of the IGF-I/IGFBP system and that of sex 
hormones occur mainly independently during aging. 
In Chapter 3 (Paragraph 3.2) we observed that higher free IGF-I levels were 
associated with a lowered prevalence of cardiovascular disease. For total IGF-I 
levels no relation with the prevalence of cardiovascular disease was found. Higher 
fasting IGFBP-l levels were associated with a more favourable cardiovascular risk 
profile. As mentioned above, previous studies have suggested that GH deficiency 
and low IGF-I levels are associated with premature and/or increased atherogenesis 
(4-6). The response-to-injury hypothesis of the pathogenesis of atherosclerosis 
suggests that injury of the vascular endothelium leads to an inflammatory-
fibroproliferative response which if occurring chronically, may culminate in the 
occlusive, advanced lesions of atherosclerosis (7). IGF-I is a well-known stimulator 
of DNA synthesis and proliferation of vascular smooth muscle cells and it is this 
effect that is generally considered to contribute to the development of 
atherosclerosis (8). Such inflammatory-fibroproliferative responses seem initially 
designed to be protective for the vascular endothelium (8). It was observed that in 
hypophysectomized rats with low IGF-I levels the proliferation of vascular smooth 
muscles is markedly delayed after endothelial damage, suggesting an impaired 
adaptive growth response in the proces of healing of the injured arterial wall, when 
compared to normal control animals (9). However, these hypophysectomized 
animals showed preserved local induction of IGF-I mRNA in the vessel wall after 
balloon injury, suggesting undisturbed autocrine and/or paracrine IGF-I secretion 
(10). Low circulating IGF-I levels have also been reported to be associated with 
angiographically documented coronary artery disease in humans (11). Moreover, 
the highest IGF-Ilevels during life are normally found at puberty (12, 13), a period 
that is characterized by the absence of atherosclerosis. All these findings together 
challenge both the view that high IGF-I levels contribute to the development of 
atherosclerosis as well as an important role for the paracrine/autocrine 
IGF-I/IGFBP system in the development of atherosclerosis. On the contrary, these 
findings might even be compatible with a protective effect of high (endocrine) 
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IGF-I levels on the development of atherosclerosis (comparable to the known 
effects of IGF-I in wound healing) and give an explanation for the observed 
decreased prevalence of cardiovascular disease in elderly subjects with the highest 
free IGF-I levels in our study. 
High fasting IGFBP-l levels were associated with a more favourable cardiovascular 
risk profile in our study (Paragraph 3.2) and this relation remained after adjustment 
for insulin levels. This suggests that IGFBP-l levels might be an independent 
marker for metaboliC disturbances, which are associated with an increased risk of 
cardiovascular diseases. An additional argument for this is the observation that in 
NIDDM subjects, low IGFBP-l levels correlate with an increased cardiovascular risk 
(14). Studies on the biological effects of IGFBP-l have shown conflicting results. 
IGFBP-l is capable of both inhibition as well as augmentation of IGF-I bioactivity 
(15). These conflicting observations may be explained by the recent findings that 
differential phosphorylation of IGFBP-l significantly alters its affinity to IGF-I, 
thereby differentially modulating IGF-I bioactivity (16). The IGFBP-l assay used in 
our study cannot discriminate between phosphorylated and non-phosphorylated 
IGFBP-l, but under normal conditions IGFBP-l circulates mainly in a highly 
phosphorylated form (17). This latter form of IGFBP-l would favor sequestration of 
IGF-I by IGFBP-l resulting in a decreased IGF-I release to IGF-I receptors (15). The 
observed lower IGFBP-l levels in subjects with a disadvantageous cardiovascular 
risk profile, might thus be an adaptive mechanism to increase IGF-I bioactivity at 
the vascular endothelium. 
In Paragraph 3.3 we observed that circulating (total and free) IGF-I levelS were 
positively related to bone mineral density in men but not in women. This suggests 
a gender-specific anabolic effect of circulating IGF-I on trabecular bone in men. 
However, this statistically significant relationship was not very powerfull suggesting 
that circulating IGF-I levels are not a very important determinant for bone mineral 
density. However, one needs to consider that interindividual differences in 
circulating IGF-I concentrations in old age may have already existed at a younger 
age. It is therefore possible that any association between IGF-I and bone mass in 
elderly subjects may be due to events that occurred long before the actual 
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measurements were performed. 
The assessment of serum free IGF-I levels did not give much additional 
information to that of total IGF-I in this latter study, since the relationships between 
free IGF-I and total IGF-I and bone mineral density were almost identical. The 
relationship between circulating IGF-I levels and bone mineral density became only 
manifest after adjustment for body mass index. Obesity is generally considered as 
a protective factor for bone mineral density (18). However, this relationship 
between body mass index and bone mineral density is not linear, and a lowered 
bone mineral density is especially observed in very thin individuals (18). We 
observed an inverse relationship between body mass index and free IGF-I levels in 
men only, supporting that this might be a possible explanation for the observed 
gender specific effect. 
It has been suggested that the anabolic actions on bone are mediated both by the 
(endocrine) production of IGF-I from the liver and by local production of IGF-I (19). 
IGF-I has been found to stimulate osteoblast activity and collagen synthesis in 
bone (20). Apart from direct effects on osteoblasts, IGF-I enhances intestinal 
absorption of calcium and phosphate by increasing the production of 1,25 (OH), 
vitamin D, and by increasing the intestinal sensitivity to vitamin D (21). However, 
the situation is even more complex since bone cells not only locally synthesize 
IGF-I but also at least six IGFBPs regulating its bioactivity in an auto- and paracrine 
manner (22). Therefore it is at present difficult to conclude whether circulating 
(endocrine) or locally produced (autocrine/paracrine) IGF-I is from a physiological 
point of view most important for the effects of IGF-I on bone. 
Finally, as physical fitness, muscle strength, and bone integrity are related, it might 
be possible that the observed relations between serum free and total IGF-I and 
skeletal BMD in our study are related to alterations in physical fitness secondary to 
aging. However, we did not observe a relation between (total and free) IGF-I and 
disability. Differences in physical activity seem thus not responsible for the 
observed relation between (total and free) IGF-I and BMD in men. 
In Paragraph 3.4 we observed lower serum free IGF-I levels in subjects, who felt 
less healthy in comparison to other individuals of their own age. No such 
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relationship was observed for total serum IGF-I levels. This study has many 
limitations in its design. The finding may be not specific, since it has been found 
that IGF-I levels are lowered in all catabolic conditions (23). Lowered IGF-I levels 
are related with indices of malnutrition, hepatic function, chronic renal failure and 
are predictive of future life-threatening complications such as severe infections (24). 
Low IGF-I levels might thus have indirectly contributed to the feelings of a lesser 
health. Lowered IGF-I levels also occur in GH deficiency. It has been found that 
subjects with GH deficiency have a decreased subjective feeling of well being (25). 
Replacement therapy with growth hormone in these GH deficient subjects 
normalizes free IGF-I levels (26) but also improves psychological well-being (27). 
To summarize the results of Chapter 3 in this healthy elderly population (age 
range 55·80 years): 
-We observed a decrease of total serum IGF-I and IGFBP-3 levels with aging. Free 
serum IGF-I levels did not decrease in this age range, and tended to be higher in 
subjects over 70 years. We did not observe a relationship between free IGF-I levels 
and free androgen and free oestrogen indices in this healthy aging population. 
-Higher free IGF-I (bul not total IGF-I) levels were associated with a lowered 
prevalence of cardiovascular disease, while IGFBP-l levels were associated with a 
more favourable cardiovascular risk profile. 
-Circulating (total and free) IGF-I levels were positively related to bone mineral 
density in men but not in women. 
-Finally, lowered free IGF-I (but not total IGF-I) levels were observed in subjects 
who felt less healthy in comparison to other individuals of their own age. 
The results of Chapter 3 suggest that measurement of free serum IGF-I levels 
provides additional and other information concerning the IGF-I/IGFBP system, 
which would not be obtained by measuring total serum IGF-I levels. We observed a 
discrepancy in the ratio of free and total IGF-I levels under several 
(patho)physiologic circumstances. Since the free serum IGF-I levels measured in 
our study probably reflect the majority of the biologically active fraction of IGF-I, 
the observed relationships for free IGF-I suggest that IGF-I has predominantly 
anabolic effects in this aging population. 
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In Chapter 4 (Paragraph 4.1) we discussed the problems encountered in the 
diagnosis of the growth deficiency syndrome. Besides discussing the parameters 
to measure when growth hormone deficiency is suspected, we have presented 
recommendations to answer the question which individuals should be tested for 
growth hormone deficiency in the first place. 
In Paragraph 4.2 we demonstrate that measurement of circulating IGFBP-3 levels 
provides no (additional) advantages above serum total IGF-I levels in the 
diagnosis of acromegaly. This is not surprising since there is a close correlation 
between serum total IGF-I and IGFBP-3 levels in all clinical conditions (1) and as 
discussed in chapter 1, IGFBP-3 binds almost 75-95% of the IGF-I present in the 
circulation (28). 
In Paragraph 4.3 we have studied the physiological and clinical relevance of the 
measurement of serum total and free IGF-I and IGFBP-3 levels in untreated patients 
with acromegaly. In acromegalics, serum free IGF-I levels did not change with age, 
while mean 24 h serum GH, total IGF-I and IGFBP-3 levels tend to decrease with 
age. We observed that although serum total and free IGF-I, but not IGFBP-3 levels 
are suitable biochemical parameters for screening for acromegaly, total and free 
serum IGF-I levels do not correlate with disease activity in acromegaly. 
Diabetic retinopathy and nephropathy develop only after the age of 15 years (29). It 
therefore has been suggested that GH and IGF-I levels are involved in the 
pathogenesis of diabetic retinopathy and nephropathy (29). In healthy subjects 
there is an almost linear increase in serum IGF-I levels from early childhood into 
adolescence, while after puberty a significant decrease is apparent throughout 
adulthood (12, 13)( see Chapter 1, Figure 5). In diabetic patients total IGF-I levels 
during puberty are lower and peak later, but statistically significant differences in 
total IGF-I levels between diabetic patients and healthy controls are only manifest 
during the later stage of puberty (30). 
In Chapter 5.1 we have studied the changes in the IGF-I/IGFBP system in IDDM 
type I, and whether these changes are related to the presence of diabetic 
microvascular complications. We observed lower free IGF-I and total IGF-I levels 
and IGFBP-3 levels and higher IGFBP-l levels in insulin-treated adult IDDM 
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subjects than in age- and sex-matched controls_ In addition, free IGF-I levels 
decreased significantly with age in 100M subjects in comparison to age- and sex-
matched healthy controls. Most previous studies in 100M also observed low to 
lowered total IGF-I and IGFBP-3 levels and high fasting IGFBP-1 levels, despite 
hypersecretion of GH (31-33). Our study confirms these previous reports and 
extends these results by demonstrating lowered fasting free IGF-I levels in insulin-
treated 100M patients. It has always been assumed that the insulin-like effects of 
IGF-I were not of physiological relevance, because IGF-I circulates bound to IGF-
binding proteins and the amounts of free IGF-I were too small as to be significant 
(34). This view has to be revised, since it is now known that IGFBPs play an 
important role in regulating bioavailability and thus bioactivity of IGF-I (35). It has 
been demonstrated in animals that infusion of IGFBP-1 leads to a prompt increase 
of blood glucose (36), which is reversed by administration of human recombinant 
IGF-1. In addition, administration of recombinant IGF-I normalizes expression of 
renal glucose transporters in diabetic rats (37). Thus, it can be argued that reduced 
circulating IGF-I levels and high IGFBP-I levels may have direct effect on glucose 
homeostasis. Generally poor glycemic control in type I diabetes, the most 
important risk factor for diabetic complications, is associated with reduced rather 
than elevated IGF-I levels (34). 
In diabetic subjects " tissue wounding" is a more common phenomenon than in 
normal subjects because of alterations in tissues induced by glycosylation, cross-
linking of proteins, shear stress and a variety of other changes (38). Moreover, it is 
now accepted that wound repair of many types requires an increase of IGF-I in the 
damaged area (39). In diabetic animals an impairment in tissue repair has been 
observed due to a deficiency in the production of IGF-I (40). 
In our study circulating free IGF-I levels were decreased to a lesser extent (after 
adjustment for age) in 100M patients with retinopathy than in those without. 
Hansson et al. have shown that immunoreactive IGF-I is greatly increased in areas 
of angiogenic activity (41). The difference in free IGF-I levels may thus be the 
expression of a different degree of (retinal) angiogenesis between 100M patients 
with retinopathy and those without. Angiogenesis occurs as response to ischemia 
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caused by nonperfusion of the smaller retinal blood vessels and capillaries (42). 
This ischemia may initiate an increased release of factors (like IGF-I) which 
stimulate local vasoproliferation and vasodifferentiation in an latest and abortive 
attempt to provide nutrition for tissue deprived of the required amount of oxygen 
(42). Oiabetic proliferative retinopathy is considered in this view as an insufficient 
adaptive growth response of the retinal microvessels. This hypothesis fits well with 
data which suggest that alterations of growth factors (like IGF-I) occur late in the 
sequence of events leading to angiogenesis, but do not play an early or initiating 
role ((43) , see Figure 1). 
IGF-I has also been found to prevent and/or to protect -in a dose dependent 
fashion against glucose-induced inhibition of neuronal growth and apoptosis in 
sensory neurons in vitro (44). Since the retina consists of neuronal tissue, while 
apoptosis is a characteristic feature of diabetic retinopathy (45), we hypothesize 
that the observed relative steeper decrease of serum free IGF-I levels in 100M 
subjects during aging in comparison to healthy controls (see Paragraph 5.1, Figure 
2), might be a mechanism contributing to the progression of diabetic retinopathy 
during aging. In other words, the progressive decline of serum free IGF-I levels and 
IGF-I bioactivity during aging in diabetics, may ultimately result in a progressive 
loss of anti-apoptotic effects by IGF-I on retinal cells, and in the progression of 
diabetic retinopathy. Unfortunately no data are available on free IGF-I levels in 
vitreous fluid of eyes from diabetic patients with proliferative retinopathy. 
The hypothesis that IGF-I is involved in the control of GFR is supported by the 
observation that GH-deficient patients have lowered renal plasma flow (RPF) and 
GFR which both normalize during GH replacement therapy (46); also infusion of 
IGF-I increases GFR and RPF (47, 48). We observed lower values of serum (free 
and total) IGF-I levels in 100M patients than in sex- and age-matched controls, 
which suggests at first glance no important role for IGF-I in the pathogenesis of 
renal hyperfiltration in 100M. 
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Low (portal) insulin levels --> Low Free IGF-I and high IGFBP-l levels 
~ 
Chronic Hyperglycemia 
~ 
Biochemical Responses 
(Sorbitol pathway, AGEs, protein kinase, hyperglycemic hypoxia) 
Capillary Loss --> Hypoxia and Capillary Leakiness 
~ 
Influx of growth factors (IGF-I)/ 
Local growth factor stimulation (VEGF, IGF-I, TNF-a)/ 
Growth Inhibitor Inactivation (TGF-J3 via a2-antiplasmin) 
~ 
Tissue Remodeling/ Angioneogenesis 
~ 
Manifest Diabetic Retinopathy 
Figure 1. A tentative model of the pathogenesis of diabetic proliferative retinopathy 
(modified after (42». 
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However, in an experimental animal model of diabetes, which was also 
characterized by low to normal serum IGF-I levels, an increased binding of IGF-I to 
the IGF-I receptors in the kidney was found in comparison to controls (49). In 
accordance with this observation, after infusion of recombinant human IGF-I, 
plasma free IGF-I and IGF-I bound IGFBP-3 levels were at any dosage lower in 
diabetic rats than in normal rats, due to the more rapid distribution and/or 
elimination of IGF-I from plasma in diabetic rats (50). The availability of circulating 
IGF-I may thus determine the degree of kidney IGF-I accumulation in diabetic 
animals, and, therefore, its contribution to the alterations that precede diabetic 
nephropathy (51). 
It has been suggested that IGF-I contributes to the kidney hypertrophy and 
glomerular hyperfiltration found in diabetes (52). Kidney hypertrophy and 
glomerular hyperfiltration are considered in diabetes mellitus as early symptoms 
detrimental to the kidney (53). However, kidney hypertrophy and glomerular 
hyperfiltration per se may not be detrimental to the kidney. Glomerular hypertrophy 
and glomerulosclerosis are not tightly linked (54). Mice transgenic for IGF-I develop 
glomerular hypertrophy but do not develop glomerulosclerosis (55). Renal disease 
is not observed in acromegaly (56), and pregnancy-induced hyperfiltration does not 
predict renal disease in non-diabetic individuals (57). Also, normal individuals with 
one kidney and hyperfiltration in that kidney appear to have a good prognosis and 
will usually not develop renal disease (58). In ischemic acute renal failure, it has 
been suggested that IGF-I, by stimulating hyperfiltration and renal blood flow, 
provides oxygen and nutrients to ischemic kidney cells thereby protecting these 
cells from dying (59). We hypothesize that increased binding of IGF-I to the IGF-I 
receptor in 100M subjects might also protect kidney cells from ischemia 
(hypoxia). The progressive decrease of serum IGF-I levels in diabetic patients 
starting in late puberty, might subsequently lead to a progressive loss of these 
IGF-I-dependent protective mechanisms during later life, thereby contributing to the 
development of manifest diabetic nephropathy. 
Our findings may have important therapeutic consequences for the treatment of 
100M. It has been suggested that under normal physiological conditions insulin 
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and IGF-I, and the insulin receptors and IGF-I receptors keep each others effects in 
check (60). Insulin is necessary for a normal GH response with a subsequent 
response of IGF-I (see Chapter I, Figure 5). In 100M there seems to be a 
derangement of the growth hormone(GH)-IGF-1 axis (61). The mechanism behind 
the imbalance in the GH-IGF-I axis in 100M has been suggested to be due to low 
portal insulin levels leading to decreased production of IGF-I with subsequent 
increased GH levels (62). The elevation in GH, due to loss of feedback inhibition of 
IGF-I as a result of low insulin, may worsen hyperglycaemia by counteracting 
insulin's action. The use of recombinant IGF-I has therefore proposed as an 
adjunct to insulin therapy and several recent studies suggest indeed beneficial 
effects of recombinant IGF-I in 100M (34, 63·66). 
However, the initial enthusiasm concerning possible beneficial effects of 
recombinant IGF-I therapy in 100M has been tempered by reported side effects of 
IGF-I in several studies. The main reasons for the occurrence of these side effects 
may be the use of supraphysiologic doses of recombinant IGF-I (uncomplexed to 
IGFBPs) and/or the use of total serum IGF-I levels to monitor IGF-I therapy. 
However, we propose that free IGF-I levels, supposedly the major biologically 
active hormonal form of IGF-I, should be primarily used to monitor recombinant 
IGF-I therapy. Measurement of serum free IGF-I levels may be necessary to ensure 
that only safe IGF-I doses are used which restore the normal physiological 
function of the GH-IGF-I axis. To illustrate this latter problem with an example: 
when normal human subjects were infused with 10 Jig IGF-I/kg per h for several 
days (67), fasting plasma glucose levels statistically significant fell from 4.7 to 4.3 
mmol/L, total IGF-I levels rose from 31 to 133 nmol/L (about 4 fold increase) and 
free IGF-I levels rose from 0.08 nmol/L to 1.5 nmol/L (almost 20 times increase). 
(For comparison: we observed mean free IGF-I levels of 0.15 nmol/L with a range 
of 0.04-0.58 nmol/L in healthy controls in Paragraph 5.1). 
In Paragraph 5.2 we have studied the role of the IGF-I/IGFBP system in four 
patients with congenital partial lipodystrophy. In the existing literature the 
acromegaloid features, acanthosis nigricans, and polycystic ovaries frequently 
observed in subjects with congenital partial lipodystrophy usually have been 
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attributed to hyperinsulinemia and insulin interaotion with the IGF-I reoeptor. Our 
study suggests that the aoromegaloid features, aoanthosis nigrioans, and 
polyoystio ovaries in this syndrome, may also be the oonsequenoe of a direot 
interaotion of IGF-I to its reoeptor through an inoreased free IGF-I/IGFBP-1 ratio. We 
suggest that the oiroulating inoreased free IGF-I/IGFBP-1 ratio in oongenital partial 
lipodystrophy may refleot inoreased IGF-I bioactivity at the target cell and is caused 
by the hyperinsulinemia. 
In conclusion, our studies suggest that determination of free IGF-I and IGFBPs is of 
help to study normal physiology and pathologic changes of the IGF-I/IGFBP 
system during aging. Determination of free IGF-I and IGFBPs seems important in 
understanding situations in which there is an apparent discrepancy between GH 
secretion and total IGF-I levels. It is of diagnostic value in acromegaly and might 
help to assess clinical disease activity in diseases like GH deficiency. 
Determination of free IGF-I and IGFBPs give new insights in the pathogenesis of 
diabetic microvascular complications and might be an important tool to assess the 
effect of IGF-I therapy in diabetes. Also it helps to unravel the contribution of the 
endocrine vs the local IGF-I/IGFBP system in the complex regulation of metabolism 
and growth in health, aging and disease. The studies presented in this thesis 
suggest that both the determination of free IGF-I as well as of IGFBPs 1 and 3 in 
serum are valuable methodological contributions to a better understanding of the 
IGF/BP system. 
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Summary 
The aim of this thesis was to investigate the (patho)physiologic role of the 
insulin-like growth factor I/insulin-like growth factor binding proteins (IGF-I/IGFBP) 
system in health and disease under several conditions like aging, GH deficiency, 
acromegaly, diabetes mellitus and congenital partial lipodystrophy. 
In Chapter 1 the homologies in molecular structure and functions between IGF-I 
and insulin and their respective receptors is discussed. IGF-I, like insulin, consists 
of an A- and B-chain, a conserved connecting C-peptide, which is shorter than the 
C-peptide of insulin, and a~-domain. IGF-I, initially also termed non-suppressible 
insulin-like activity, stimulates glucose uptake, amino acid uptake, and inhibits 
lipolysis. IGF-I also has insulin-like effects on cellular proliferation and 
differentiation. Since IGF-I at high concentrations crossreacts with insulin receptors 
and insulin at high concentrations cross reacts with the IGF-I receptor, it is difficult 
to distinguish the components activated in the IGF-I signal transduction pathway 
through the IGF-I receptor from those activated via the insulin receptor. IGF-I and 
insulin are complementary in their anabolic actions in vivo and although there is 
also some overlap in functions: IGF-I, be it as an endocrine hormone or as an 
autocrine/paracrine cytokine, is considered to be more primarily involved in cell 
and tissue differentiation, whereas insulin mediates more primarily the metabolic 
functions such as lowering of blood glucose and glucose homeostasis. 
Most circulating IGF-I is bound to the insulin-like growth factor binding proteins 
(IGFBPs), which titrate the supply of IGF-I to its receptors in the target tissues, 
while a very small component circulates as the free form. The IGFBPs are a family 
of proteins that non-covalently bind IGF-I with high affinity. To date at least six 
IGFBPS have been identified. They have a high degree of sequence homology. 
The IGFBPs have been proposed to have four major functions that are essential to 
coordinate and regulate the biological activities of the IGF-I: 1] to act as transport 
proteins in plasma and to control the efflux of IGF-I from the vascular space; 2] to 
prolong the half-life of IGF-I and thereby regulating its metabolic clearance; 3] to 
provide a means of tissue- and cell-type specific localization; and 4] to directly 
modulate interaction between IGF-I and the IGF-I receptor, thereby indirectly 
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controlling its biological actions. Free IGF·I, by analogy with sex and adrenal 
steroids and thyroid hormones, may be the major biological active hormonal form 
of IGF·1. The levels of free IGF·I at the tissue level are modulated by the rate of 
IGF·I production, the clearance, and the degree of binding to IGFBPs. Growth 
hormone (GH) and insulin both stimulate hepatic IGF·I production, and IGF·I feeds 
back to suppress GH and insulin release. Age is also a major determinant of 
plasma IGF·I concentrations. Part of the age·related decrease of plasma IGF·I 
levels in adults is believed to be due to the decrease in GH secretion after puberty. 
The aim of this thesis is presented in the final part of chapter I. 
In Chapter 2 we have investigated the relationship between the IGF·I/IGFBP 
system and blood cells in healthy subjects. Is it possible to measure IGF·I 
receptors on blood cells in vitro and what is the (clinical) importance of this assay. 
We studied especially the following questions: do IGF·I receptors on peripheral 
blood cells reflect what happens with the IGF·I receptors on other IGF·I target cells 
elsewhere in the body and what are the relationships and effects of (free and total) 
IGF·I and the IGFBPs on IGF·I receptor characteristics and what happens with the 
IGF·I receptor characteristics after an oral glucose load? We have adapted and 
further developed a previously described method to measure the IGF·I receptor 
characteristics on blood cells in vitro. The observed affinity constants for the IGF·I 
receptor on blood cells using this method showed a concentration range that was 
the same as that measured for serum free IGF·I levels. The number and affinity of 
IGF·I binding sites on PBMCs did not change 120 minutes after an oral glucose 
load. Our observations suggest that studies of the IGF·I receptor characteristics on 
blood cells are cell·specific, and cannot be extrapolated to other cell types in the 
body without restrictions. We therefore concluded that measurement of IGF·I 
receptors on blood cells does not give a good impression of the action of IGF·I on 
other (relevant) target tissues in the body and do not acutely change after a oral 
glucose load. 
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In Chapter 3 we have investigated the relationships between the IGF-I/IGFBP 
system and age, sex steroids, cardiovascular diseases, bone mineral density and 
quality of health in a healthy elderly population. Other questions studied were: what 
is the potential significance of measuring serum free IGF-I levelsand does the 
measurement of serum free IGF-I levels give additional and/or other information 
than the total IGF-I assay? 
We observed a decrease of total serum IGF-I and IGFBP-3 levels with aging in a 
healthy elderly population (age range 55-88 years). Free serum IGF-I levels did not 
decrease in this age range, and tended to be higher in subjects over 70 years. We 
did not observe a relationship between free serum IGF-I levels and free androgen 
and free oestrogen indices in this healthy aging population. 
Higher serum free IGF-I (but not total IGF-I) levels were associated with a lowered 
prevalence of cardiovascular disease, while higher IGFBP-l levels were associated 
with a more favourable cardiovascular risk profile. 
Circulating (total and free) IGF-I levels were positively related to bone mineral 
density in the lumbar spine in men but not in women. 
Finally, lowered free IGF-I (but not total IGF-I) levelS were observed in subjects who 
felt less healthy in comparison to other individuals of their own age. 
The results of Chapter 3 suggest that measurement of free serum IGF-I levels 
provides additional and other information concerning the IGF-I/IGFBP system, 
which would not be obtained by measuring total serum IGF-I levels. We observed a 
discrepancy in the ratio of free and total IGF-I levels under several 
(patho)physiologic circumstances. Since the free serum IGF-I levels measured in 
our study probably reflect the majority of the biologically active fraction of IGF-I, 
the observed relationships for free IGF-I suggest that IGF-I has predominantly 
anabolic effects in this aging population. 
In Chapter 4 the potential role of the IGF-I/IGFBP system in disorders of GH 
secretion (GH deficiency, acromegaly) were investigated. We have studied the 
following questions: Whom is to be tested and how to diagnose growth hormone 
deficiency in adults? Which components of the circulating IGF-I/IGFBP system can 
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be used for this purpose? Do serum IGFBP-3 and/or free IGF-I levels reflect the 
clinical activity in acromegaly better than serum total IGF-I levels? 
Besides discussing the parameters to measure when growth hormone deficiency is 
suspected, we have presented recommendations to answer the question which 
individuals should be tested for growth hormone deficiency in the first place. 
Measurement of circulating IGFBP-3 levels provides no (additional) advantages 
above serum total IGF-I levels in the diagnosis of acromegaly and we observed 
that both serum total and free IGF-I levels are suitable biochemical parameters for 
screening for acromegaly, although total and free serum IGF-I levels do not 
correlate with disease activity in acromegaly. 
In Chapter 5 we have focused on the relationship between the IGF-I/IGFBP 
system, age and the presence of diabetic microvascular complications in insulin-
dependent diabetes mellitus (100M) type I. We observed lower fasting free IGF-I 
and total IGF-I levels and IGFBP-3 levels and higher IGFBP-1 levels in insulin-
treated adult 100M subjects than in age- and sex-matched controls. In addition, 
free IGF-I decreased significantly with age in 100M subjects, but not in the healthy 
controls. Circulating free IGF-I levels were decreased to a lesser extent (after 
adjustment for age) in 100M patients with retinopathy than in those without. 
In chapter 5 we have also studied the relationships between the IGF-I/IGFBP 
system and the IGF-I receptors on peripheral blood cells in patients with congenital 
partial lipodystrophy in order to study the role of the IGF-I/IGFBP system in the 
development of this syndrome which is characterized among other things by 
severe insulin resistance, hyperinsulinemia and acromegaloid features. Our study 
suggests that the acromegaloid features, acanthosis nlgricans, and polycystic 
ovaries in this syndrome, may be the consequence of a direct interaction of IGF-I 
to its receptor through an increased free IGF-I/IGFBP-1 ratio. We suggest that the 
circulating increased free IGF-I/IGFBP-1 ratio in congenital partial lipodystrophy 
may reflect increased IGF-I bioactivity at the target cell and is caused by the 
hyperinsulinemia. 
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Finally, conclusions and the general discussion are presented in Chapter 6. 
Our studies suggest that determination of free IGF-I and IGFBPs is of help to study 
normal physiology and pathologic changes of the IGF-I/IGFBP system during 
aging. Determination of free IGF-I and IGFBPs seems important in understanding 
conditions in which there is an apparent discrepancy between GH secretion and 
total IGF-I levels. It is of diagnostic value in acromegaly and might help to assess 
clinical disease activity in diseases like GH deficiency. 
Determination of free IGF-I and IGFBPs give new insights in the pathogenesis of 
diabetic microvascular complications and might be an important tool in the future 
to assess the effect of IGF-I therapy in diabetes. Also it helps to unravel the 
contribution of the endocrine vs the local IGF-I/IGFBP system in the complex 
regulation of metabolism and growth in health, aging and disease. The studies 
presented in this thesis suggest that both the determination of free IGF-I as well as 
of IGFBPs 1 and 3 in serum are valuable methodological contributions to a better 
understanding of the IGF/BP system. 
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Samenvatting 
Samenvatting 
In dit proefschrilt werd bij volwassenen de rol van de insuline-achtige groeifactor I 
(in het Engels afgekort als: IGF-I: Insulin-like Growth Factor I) en de eiwitten, 
waaraan het IGF-I gebonden is (in het Engels afgekort als IGFBPs: Insulin-like 
Growth Factor Binding Proteins) onderzocht. Zo werd gekeken naar veranderingen 
in het IGF-I en de IGFBPs bij het ouder worden, bij mensen met een tekort aan 
groeihormoon op de volwassen leeltijd (groeihormoondeficientie), bij mensen, die 
continu teveel groeihormoon aanmaken (acromegalie), bij mensen met 
suikerziekte, die helemaal geen insuline meer kunnen maken (ook wei type 1 
insuline-afhankelijke diabetes genoemd) en een zeer zeldzame ziekte, de 
congenitale partiele lipodystrofie, een aandoening, die onder andere gekenmerkt 
wordt door insuline resistentie (van insulineresistentie is sprake wanneer normale 
insuline spiegels de bloedsuikers onvoldoende kunnen doen dalen. Ais gevolg 
hiervan hebben personen met congenitale partiele lipodystrofie hogere insuline-
spiegels (nodig) om een normale bloedsuikerspiegel te bereiken). 
In Hoofdsluk 1 worden de overenkomsten lussen de moleculaire structuur en de 
functies van respektievelijk het IGF-I en het insuline, en de IGF+ en insuline-
receploren besproken. Het IGF-I molecuul is (vergelijkbaar met het insuline) 
opgebouwd uil een zogenaamde A en B keten, een C(connecting)-peptide, en een 
D-keten. Het IGF-I werd aanvankelijk in de literatuur aangeduid als de non-
sup res sible insulin-like factor, dat wi! zeggen een factor, die weliswaar de werking 
van insuline vertoonde, maar waarvan de werking niet onderdrukt kon worden met 
anlilichamen, die specifiek gericht waren tegen het insuline molecuul. 
Het IGF-I stimuleert evenals insuline de opname van glucose en aminozuren in de 
weefsels en onderdrukt de vetafbraak. Het IGF-I heelt daarnaast evenals insuline 
een stimulerende werking op celgroei en -dillerentiatie. 
Aangezien IGF-I zich bij relatief hoge concentraties ook nog kan binden aan de 
insuline receptor, en omgekeerd het insuline zich bij relatief hoge concentraties kan 
bind en aan de IGF-I receptor, is het moeilijk om de ellecten van IGF-I en van 
insuline van elkaar te onderscheiden. Bovendien vullen IGF-I en insuline elkaar 
aan (zijn complementair) in hun werking in het menselijk lichaam. De functies van 
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beide moleculen en hun receptoren overlappen elkaar in zekere mate, Toch is er 
een zekere mate van specialisatie: IGF-I lijkt vooral betrokken bij (de vaak 
chronische) effecten opcelgroei en -differentiatie, terwijl het insuline de belangrijk-
ste rol speeit bij de (meer acute) metabole effecten op de suiker- en 
vetstofwisseling, 
Ongeveer 99% van het IGF-I is in het bloed in een niet-vrije vorm aanwezig en 
gebonden aan eiwitten (de reeds bovengenoemde IGFBPs), Deze IGFBPs 
be'invloeden de mate waarin het IGF-I zich kan binden aan de IGF-I receptor. Op 
dit moment zijn er in ieder geval zes verschillende IGFBPs bekend, De 
belangrijkste vier functies van de IGFBPs zijn: lJhet transporteren van het IGF-I in 
het bloed en het transport van het IGF-I vanuit de bloedbaan naar de weefsels, 2J 
het reguleren van het metabolisme en daardoor het be'invloeden van de 
halfwaardetijd van het IGF-I in het bloed en in de weefsels, 3J het afgeven van IGF-I 
op een cel- en weefselspecifieke manier, en 4J het direct be'invloeden van de 
interactie tussen IGF-I en haar receptor, Op deze manier worden door de IGFBPs 
langs een indirecte weg de biologische effecten van het IGF-I gecontroleerd, 
Slechts een klein gedeeite van het IGF-I is in het bloed in een vrije (niet aan de 
IGFBPs gebonden) vorm aanwezig (ongeveer 1%), De vrije (niet gebonden) vorm 
van het IGF-I is te beschouwen als de belangrijkste biologische werkzame vorm 
van IGF-I in het Iichaam en het vrije IGF-I is in dit opzicht vergelijkbaar met de vrije 
schildklierhormoon- en geslachtshormoonspiegels, De mate waarin het IGF-I in de 
vrije (niet gebonden) vorm in het serum aanwezig is, is afhankelijk van de mate van 
produkJie en klaring van het IGF-I, en van de binding van het IGF-I aan de IGFBPs, 
Het groeihormoon en het insuline hebben ook invloed op de IGF-I spiegels in het 
bloed en stimuleren beiden de aanmaak van het IGF-I in de lever. Het IGF-I heeft 
op zijn beurt weer een negatieve feedback op de groelhormoon- en Insuline-afgifte, 
Leeftijd is een ander belangrijke factor, die effect heeft op de spiegels van het IGF-I 
in het bloed, De daling van de IGF-I spiegels in het bloed, die doorgaans met het 
ouder worden optreedt, Is volgens de huidlge inzlchten ten dele toe te schrijven 
aan een afname van de groelhormoonsecretie met de leeftijd, 
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De vraagstelling van dit proefschrift wordt In het laatste deel van hoofdstuk 1 
gepresenteerd. 
In Hoofdsluk 2 werden bij gezonde vrijwilligers de relaties tussen IGF-I en de 
IGFBPs enerzijds en bloedcellen anderzijds onderzocht. Is het mogelijk om IGF-I 
receptoren op bloedcellen te meten onder laboratorium omstandigheden en wat 
heb je daaraan in de kliniek? Specifiek werden de volgende vragen bestudeerd: 
weerspiegelen de IGF-I receptoren op bloedcellen de situatie van de IGF-I 
receptoren in andere weefsels van het menselijk lichaam en wat zijn daarbij de 
relaties en effecten van het (vrije en total e) IGF-I en de IGFBPs in het bloed op de 
affiniteit en het aantal bindingsplaatsen van de IGF-I receptor aanwezig op bloed-
cell en. Zijn er acute veranderingen van de IGF-I receptorkarakteristieken zichtbaar 
na een acute glucose gift? Om de IGF-I receptor op bloedcellen te meten hebben 
we een eerder beschreven methode aangepast en verder ontwikkeld waarmee in 
het laboratorium een aantal karakteristieken van de IGF-I receptor (aantal bindings-
plaatsen en affiniteit) op bloedcellen gemeten kunnen worden. De zo door ons 
gevonden waarden voor de affiniteits·constanten van de IGF-I receptor op (rode en 
witte) bloedcellen, vertoonde dezelfde concentratie range als die van de vrije IGF-I 
spiegels in het serum. Er werden geen veranderingen gezien in de IGF-I receptor 
karakteristieken na een acute glucose gift. Onze experimenten suggereren dat de 
bestudering van de IGF-I receptor cel- en weefsel-specifieke resultaten oplevert 
en dat de IGF-I receptor in het ene weefsel niet zonder meer, die in andere 
weefsels weerspiegelt. Hieruit hebben we de conclusie getrokken dat de meting 
van IGF-I receptoren op bloedcellen niet gebruikt kan worden om een goede 
indruk te krijgen over de werking van het IGF-I en de IGF-I receptor op andere 
(relevante) doelwitweefsels in het lichaam. Bovendien lijkt het erop dat de IGF-I 
receptor geen acute veranderingen vertoont na een orale glucose belasting. 
In Hoofdsluk 3 hebben we gekeken naar de relaties van het IGF-I/IGFBP systeem 
met, respektievelijk, de leeftijd, geslachtshormonen, het optreden van 
cardiovasculaire ziekten, botdichtheid en de kwaliteit van leven in een populatie 
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gezonde ouderen. Andere vragen, die hierbij door ons aan de orde zijn gesteld, 
waren: wat is de betekenis van het meten van vrije IGF-I spiegels in het serum en 
geeft bepaling van de vrije IGF-I spiegel in het serum additionele en/of andere 
informatie dan bepaling van de totale IGF-I spiegels in het serum? 
In een gezonde populatie ouderen in de leeftijd van 55 tot 80 jaar oud, vonden we 
met toenemende leeftijd een afname van de totale IGF-I en IGFBP-3 spiegels in het 
serum. De vrije serum IGF-I spiegels namen in deze groep ouderen echter niet af 
met de leeftijd. We vonden zelfs relatief de hoogste spiegels in personen van 
zeventig jaar en ouder. Er waren bovendien geen relaties tussen de vrije serum 
IGF-I spiegels en de vrije androgeen- en vrije oestrogeen-indices in deze gezonde 
oudere populatie. 
Hogere vrije IGF-I spiegels in het serum waren geassocieerd met een verminderde 
prevalentie van cardiovasculaire ziekten, terwijl een dergelijk verband niet voor de 
totale IGF-I spiegels in,het serum werd gevonden. Hogere IGFBP-l spiegels in het 
serum waren geassocieerd met een gunstiger cardiovasculair protie!. 
Circulerende (totale en vrije) IGF-I spiegels waren positief geassocieerd met een 
hog ere botdichtheid in de lumbale wervelkolom bij oudere mannen maar niet bij 
oudere vrouwen. Tenslotte, werden verlaagde vrije (maar niet totale) IGF-I spiegels 
in het serum gevonden bij die ouderen, die zich minder gezond voelden dan hun 
leeftijdsgenoten. 
De resultaten beschreven in Hoofdstuk 3 suggereren dat de meting van vrije IGF-I 
spiegels in het serum in een aantal gevallen additionele en andere informatie 
oplevert over het IGF-I/IGFBP systeem dan die verkregen wordt na de meting van 
de totale IGF-I spiegels in het serum. Aangezien de vrije IGF-I spiegel in het serum 
waarschijnlijk de belangrijkste biologische fractie van het IGF-I in het lichaam 
weerspiegelt, suggeren onze resultaten dat IGF-I vooral anabole effecten heeft in 
bij ouderen. 
In Hoofdstuk 4 werd bekeken welke personen in eerste instantie getest dienen te 
worden op groeihormoondeficientie en welke parameters hiervoor gebruikt dienen 
te worden. We stelden ons in het bijzonder de vraag welke componenten van het 
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circulerend IGF-I/IGFBPsysteem voor dit doel gebruikt kunnen worden. Bovendien 
stelden we ons de vraag of door meting van IGFBP-3 en/of vrije IGF-I spiegels in 
het serum betere informatie kan worden gekregen over de klinische activiteit van 
acromegalie dan door de meting van de totale IGF-I spiegels in het serum. 
Behalve het bespreken van de parameters, die ons inziens gebruikt dienen te 
worden om een groeihormoon-tekort te objectiveren, presenteren we in dit 
hoofdstuk een praktische beslisboom, die gebruikt kan worden om uit te maken of 
iemand op het bestaan van groeihormoondeficientie getest dient te worden. 
We stelden vast dat meting van IGFBP-3 spiegels in het serum geen extra 
voordelen heelt boven het bepalen van de totale IGF-I spiegels in het serum bij het 
stellen van de diagnose acromegalie. We vonden dat zowel de totale als de vrije 
IGF-I spiegels in het serum gebruikt kunnen worden voor de screening op 
acromegalie, maar dat beide parameters niet goed correleren met de klinische 
ziekteaktiviteit van de acromegalie. 
In hoofdstuk 5 hebben we gekeken naar de relatie tussen het IGF-I/IGFBP 
systeem, leeltijd, en het optreden van diabetische microvasculaire complicaties bij 
type I insuline-afhankelijke diabetes mellitus (100M). In de nuchtere toestand 
vonden we lag ere vrije en totale IGF-I spiegels, lag ere IGFBP-3 spiegels en hogere 
IGFBP-l spiegels in het serum bij 100M patienten dan in een voor de leeftijd- en 
geslacht gematchte gezonde controle groep. Bovendien namen de vrije IGF-I 
spiegels in het serum bij 100M diabetes patienten in tegenstelling tot de gezonde 
controle groep significant met de leeltijd af. Oe vrije IGF-I spiegels in het serum 
waren (na correctie voor de leeltijd) relatief minder verlaagd bij 100M patienten met 
diabetische retinopathie dan bij patienten zander diabetische retinopathie. 
In hoofdstuk 5 hebben we ook de relatie van het IGF-I/IGFBP systeem met de 
IGF-I receptoren op perifere bloedcellen bestudeerd bij patienten met congenitale 
partiele lipodystrophie. We wilden nader bekijken of er veranderingen zijn in het 
IGF-I/IGFBP systeem bij deze patienten en wat de rol van het IGF-I/IGFBP systeem 
is bij het onstaan van dit syndroom. Een congenitale partiele lipodystrophie wordt 
onder andere gekenmerkt door een ernstige insuline resistentie, hyperinsulinemie 
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en door acromegale kenmerken. Onze studie suggereert dat de acromegale 
kenmerken, maar ook het bij dit syndroom vaak optredende polycysteuze ovarium 
syndroom en acanthosis nigricans het gevolg zou kunnen zijn van een verhoogde 
directe interactie van IGF-I met de IGF-I receptor secundair aan het verhoogde vrije 
IGF-I/IGFBP-l ratio in het serum bij deze patienten. 
Tenslotte worden in Hoofdstuk 6 conclusies en de generale discussie 
gepresenteerd. De resultaten van onze studies suggereren dat het meten van het 
vrije serum IGF-I en de IGFBPs zinvol is om de normale fysiologie maar ook 
pathologische veranderingen in het IGF-I/IGFBP systeem bij het ouder worden te 
bestuderen. Bepaling van de vrije serum IGF-I spiegel en de IGFBPs lijkt belangrijk 
om die (pathologische) situaties te begrijpen waarbij er ogenschijnlijk een 
discrepantie bestaat tussen de mate van groeihormoonsecretie en de circulerende 
totale IGF-I spiegels. Ook kunnen ze een hulp zijn bij het stell en van de diagnose 
acromegalie en het meten van ziekteaktiviteit bij aandoeningen als groeihormoon-
deficientie. Bepaling van de vrije IGF-I spiegels en de IGFBPs kan nieuwe 
inzichten in de pathogenese van de diabetische microvasculaire complicaties 
geven en kan in de toekomst een een belangrijk hulpmiddel worden om het effect 
van IGF-I therapie bij diabetes te monitoren. Het kan help en om een beter inzicht 
te krijgen wat de bijdrage is van het endocriene IGF-I/IGFBP systeem en wat de 
bijdrage van het autocriene/paracriene IGF-I/IGFBP systeem in gezonde situaties, 
bij het ouder worden en bij het optreden van ziekten. 
De gepresenteerde studies in dit proefschrift suggereren dat zowel de bepaling van 
het serum vrije IGF-I als van IGFBP-l en IGFBP-3 waardevolle bijdragen leveren 
om de betekenis van het IGF-I/IGFBP systeem beter te kunnen begrijpen. 
261 

Dankwoord 

Dankwoord 
Dankwoord 
Bij deze wil ik een ieder bed an ken, die een bijgedrage heelt geleverd aan de tot 
standkoming van dit proefschrilt. Een aantal person en wil ik met name noemen. 
Allereerst mijn promotor Steven Lamberts. Ik wil je bedanken voor de snelle 
wijze waarop je de manuscripten doorlas en van waardevol commentaar voorzag. 
Ook wil ik je bedanken voor de ruimte, die je me gegeven hebt om een deel van 
mijn elgen ideeen te ontwikkelen en te publiceren. 
Professor Rick Grobbee wil ik bedanken voor de goede samenwerking, en 
nuttige adviezen, die een belangrijke bijdragen hebben geleverd aan het het tot 
standkomen van verschillende publicaties in dit proefschrilt. 
Professor SLS Drop en professor Theo Visser wil ik bedanken aan hun bereidheid 
om zitting te nemen in de promotiecommissie. 
Voorts wil ik zowel professor Huib Pols en professor Frank de Jong bedanken voor 
hun bijdragen aan verschillende manuscripten in dit proefschrilt. 
Een verder woord van dank zou ik willen richten tot Ronald Stolk en Piet 
Uitterlinden, die bij het tot standkomen van dit proefschrilt onmisbaar zijn geweest 
en een belangrijke rol hebben gespeeld. 
Leo Hofland, Jan-Willem Koper, Nicoline Hoogerbrugge, Han van Neck, 
Marloes Jacobs, Frans Derkx, Rob Weber, Aart-Jan van der Lely, Wouter de 
Herder, Huib Burger en Michiel Bots wil ik bedanken voor hun bijdragen. 
Aile medewerkers van het laboratorium Interne III, en met name de 'hypofyse 
groep' wil ik bedanken voor de plezierige sfeer en de collegiale omgang, die ik van 
hen mocht ondervinden. 
265 
Dankwoord 
Aile patienten en vrijwilligers, die belangeloos bereid waren aan het onderzoek mee 
te doen, wil ik danken voor hun medewerking. 
Een speciaal woord van dank zou ik willen brengen aan de dames van de 
prikkamer van de polikliniek Interne geneeskunde (Betty, Marguereta en Heleen) 
voor hun enthousiaste medewerking bij het onderzoek. 
Het Diabetesfonds Nederland wil ik bed an ken voor de financiele ondersteuning van 
dit promotie-onderzoek. 
Tenslotte zou ik nog mevrouw Bleeker en de overige medewerkers van de 
Medische Bibliotheek van de Erasmus universiteit willen bedanken voor hun 
jarenlange voorlreffelijke service. 
266 
Curriculum Vitae 
Curriculum Vitae 
Geboren te Roermond 
1976 Eindexamen Gymnasium {3 
Bisschoppelijk College Roermond 
1978 Aanvang studie geneeskunde 
Katholieke Universiteit Nijmegen 
1980 Kandidaatsexamen geneeskunde (cum laude) 
1983 Doctoraalexamen geneeskunde (cum laude) 
1985 Artsexamen 
1986 Winnaar jaarlijkse prijs ter bevordering van de studiezin, toegekend door 
het College van Bestuur van de Katholieke Universiteit Nijmegen 
1986 1 maart: Aanvang opleiding inwendige geneeskunde, 
Afdeling Interne I, Dijkzigt Ziekenhuis, Rotterdam 
1991 1 maart Registratie als internist 
1991 -september 1993 Onderzoekmedewerker Afdeling Interne I, 
Dijkzigt Ziekenhuis, Rotterdam bij onderzoek naar de 
relatie prorenine bij secundaire orgaancomplicaties bij diabetes. 
267 
Curriculum Vitae 
1993 1997 Opleiding in aandachtsgebied endocrinologie ( plaats 
gesubsidieerd door het Diabetesfonds Nederland). In dit kader tevens 
van: 
1993 -Heden wetenchappelijk onderzoek naar ral van het 
IGF-I/IGFBP systeem bij het insuline-resistentiesyndraom. 
268 
Publikaties 
Publlkaties 
1. Yap SH, Moshage HJ, Janssen JAM, Franssen JH. The role of glucose in 
regulation of liver protein synthesis; in Nutritional Diseases: Research directions in 
comparative pathobiology, Scarpelli DG, Migaki G (eds), Alan R liss Inc, New York 
1986, pp 91·101. 
2. Moshage HJ, Janssen JAM, Franssen JH, Hafkenscheid JCM, Yap SH. 
Study of the molecular mechanism of decreased liver synthesis of albumin in 
inflammation. J Clin Invest 1987; 79: 1635·1641. 
3. Janssen JAMJL, Blankestijn PJ, Docter R, Blijenberg BG, Splinter TAW, Van Toor 
H, Schalekamp MADH, Lamberts SWJ, Krenning EP. Effects of immunoscintigraphy 
with monoclonal antibodies in assays of hormones and tumour markers. Br Med J 
1989; 298: 1511·1513. 
4. Janssen JAMJL, Blankestijn PJ, Docter R, Blijenberg BG, Splinter TAW, Van Toor 
H, Schalekamp MADH, Lamberts SWJ, Krenning EP. De invloed van 
immunoscintigrafie met met monoklonale antilichamen op bepaling van hormonen 
en tumormerkstoffen. Een muis met een staartjel NTVG 1989; 29: 1455·1458. 
5. Janssen JAMJL, Pols HAP, Baggen MGA, Birkenhager JC. Hypercalciemie bij 
sarcoidosis. NTVG 1989; 133: 2399·2402. 
6. Janssen JAMJL, Michiels JJ. Favourable effect of plasma exchange and 
chlorambucil on generalized vasculitis in essential cryoglobulinemia; in monoclonal 
gammopathies II, Radl J, Van Camp B, Eurage, Rijswijk, The Netherlands, 1989,12: 
pp 265·269. 
7. Janssen JAMJL, Tjiong HL. Bronchial asthma improved after removal of 
pheochromocytoma. Eur J Resp 1991; 4: 1021·1022. 
8. Janssen JAMJL, Kint PAM, Meeter K. Een patient met een zeldzame oorzaak van 
pijn op de bors!. Nederlands Tijdschrift voor Cardiologie 1991; 5: 226·230. 
9. Janssen JAMJL, Kint PAM, Meeter K. Un patient presentant une douleur 
thoracique d'une origine inhabituelle. Journal de Cardiologie 1991; 8: 372·376. 
10. Franken MM, Derkx FHM, Blankestijn PJ, Janssen JAMJL, Mannesse CK, Hop 
W, Boomsma F, Weber R, Peperkamp E, De Jong PTVM, Schalekamp MADH. 
Plasma prorenin as an early marker of microvascular disease in patients with 
diabetes mellitus. Diabete & Metabolisme 1992; 18: 137·143. 
11. Derkx FHM, Janssen JAMJL, Danser AHJ, Schalekamp MADH. The renin 
angiotensin therapy in patients with diabetes mellitus. In: Diabetic Nephropathy Bilo 
HJG, Viberti GC, (eds) De Weezenlanden, Series no 2, Zwolle 1994: 164·183. 
269 
PlIblikaties 
12. Van den Meiracker AH, Admiraal PJ, Janssen JA, Kroodsma JM, de Ronde WA, 
Boomsma F, Sissman J, Blankestijn PJ, Mulder PG, Man in 't Veld AJ. 
Hemodynamic and biochemical effects of the AT1 receptor antagonist irbesartan in 
hypertension. Hypertension 1995; 25: 22-29. 
13. de Herder WW, van der Lely AJ, Janssen JA, Uitterlinden P, Hofland LJ, 
Lamberts SW. IGFBP-3 is a poor parameter for assessment of clinical activity in 
acromegaly. Clin Endocrinol 1995; 43: 501-505. 
14. Derkx FHM, Janssen JAMJL, Schalekamp MADH. Measurements of 
components of the renin angiotensin system in humans: relationship with diabetic 
complications and antihypertensive treatment. Research methodologies in human 
diabetes-Part 2 Walter de Gruyter, New York, 1995: 491-504. 
15. Janssen JAMJL, Heine RJ. Prevalentie, behandeling en preventie van 
hypoglycemie. In: Erasmus Endocrinologie curs us Weber RFA (ed) Novo Nordisk. 
Rotterdam 1995: biz 109-112. 
16. Van der Lely AJ, de Herder WW, Janssen JAMJL, Lamberts SWJ. Acromegaly: 
the significance of serum total and free IGF-I and IGFBP-3 in the diagnosis. J 
Endocrinology 1997; 155 (SuppI1): S9-S13. 
17. Janssen JAMJL, Jacobs ML, Derkx FHM, Weber RFA, van der Lely AJ, 
Lamberts SWJ. Free and Total IGF-I, IGFBP-1 and IGFBP-3 and their relationships 
to the presence of diabetic retinopathy and glomerular hyperfiltration in insulin-
dependent diabetes mellitus (100M). J Clin Endocrinol Metab 1997; 82: 2809-2815. 
18. Janssen JAMJL, Stolk RP, Pols HAP, Grobbee DE, de Jong FH, Lamberts SWJ. 
Serum free IGF-I, totaIIGF-I, IGFBP-1 and IGFBP-3 levels in an elderly population: 
relation to age and sex steroid levels. Clin Endocrinol1998; 48: 471-478. 
19. Janssen JAMJL, Stolk RP, Pols HAP, Grobbee DE, Lamberts SWJ. Serum total 
IGF-I, free IGF-I and IGFBP-1 levels in an elderly population: relation to 
cardiovascular risk factors and disease. Arteriosclerosis, Thrombosis and Vascular 
Pathology 1998; 18: 277-282. 
20. Janssen JAMJL, Stolk RP, Pols HAP, Grobbee DE, Lamberts SWJ. Serum free 
and total IGF-I, IGFBP-1 and IGFBP-3 levels in healthy elderly individuals: relation 
to self-reported quality of health and disability. Gerontology 1998, in press. 
21. Janssen JAMJL, Uitterlinden P, Hofland LJ, Lamberts SWJ. IGF-I receptors on 
blood cells: their relationship to circulating total and '1ree" IGF-I, IGFBP-1, IGFBP-3, 
and insulin levels in healthy subjects. Growth Hormone and IGF Research 1998; 8: 
47-54. 
270 
Publikaties 
22. Janssen JAMJL, Hoogerbrugge N, van Neck JW, Uitterlinden P, Lamberts SWJ. 
The IGF-I/IGFBP system in congenital partial lipodystrophy. Clin Endocrinol 1998, 
in press. 
23. Janssen JAMJL, Burger H, Stolk RP, Grobbee DE, de Jong FH, Lamberts SWJ, 
Pols HAP. Gender-specific relationship between serum free and totallGF-1 and 
bone mineral density in elderly men and women. Eur J Endocrinol1998; 6: 627-
632. 
24. Janssen JAMJL, Huizenga NATM, Stolk RP, Grobbee DE, Pols HAP, de Jong 
FH, Attanasio AMF, Blum WF, Lamberts SWJ. The acute effect of dexamethasone 
on plasma leplin concentrations and the relation between fasting leptin, the IGF-
I/IGFBP system, dehydroepiandrosterone, androstenedione, and testosterone 
concentrations in an elderly population. Clin Endocrinol 1998; 48: 621-626. 
25. Van der Lely AJ, Janssen JAMJL, Attanasio AF, de Herder WW, Lamberts SWJ. 
Practical aspects of the diagnosis of growth hormone deficiency in adults. In: The 
diagnosis and treatment of pituitary insufficiency, Lamberts SWJ (ed), Bioscienlifica 
LTD, Woodlands, UK, 1997, pp 241-261. 
26. Janssen JAMJL, Koper JW, Stolk RP, Englaro P, Uitterlinden AG, Huang Q, van 
Leeuwen JPTM, Blum WF, Attanasio AMF, Pols HAP, Grobbee DE, de Jong FH, 
Lamberts SWJ. Lack of associations between serum leptin, a polymorphism in the 
gene for the B,-adrenergic receptor and glucose tolerance in the Dutch population. 
Clin Endocrinol 1998, in press 
27. Janssen JAMJL, Lamberts SWJ. Circulating concentrations of insulin-like 
growth factor I and risk of breast cancer. Lancet 1998, in press (letter). 
28. Janssen JAMJL, Lamberts SWJ. The age-related loss of the insulin-like growth 
factor I activity in insulin-dependent diabetes mellitus (100M) type I contributes to 
the development of microvascular complications. Submitted for publication 
271 

